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Abstract 
Cancer remains one of the leading causes of death worldwide. Many novel anticancer 
drugs have been identified to improve cancer treatment. However, demerits such as 
toxic side effects and development of resistance to chemical agents limit its 
effectiveness. Hence, development and identification of a safer and more effective 
therapeutic drug is a need of an hour. Nowadays, majority of research focuses on 
discovering natural therapeutics such as plant derived products with minimal side 
effects as effective anticancer drugs.  
Ribosome inactivating proteins (RIPs) are RNA N-glycosidases that inactivate 
ribosomes in an irreversible manner through depurination of specific adenine residues 
found in a highly conserved SR (α-sarcin/ricin) loop on the large ribosomal subunit. 
The inactivation of ribosomes prevents binding to elongation factor-2 (eF-2), thus 
arresting protein synthesis. RIPs are widely distributed in plants, and certain bacteria, 
fungi and algae. In recent years, RIPs have received considerable attention as they 
target conserved host protein synthesis machinery, which makes it difficult to develop 
drug resistance, a common problem observed during chemotherapy. In addition, RIPs 
exhibit low or no detectable side effect on normal cells as they recognize specific 
receptors expressed on the surface of tumor cells, which makes them a promising tool 
for cancer treatment. 
Balsamin, a type I RIP, has been purified from Momordica balsamina. Previous 
studies from our group have demonstrated that balsamin exhibits potent growth 
inhibitory activity against human immunodeficiency virus (HIV). In this study, we 
investigated other biological and therapeutic activities of balsamin. Balsamin purified 
from Momordica balsamina (nBalsamin) exhibited DNase-like activity, converting the 
supercoiled form of a plasmid DNA into the linear form in a concentration-dependent 
manner. DNase-like activity of nBalsamin towards plasmid DNA was pH, incubation 
time and temperature dependent. In addition, nBalsamin exhibited antioxidant and 
broad-spectrum antimicrobial activity, suggesting potential utility of this bioactive as a 
nutraceutical. 
We further investigated the role of nBalsamin as a potent therapeutic agent for cancer. 
The anti-proliferative effects of nBalsamin and its associated mechanism on liver 
ix 
(HepG2 and H4IIE) and breast cancer (MCF-7 and BT549) cells were evaluated. 
nBalsamin inhibited the viability of liver and breast cancer cells in a dose and time 
dependent manner. nBalsamin-induced apoptosis involved DNA fragmentation, G/S 
phase cell cycle arrest, increase in caspase-3 and -8 activities, upregulation of Bax, 
Bid, Bad and p53 and downregulation of Bcl-2 and Bcl-XL, suggesting that nBalsamin 
activates intrinsic and extrinsic apoptotic pathways in these cells. Increase in the 
expression of GRP78 and CHOP in liver cancer cells and not in breast cancer cells, 
indicated that nBalsamin activates an additional, ER-stress mediated, apoptotic 
pathway in liver cancer cells. These findings suggest that nBalsamin with anti-tumor 
activities could be used as a nutraceutical for the treatment of liver and breast cancer. 
Recovery and purification of Balsamin from natural sources involves multiple 
purification steps that compromises protein yield. Heterologous protein expression in 
E.coli strain offers an alternative strategy with higher yields and shorter fermentation 
time. Herein, we reported a successful heterologous expression of Balsamin 
(rBalsamin) in E.coli strain. The protein was expressed in E.coli BL21(DE3) strain 
and purified by nickel affinity chromatography. A total of 45 mg of protein was 
obtained from a 1 L of induced culture. rBalsamin was found to be sensitive to change 
in temperature and pH, suggesting that any change in pH and temperature are likely to 
affect its structure and function. Further, rBalsamin exhibited RNA N-glycosidase, 
DNase-like and broad-spectrum antimicrobial activity suggesting that rBalsamin 
carries a high potential for the design of new antimicrobial drugs against human and 
plant infections. 
Investigation of the cytotoxicity of rBalsamin on cancer cells could be beneficial to 
explore its potential use in cancer therapeutics. Therefore, we investigated the anti-
tumor potential of rBalsamin on liver (HepG2 and H4IIE) and breast cancer (MCF-7 
and BT549) cells. rBalsamin significantly inhibited the growth and proliferation of 
liver and breast cancer cells in a dose and time dependent manner. rBalsamin induced 
apoptosis in these cells via DNA fragmentation, cell cycle arrest, increasing the 
activity of casapse-3 and -8, and regulating the expression of various pro-apoptotic 
(Bax, Bid, Bad, p53) and anti-apoptotic (Bcl-2 and Bcl-XL) genes. Interestingly, 
rBalsamin upregulated the expression of genes, GRP78 and CHOP, involved in ER-
stress mediated apoptosis in liver cancer cells and not in breast cancer cells. These 
x 
findings suggest that rBalsamin with such variant characteristics could find potential 
application in the field of cancer therapeutics. 
Flavonoids are known to increase and synergize the effects of various 
chemotherapeutic drugs. We investigated the apoptotic effects of nBalsamin (nBal) in 
presence of three flavonoids, namely naringenin (Nar), naringin (Nir) and quercetin 
(Qu). Three concentrations (0.5 X IC50, 1.0 X IC50 and 2.0 X IC50) of flavonoids were 
tested in combination with nBal (25µg/ml). Nar Nir and Qu increased the anti-
proliferative effects of nBal on HepG2 and MCF-7 cells compared to nBal treatment 
alone. The effect appeared to be more pronounced with increasing flavonoid 
concentrations. Interestingly, low concentration (0.5 X IC50) of flavonoids appeared to 
produce an additive but higher concentrations did not (1.0 X IC50 and 2.0 X IC50). 
Therefore, low concentration of flavonoids; Nar, Nir and Qu in combination with nBal 
were selected for further study. Mechanically, Nar, Nir and Qu tended to increase the 
activation of caspase-3 and -8, upregulate the expression of pro-apoptotic gene (Bax, 
Bid, Bad, p53) and downregulate the expression of anti-apoptotic genes (Bcl-2 and 
Bcl-XL), indicating that these flavonoids could possibly enhance nBal-induced 
apoptosis in HepG2 and MCF-7 cells. These findings suggest that nBalsamin in 
combination with flavonoids could serve as a novel combinational strategy for the 
treatment of liver and breast cancer. However, in vivo studies are warranted to 
establish its potential as an effective therapeutic agent.  
Scope of work 
The present study provides an insight into the anti-tumor properties of nBalsamin and 
rBalsamin and unveils the molecular mechanism involved in Balsamin-induced 
apoptosis in liver and breast cancer cells. Combination of nBalsamin with flavonoids 
enhanced the cytotoxic potential of nBalsamin towards liver and breast cancer cells.   
This approach could serve as a novel combinational strategy for the treatment of liver 
and breast cancer. The present study offers far-reaching implications of exploring new 
balsamin targets and delivery systems for cancer therapy.  
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1.1 Introduction 
Plants represent the first stage in the evolution of living things. During evolution, 
there has been association between plants and man. In ancient times, human beings 
solely depended on plants for food, medicine, animal feed, fuel and clothes. Plants 
with medicinal values were extensively used by Vedas to develop medicines applied 
for the cure and relief of various illnesses (Petrovska 2012). Plants have been 
considered a natural reservoir of organic compounds with great importance. These 
compounds have been employed in the manufacture of food items, cosmetics, paints 
and medicines that hold major significance in everyday life. Medicinal remedies 
from plant products have been encouraged as the formulations obtained are cheap 
and can significantly contribute towards prevention and treatment of various 
diseases (Howard 2005).   
With the development in the scientific world, higher plants have provided a good 
source for the development of therapeutic agents. Around one quarter of the modern 
medicinal products are directly or indirectly obtained from plants (Shu 1998). It has 
been reported by World Health Organisation (WHO) that around 80% of the human 
population rely on medicinal plants for their primary health care. During the last 30 
years, up to 50% of the approved therapeutic agents are either directly or indirectly 
obtained from natural products (Veeresham & Chitti 2013). 
Plants are known to contain variety of secondary metabolites (such as tannins, 
terpenoids, alkaloids, flavonoids, phenols, oils, etc) that exhibit therapeutic 
importance and are employed by herbalists in the treatment of various ailments. 
Despite the presence of secondary metabolites, plants are rich in variety of 
constitutive and inducible defense mechanisms, such as constitutive inhibitine and 
phytoalexin, and certain proteins such as peroxidases, proteinase inhibitors, 
chitinases that accumulate to high concentration in plants in response to infection by 
viruses, bacteria and fungi and other stresses (Wittstock & Gershenzon 2002).  New 
approaches, involving the production of therapeutic proteins or peptides, have been 
recently used for the treatment of various diseases such as arthritis, skin ulcers, 
metabolic disorders, cancer, HIV, myocardial infarction and so on. However, large 
scale, safe and economic production of these therapeutic proteins remains a 
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challenge as various parameters need to be considered while manufacturing (Katsila, 
Siskos & Tamvakopoulos 2012). The by-products generated during downstream 
processing of therapeutic proteins need to be removed, which incurs cost. Unlike 
synthetic therapeutic peptides, purifying naturally occurring therapeutic proteins 
from plants is safe and involves less cost as plant system utilizes its own machinery 
to produce the protein (Menkhaus et al. 2004). Instead of large capital investment in 
the manufacturing unit, simply growing and harvesting additional plants can expand 
a plant protein production system. Apart from this, a plant based production system 
also has advantage over animal cells, as plants do not present risk of viral infection. 
Also, the safety advantage over microbial systems is related to the endotoxins and 
related impurities that come from microbes. However, these kinds of contaminations 
are not associated with plant-based systems. A number of therapeutic proteins such 
as hirudin, enkephalins, lactoferrin, serum albumin and many more have been 
obtained through plant based systems (Thomas, Van Deynze & Bradford 2002) and 
one such protein that naturally occurs in the plant kingdom is ribosome inactivating 
protein (RIP). The section below describes in detail the various aspects of RIPs. 
1.2 Ribosome inactivating proteins (RIPs) 
RIPs are a group of ribotoxins that inhibit protein synthesis in various prokaryotic 
and eukaryotic cells. These proteins are categorized as RNA N-glycosidases that 
inactivate ribosomes in an irreversible manner through depurination of specific 
adenine residues, A2660 in E.coli 23S rRNA or A4324 in eukaryotic 28S rRNA, 
found in a highly conserved SR (α-sarcin/ricin) loop on the large ribosomal subunit. 
The inactivation of ribosomes prevents the binding to elongation factor-2 (eF-2), 
thus arresting protein synthesis (Endo et al. 1987) (Figure 1.1). These proteins are 
widely distributed in Angiosperms and highly expressed in the seeds of many plants 
(Puri et al. 2009; Stirpe & Barbieri 1986). Besides RNA N-glycosidase activity, 
RIPs also display additional activities including DNA, poly(A) and mRNA 
polynucleotide depurination (Barbieri et al. 1997), superoxide dismutase (Sharma et 
al. 2004), phospholipase and antioxidant activity (Bhaskar et al. 2008). The activities 
of these proteins probably explain their putative role in plant protection against 
various pathogenic infections. The other activities of RIPs include anti-tumor, 
antiviral, anti-HIV, antiproliferative, immunosuppressive and abortifacient activities 
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(Ng, Wong & Wang 2010). These proteins have been employed in therapeutics to 
develop immunotoxins for cancer (Cimini et al. 2012) and AIDS therapy (Uckun et 
al. 1998). Therefore, RIPs with various beneficial activities are of considerable 
interest.    
 
 
Figure 1.1: The site of action of RIPs on 28S rRNA in eukaryotic ribosomes 
(Fracasso, Stirpe and Colombatti, 2010). 
1.3 Classification of RIPs 
In 1986, based on their primary structure, RIPs were categorized as type I or type II 
RIPs (Stirpe & Barbieri 1986). However, later in 1994, these RIPs were classified 
into three groups (type I, type II and type III RIPs) based on their physical properties 
(Mundy et al. 1994) (Figure 1.2). 
Type I RIPs, also called Halo RIPs, are comprised of a single polypeptide chain, 
with a molecular weight ranging between 26-35 KDa, either linked to carbohydrate 
moieties or not. These RIPs are known to possess N-glycosidase activity (Peumans, 
Hao & van Damme 2001). Type II RIPs, also called Chimero RIPs, are heterodimers 
that comprise an A (active) chain and a lectin B (binding) chain linked through a 
disulphide bond. The A chain resembles Type I RIPs and exhibits N-glycosidase 
activity. The B chain with lectin properties recognizes receptors on cell membranes 
and promotes endocytosis (Ng et al. 2011).  These proteins are highly cytotoxic as 
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the lectin B-chain has the ability to bind to galactose residues present on the surface 
of animal cells that mediate retrograde transport of the A-chain to the cytosol where 
it interferes with the translational machinery and arrests protein synthesis (Lord & 
Roberts 1996). The molecular weight of type II RIPs ranges between 60-65 KDa 
with each polypeptide chain of approximately 30 KDa. They are basic proteins and 
their active site contains highly conserved secondary structure and amino acid 
residues. However, their sequence homology and post-translational modifications 
are distinctly different (Hartley & Lord 1993). Type III RIPs are rarely found and 
consist of single polypeptide chain synthesized as a zymogen (inactive precursors) 
that undergoes proteolytic cleavage to produce two noncovalently linked active 
chains identical to Type I RIPs (Mak et al. 2007). These RIPs have been 
characterized from maize, including sorghum, and barley. In maize, these RIPs are 
synthesised as acidic proteins that enter proteolytic processing events involving 
removal of short polypeptides from the N- and C- terminals, and amino acids from 
the middle region resulting in a protein with two polypeptide subunits (Walsh, 
Morgan & Hey 1991). b-32 is an example of a type III RIP that is synthesised in 
maize endosperm in an inactive form and undergoes cleavage of amino acid 1-16 
from the N-terminal, 25 amino acids (position 162-186) from middle region of the 
peptide and 14 amino acids (position 289-301) from the C-terminal to produce two 
peptides, α and β-RIP, in the active form (Hey, Hartley & Walsh 1995). In barley, 
jasmonate induced protein, a type III RIP is induced by jasmonic acid and undergoes 
proteolytic cleavage of the middle and C-terminal domains to become active 
(Chaudhry et al. 1994). The function of the extra domain in type III RIP is still 
unknown. However, once this domain is cleaved, the active protein produced 
displays activity similar to that of Type I RIPs. 
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Figure 1.2: Structure description of RIPs. (A) Schematic representations of 
primary structure of type-I, type-II and type-III ribosome-inactivating protein 
(active chain: ; lectin binding chain: ; unknown activity domain: ; signal 
peptide: ; C-terminal domain: ). (B) Ribbon diagram of type-I (e.g. 
balsamin; PDB: 3NFM; DOI:10.2210/pdb3nfm/pdb), type-II (e.g. ricin; PDB: 
2AAI; DOI:10.2210/pdb2aai/pdb) and type-III (e.g. maize b-32; PDB: 2PQI; 
DOI:10.2210/pdb2pqi/pdb) ribosome-inactivating protein. Protein chains are 
coloured from the N-terminal to the C-terminal using a rainbow (spectral) 
colour gradient. This figure has been reproduced from Stirpe and Battelli 
(2006). 
1.4 Distribution of RIPs 
RIPs are widely distributed in several plants, and certain fungi, bacteria and algae. In 
addition, RIP activity has been reported in mammalian tissues (Girbes et al. 2004). 
RIPs are ubiquitous in the plant kingdom, mostly found in Angiopermae including 
monocotyledons and dicotyledons, and have been reported from over 50 different 
plant species covering 14 families. These families include Cucurbitaceae, 
Euphorbiaceae, Iridaceae, Fabaceae, Amaranthaceae, Basellaceae, Lamiaceae, 
Lauraceae, Nyctaginaceae, Sambucaceae, Poaceae, Caryophyllaceae and 
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Phytolaccaceae (Schrot, Weng & Melzig 2015; Stirpe 2004). RIP producing plants 
are distributed in diversified regions such as tropical trees, desert succulents, weedy 
opportunists, spring annuals and obligate parasites. RIPs are found in plants at 
various concentrations including plants that are eaten raw (such as spinach, tomato) 
(Stirpe & Battelli 2006). Synthesis of RIPs in plants can be influenced by various 
factors such as senescence, stress, viral infection and development. Both type I and 
type II proteins are located in more than one plant tissue and organ including stems, 
leaves, bark, fruit, latex, endosperm and seeds. However, the most abundantly found 
RIPs are type I ribosome inactivating proteins (Hartley, Chaddock & Bonness 1996). 
Pokeweed antiviral protein (PAP) was the first type I RIP purified from Phytolacca 
americana and thereafter the number has dramatically increased with type I RIPs 
isolated from different plant tissues and organs (Stirpe & Barbieri 1986). Some of 
the examples of type I RIPs include α-, β- momorcharin (MMC) and momordica 
anti-viral protein 30 (MAP-30) (Momordica charantia); gelonin and gelonium anti-
HIV protein 31 (GAP-31) (Gelonium multiflorum); luffin (Luffa cylindrica); saporin 
(Saponaria officinalis); trichosanthin (TCS) (Trichosanthes kirilowii); cucurmosin 
(Cucurbita moschata); and velin and flammin (Flammulina velutipes) (Puri et al. 
2012). It has been noted that more than one RIP isolated from same source of plant 
exhibits similar physicochemical properties and structure, and consists of highly 
conserved amino acid sequence. The examples include RIPs isoforms identified 
from Momordica charantia, Dianthus carophyllus and Phytolacca amerciana leaves 
(Stirpe et al. 1992). RIP isoforms may sometimes be found in more than one plant 
tissue. Different isoform of RIPs such as PD-L1, PD-L2, PD-L3 and PD-L4 have 
been isolated from the leaves of Phytolacca dioica L. (Di Maro et al. 2009). Another 
example includes RIP isoforms, PAP-I, PAP-II and PAP-III obtained from the 
leaves of Phytolacca americana (Domashevskiy & Goss 2015). Type I RIPs isolated 
from different plant species, with various activities, are listed in Table 1.1. 
Type II RIPs are less abundant and are more toxic in nature than single chain type I 
RIPs. Ricin from the seeds of Ricinus communis, and abrin from the seeds of Abrus 
precatorius were the first type II RIPs discovered at the end of the 19th century 
(Olsnes, Refsnes & Pihl 1974). To date few type II RIPs have been identified and 
recent findings are shown in Table 1.1. Some of the examples of Type II RIPs 
include viscumin (Viscum album L.) (Olsnes et al. 1982), nigrin-b (Sambucus nigra 
Chapter 1 
8 
L.) (Girbes et al. 1993), aralin (Aralia elata) (Tomatsu, Ohnishi-Kameyama & 
Shibamoto 2003), riproximin (Ximenia americana) (Voss et al. 2006) and ebulin I 
(Sambucus ebulus) (Ferreras et al. 2011).  
Type III RIPs are neither a subset of type I RIPs nor type II RIPs and are less 
prevalent than other two RIPs. These proteins have been identified in a few plants, 
such as sorghum and barley, certain algal and fungal species. Examples include 
Shiga toxin I and II (Shigella dysenteria); α- sarcin (Aspergillus niger); restrictocin 
and mitogillin (Aspergillus restrictus) and tricholin (Trichoderma viride) (Nielsen & 
Boston 2001).  
Off all the natural reservoirs exploited for RIPs, RIPs have been obtained largely 
from plants with a purpose to understand the role of RIPs in plants. 
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Table 1.1: Overview of RIPs with various activities. 
RIP Source Activity References 
Type I RIPs 
Saporin-6 Saponaria officinalis N-glycosidase, protein synthesis inhibition, DNase activity, 
antitumor and anti-HIV activity 
(Au et al. 2000; Bagga S 2003) 
Balsamin Momordica balsamina  N-glycosidase, in vitro translation inhibitory, anti-HIV activity (Kaur et al. 2013; Kaur et al. 
2012) 
MAP 30 Momordica charantia N-glycosidase, anti-HIV and antitumor, cell free translation 
inhibitory, anti-HSV activity, DNA glycosylase activity 
(Bourinbaiar & Lee-Huang 1996; 
Lee-Huang et al. 1995b; Wang et 
al. 1999) 
α- momorcharin Momordica charantia Immunosuppressive, abortifacient, antitumor and anti-HIV 
activity, DNA cleavage activity, antifungal and antiviral activity 
(Puri et al. 2009; Wang et al. 
2013; Zhu et al. 2013)  
β- momorcharin Momordica charantia Abortifacient, antitumor and anti-HIV activity, DNase activity, 
immunosuppressive 
(Puri et al. 2009) 
Cochinin Momordica cochinchinensis N-glycosidase, protein synthesis inhibition, antitumor activity (Chuethong et al. 2007) 
GAP-31 Gelonium multiflorum N-glycosidase, protein synthesis inhibition, anti-HIV and 
antitumor activity, anti-HSV activity 
(Bourinbaiar & Lee-Huang 1996; 
Lee-Huang et al. 1999)  
Gelonin Gelonium multiflorum DNase activity, HSV and HIV integrase inhibitor, N-
glycosidase, antitumor activity, protein synthesis inhibition 
(Au et al. 2000; Li et al. 2007b; 
Nicolas et al. 1997) 
Marmorin Hypsizigus marmoreus Cell free-translation inhibitory, HIV-1 reverse transcriptase 
inhibitory, antiproliferative activity, antitumor activity 
(Pan et al. 2013; Wong, Wang & 
Ng 2008) 
Lyophyllin Lyophyllum shimeji Antimitogenic, HIV-1 reverse transcriptase inhibitory, 
antifungal activity 
(Ng, Wong & Wang 2010) 
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RIP Source Activity References 
Type I RIPs    
Trichosanthin Trichosanthes kirilowii Antitumor, anti-HIV and anti-HSV activity, abortifacient, N-
glycosidase, cell free translation inhibitory, DNA cleavage 
activity 
(He, Zheng & Tam 2012; Li et al. 
1991; Sha et al. 2013; Shu et al. 
2009) 
 
Hispin Benin hispada tRNA ribonuclease, N-glycosidase, antifungal activity (Ng & Parkash 2002) 
Heterotepalins Phytolacca heterotepala tRNA ribonuclease, N-glycosidase, antifungal activity (Di Maro et al. 2007) 
Velin Flammulina velutipes N-glycosidase, cell-free translation inhibitory (Ng & Wang 2004) 
Flammin Flammulina velutipes N-glycosidase, cell-free translation inhibitory (Ng & Wang 2004) 
Amaranthin  Amaranthus viridis N-glycosidase, in vitro translation inhibitory (Kwon et al. 2000) 
Bouganin Bougainvillea spectabilis Adenine polynucleotide glycosylase, protein synthesis inhibition (Fermani et al. 2009) 
Lychnin Lychnis chalcedonica Adenine polynucleotide glycosylase, protein synthesis inhibition (Fermani et al. 2009) 
PD L1-L4, 
Dioicin 1 & 2 
Phytolacca dioica L Polynucleotide: adenosine glycosidase activity, N-glycosidase, 
protein synthesis inhibition, DNA cleavage activity 
(Blanco et al. 1998; Di Maro et 
al. 2009; Ruggiero et al. 2009; 
Russo et al. 2015) 
Dianthin 30 Dianthus caryophyllus DNase activity, N-glycosidase, protein synthesis inhibition, anti-
TMV activity 
(Foa-Tomasi et al. 1982; 
Roncuzzi & Gasperi-Campani 
1996; Stirpe et al. 1981) 
PAP isoforms Phytolacca americana N-glycosidase, protein synthesis inhibition, anti-HIV and 
antitumor activity, TMV growth inhibitor, DNA cleavage 
activity 
(Domashevskiy & Goss 2015; 
Irvin 1975; Mansouri, Kutky & 
Hudak 2012; Taylor et al. 1994)  
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RIP Source Activity References 
Type II RIPs    
Ricin Ricinus communis N-glycosidase, protein synthesis inhibition, DNase activity, 
antitumor and anti-HIV activity, hemagglutinating activity 
(Au et al. 2014; Brigotti et al. 
2002; Kumar et al. 2004; Rao et 
al. 2005) 
Abrin Abrus precatorius N-glycosidase, protein synthesis inhibition, antitumor activity (Bora, Gadadhar & Karande 
2010; Narayanan, Surolia & 
Karande 2004) 
Viscumin Viscum album L.  N-glycosidase, cell free protein synthesis inhibition, catalytic 
and hemagglutinating activity, antitumor activity  
(Olsnes et al. 1982; Pryme et al. 
2006; Stirpe et al. 1982) 
Riproximin Ximenia americana. N-glycosidase, protein synthesis inhibition, antineoplastic 
activity, antitumor activity 
(Adwan et al. 2014; Voss et al. 
2006)  
Aralin Aralia elata N-glycosidase, protein synthesis inhibition, antitumor activity (Tomatsu et al. 2004; Tomatsu, 
Ohnishi-Kameyama & Shibamoto 
2003) 
Sieboldin-b Sambucus sieboldiana Gal/Gal NAC binding ability, in vitro ribosome inactivating 
activity, hemagglutinating activity 
(Rojo et al. 1997) 
Nigrin-b Sambucus nigra L. RNA N-glycosidase, protein synthesis inhibition, antitumor 
activity, hemagglutinating activity 
(Girbés et al. 1993; Girbes et al. 
2004; Muñoz et al. 2001) 
Lanceolin Adenia lanceolata Polynucleotide glycosylase activity, cell-free translation 
inhibitory, hemagglutinating activity 
(Stirpe et al. 2007) 
Stenodactylin Adenia stenodactyla Polynucleotide glycosylase activity, cell-free translation 
inhibitory, hemagglutinating activity 
(Stirpe et al. 2007) 
Foetidissimin II Cucurbita foetissima N-glycosidase, anticancer activity, cell-free protein synthesis 
inhibition 
(Zhang & Halaweish 2007) 
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RIP Source Activity References 
Type II RIPs 
   
Articulatin D Viscum articulatum N-glycosidase, hemagglutinating activity, cell-free translation 
inhibitory 
(Das, Sharma & Mishra 2011) 
Ebulin I Sambucus ebulus N-glycosidase, protein synthesis inhibition (Ferreras et al. 2011) 
Cinnamomin Cinnamomum camphora N-glycosidase, antitumor activity (He & Liu 2003) 
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1.5 Role of RIPs in plants 
The importance of RIPs in plant activities and metabolism is not well 
understood. However, evidences gained from both in vitro and in vivo studies 
indicate that some RIPs play a role in plant defense. Two type I RIPs from 
Mirabilis expansa roots were found to be active against several soil borne 
bacterial pathogens. In addition, these RIPs were active against wide variety 
of both pathogenic and non-pathogenic fungal pathogens including 
Trichoderma and Fusarium species (Vivanco, Savary & Flores 1999). 
Besides bacterial and fungal pathogens, RIPs are also known to be active 
against certain insect pests. Cinnamomin, a type-II RIP from Cinnamomum 
camphora, was toxic to mosquito larvae and cotton bollworm (Zhou et al. 
2000). In other studies, saporin and ricin demonstrated significant toxicity 
towards larvae of two Coleopteran species but had no effect on Lepidotera 
(Gatehouse et al. 1990). These studies suggested that RIPs have varied degree 
of susceptibility and resistance to plant insects and that defense is atleast one 
function of RIPs in plant. 
In addition, some studies indicated that RIPs provide seeds with nutritional 
benefits and protection against pathogenic attacks. Saporin activity was found 
to be highest in mature seeds (Barbieri, Battelli & Stirpe 1993), suggesting 
that RIPs might play an important role during seed germination. Besides this, 
RIPs have been reported to accumulate in abundance in storage organs in 
response to stress. RIP activity increased in leaves of pokeweed and Hura 
crepitans in response to osmotic stress and leaf senescence (Stirpe et al. 
1996) and in Mesembryanthemum crystallinum plant in response to salt stress 
(Rippmann et al. 1997). Stress induction of RIPs in plant is not limited to 
abiotic factors but also occurs in response to biotic stress in some plants. The 
activity of trichosanthin, a type-I RIP from Trichosanthes kirilowii, increased 
upto 19 fold in roots of plant co-cultivated with pathogens than in sterile soil 
(Wong et al. 1995). These evidences suggest that RIPs play an influential role 
in plant defense and protection during abiotic and biotic stress.  
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1.6 Mechanism of action of RIPs 
The most remarkable and unique feature of RIPs that distinguishes them from 
other proteins is RNA N-glycosidase activity. It is this activity through which 
RIPs act on the cellular machinery. Endo and co-workers demonstrated for 
the first time that RIPs are enzymes (N-glycosidases) that cause hydrolysis of 
the N-glycosylic bond at A-4324 in 28S rRNA from eukaryotic ribosomes 
(Endo et al. 1987). This activity was demonstrated by Ricin, a type-II RIP 
isolated from the seeds of Ricinus communis. Ricin consists of two-
polypeptide chains joined by a single disulfide bond. This protein removes 
the adenine residue located at position 4324 in the 28S rRNA of rat liver 
ribosomes, defining RIPs as ribosome specific N-glycosidases (Endo & 
Tsurugi 1987). The mechanism of action consists of two steps; the first step 
involves recognition of a highly conserved (GAGA) sequence in the stem 
loop region or sarcin/ricin loop in 28S rRNA, and depurination of adenine 
from this sequence that is known to be important for the interaction with 
ribosome elongation factor, making the site unstable. The site is located in 
domain VII, around 400 nucleotides from the 3’ end of the rRNA. The 
second step involves the β-elimination reaction that results in cleavage of the 
3’ end of the rRNA on treatment of RNA with acidic aniline (Figure 1.3) 
(Endo et al. 1987). Subsequent work revealed that this particular site-specific 
RNA N-glycosidase activity towards the ribosome is a unique characteristic 
of all RIPs identified to date.  
However, RIPs are highly substrate dependent for this activity. It has been 
observed that most type 1 RIPs possess broad substrate specificity while type 
II RIPs are highly specific towards animal ribosomes. Ricin (Ricinus 
communis) exhibited highest activity toward ribosomes from animals and 
yeast, but showed low adenine-cleavage activity towards E.coli and plant 
ribosomes (Barbieri, Battelli & Stirpe 1993). Contrary to this, PAP can act 
upon bacterial, plant, animal and fungal ribosomes (PAP-2015). PAP, a type I 
RIP, inactivated ribosomes isolated from RIP-free pokeweed and endod 
suspension culture cells. The sensitivity of pokeweed ribosome to PAP was 
found to be similar to wheat ribosome (Bonness et al. 1994). Further, α- and 
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β-MMC from Momordica charantia showed high specificity towards 
eukaryotic ribosomes and cleaved 28S rRNA, but not on 18S, 5.8S and 5S 
rRNA, releasing around 400 bp long nucleotide fragment, named as Endo’s 
fragment. The activity was influenced by different physicochemical 
conditions. The increase in concentration of [NH4+] from 0.1-0.25 M slightly 
affected the enzyme activity of β-MMC. The N-glycosidase activity of the 
MMCs remained uninfluenced by a change in pH from 6.5-9. However, the 
activity increased with increasing K+ concentration (Fong et al. 1996). 
Recently, balsamin from Momordica balsamina was shown to mediate 
depurination of 28S rRNA. When depurinated rRNA was treated with 
aniline, cleavage occurred at the depurinated site and a small ~400 nucleotide 
fragment (Endo fragment) was released (Kaur et al. 2012). 
Further, it has been shown that some RIPs are much more active on 
mammalian ribosomes. However, they also depurinate rRNA from other 
organisms such as plants, fungi and bacteria (Puri et al. 2012). ME1 and ME2 
(Mirabilis expansa) and TRIP (Nicotiana tabacum) exhibited N-glycosidase 
activity. These proteins showed specificity towards yeast ribosomes and 
depurinated 26S rRNA and released a 367-nucleotide fragment upon 
treatment with aniline (Sharma et al. 2004; Vivanco, Savary & Flores 1999). 
In other studies, BBAP1 (Bougainvillea xbuttiana) released a rRNA fragment 
when incubated with tobacco ribosome (Choudhary, Kapoor & Lodha 2008).  
The rRNA in native ribosomes is the best substrate for RIPs. However, RIPs 
also have the ability to act on protein free rRNA and synthetic 
oligoribonucleotides that resemble the sarcin/ricin domain of 28S rRNA 
(Domashevskiy, Miyoshi & Goss 2012; Tan et al. 2009). In addition, several 
RIPs are able to depurinate naked rRNA from non-substrate ribosomes. For 
instance, Ricin could depurinate E.coli 23S rRNA, however, didn’t possess 
any activity against the intact E.coli ribosome (Endo, Gluck & Wool 1991). 
Also, many RIPs have the ability to depurinate guanine residues within their 
substrate. Ricin A-chain, under acidic conditions, can release not only 
adenine but also guanine from synthetic oligonucleotides that mimic the 
sarcin/ricin domain or 5S rRNA (Tang et al. 2001). Similarly, PAP cleaved 
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both adenyl-guanosine (ApG) and adenyl-cytosine-cytosine (ApCpC) 
nucleotides leaving only adenine bases clearly visible in the active site pocket 
of PAP (Kurinov et al. 1999). 
Interestingly, some RIPs also have the tendency to distinguish between 
capped and uncapped transcripts. A novel mechanism of inhibition of 
translation was put forward suggesting that PAP causes specific depurination 
of capped mRNA but not of uncapped RNA. PAP treated luciferase 
transcripts inhibited translation by binding to the capped structure and 
depurinating mRNA downstream of the cap, while no degradation was 
observed in PAP treated uncapped luciferase mRNAs (Hudak, Bauman & 
Tumer 2002).  
These evidences suggested that RIPs have the ability to act on diverse form 
of rRNA’s with broad-spectrum substrate specificity that encouraged 
researchers to further investigate enzymatic activities of RIPs on different 
substrates. 
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Figure 1.3: Steps involved in the mechanism of action of RIPs: A specific 
N-glycosidase activity attacks adenine (A4324) found in the sarcin/ricin 
loop of the large subunit of the ribosomal RNA. The deadenylated rRNA 
product acts as a substrate for ribosomal RNA apurinic site-specific 
lyase (RALyase), which cleaves the phosphodiester bond at 3' end. The 
reaction products are a short (4325-4785) 3'-end fragment and a long (1-
4324) 5'-fragment with free 3'-hydroxyl terminus. This figure has been 
reproduced from Puri et al. (2012).  
1.7 Enzymatic activities of RIPs 
1.7.1 Inhibition of protein synthesis 
Inhibition of protein synthesis is an essential step involved in cell death. 
Proteins known to block translation can be employed in various ways to treat 
a number of diseases. Interestingly, plant RIPs are found to be potent 
inhibitors of protein synthesis in a cell free system. Ricin from Ricinus 
communis was first demonstrated to inhibit protein synthesis in vitro. Ricin 
inhibited the elongation step by blocking the interaction of elongation factor 
2 (EF2) with ribosomes, which in turn, blocks GTP hydrolysis catalysed by 
EF-2 resulting in arrest of protein synthesis. However, the protein did not 
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affect ribosome linked phenylalanyl-tRNA binding catalysed by EF-1 
(Montanaro, Sperti & Stirpe 1973). 
RIPs from Momordica charantia have also been found to inhibit translational 
systems in vitro. α- and β- MMC exhibited inhibition of protein synthesis at 
nM concentration in rabbit reticulocyte cell free lysate with IC50 of 0.12 nM 
and  0.11 nM respectively (Yeung et al. 1988). On the other hand, MAP30 
inhibited cell free protein synthesis in a dose dependent manner with IC50 of 
3.3 nM, same as observed with rMAP30, but did not affect translation in 
normal cells (Lee-Huang et al. 1995b; Lee-Huang et al. 1990). Recently, 
balsamin from Momordica balsamina demonstrated inhibition of protein 
synthesis in a rabbit reticulocyte lysate based cell free translation system. It 
was found that the protein inhibited protein synthesis at IC50 of 90.6 ng/ml 
(Kaur et al. 2012). Furthermore, the effect of natural and recombinant PD-L4 
from Phytolacca dioica L. on protein biosynthesis was determined by 
radiolabelled methionine incoporation into translational products. Natural and 
recombinant PD-L4 displayed cell free translation inhibition at IC50 of 151±8 
pM and 142±7 pM, respectively (Blanco et al. 1998) 
It has been shown that some RIPs require cofactors such as ATP for 
inhibition of the translation process. Gelonin (Gelonium multiflorum), PAP-S 
(Phytolacca americana), Barley RIP (Hordeum vulgare) and Tritin-S 
(Triticum aestivum) require ATP to achieve maximum activity. However, 
other RIPs such as saporin (Saponaria officinalis), momordin (Momordica 
charantia) and TCS (Trichosanthes kirilowii) inhibited protein synthesis 
without the requirement of ATP (Carnicelli et al. 1997). The translational 
inhibitory activity of some RIPs is also influenced by the presence of ions. 
Out of the 7 saporin isoforms isolated from Saponaria officinalis, the activity 
of one saporin isoform was found to be dependent on magnesium ion 
concentration in a rat liver cell free system (Ferreras et al. 1993). 
Some RIPs are capable of inhibiting translation in several cell free systems 
from mammals and plants. For instance, TRIP (Nicotiana tabaccum) 
inhibited translation in a rabbit reticulocyte lysate and a wheat germ system. 
TRIP demonstrated a higher inhibitory effect in the wheat germ system with 
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IC50 of 30 ng/ml compared to 100 ng/ml in the rabbit reticulocyte system 
(Sharma et al. 2004). The effect of saporin isoforms isolated from various 
parts (leaves, roots and seeds) of Saponaria officinalis L. was tested on 
mammalian, plant and bacterial cell free systems. All isoforms inhibited 
protein synthesis in the cell free system derived from rabbit reticulocyte 
lysate, rat liver, wheat species, Triticum aestivum L., and plants including 
Cucumis sativus L. and Vicia sativa L. However, they were found to be poor 
inhibitors of the E.coli protein synthesis system. In the mammalian cell free 
system, a greater difference in protein synthesis inhibition was observed in 
the cell lines of human origin. All of the saporin isoforms inhibited protein 
synthesis in HeLa, BeWo and NB100 cells with IC50 of 76 nM or less 
(Ferreras et al. 1993). The response of MU isoforms (MU 1, 2 & 3) from 
Muscari armeniacum on cell free systems from mammals and plants showed 
that all the isoforms exhibited strong inhibitory activity in the rabbit 
reticulocyte system with IC50 of 7, 9.5 and 4 ng/ml, respectively. The values 
were higher in case of the rat liver system with IC50 of 79, 95 and 101 ng/ml 
for MU 1, 2 & 3, respectively. However, the protein did not exhibit any 
activity towards the plant derived cell free system (Arias et al. 2003). 
These evidences suggest that RIPs are capable of inhibiting protein 
translation at different levels in variety of cell free systems. This 
characteristic of RIPs could prove beneficial in suppressing the growth of 
diseased cells and be considered as a possible strategy of disease treatment in 
plants, animals and humans. Apart from rRNA cleavage and translation 
inhibiting activity, some RIPs also exhibit nuclease activities towards various 
other substrates. 
1.7.2 DNase activity 
RIPs from plants have been known to remove adenine from DNA, thereby 
converting supercoiled DNA into open circular and linear forms. TCS 
demonstrated deoxyribonuclease activity towards supercoiled DNA 
(pBluescript II, SV40, Φ X 174 RF) in vitro. TCS cleaved supercoiled 
dsDNA into nicked circular and linear DNA. However, no effect was 
observed on linear dsDNA (Li et al. 1991). α- and β- MMC were shown to 
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cleave supercoiled dsSV-40 DNA into nicked circular and linear forms with 
no activity towards linear DNA such as lambda, Ad-2 and T7 (Go, Yeung & 
Fong 1992). Interestingly, it was stated that RIP preparation contaminated 
with DNase and RNase was responsible for this observation, which raised a 
serious concern. Day and co-workers presented evidence of contamination of 
PAP isoforms with nucleases (Day, Lord & Roberts 1998).  Subsequent 
efforts were made to report the DNase activity of RIPs. Dianthin 30, saporin-
S6 and gelonin demonstrated DNase activity towards single stranded DNA 
(Nicolas et al. 1997; Roncuzzi & Gasperi-Campani 1996). In addition, 
gelonin, ricin and PAP could damage ssDNA (pUC18) via removal of 
specific adenine residues followed by cleavage at the resulting abasic site. 
Further studies reported that high concentrations of PAP could also cleave 
double stranded supercoiled DNA using the same site that depurinates rRNA 
and pG-1 DNA (Wang & Tumer 1999).  
Saporin-6 exhibited fragmentation activity towards genomic DNA of U937 
cells (Bagga, Seth & Batra 2003). Higher concentrations of recombinant 
BBAP1 were able to depurinate supercoiled pBlueScript SK+ plasmid DNA 
in a concentration dependent manner (Choudhary, Kapoor & Lodha 2008). 
Recent studies showed that DNase cleavage activity of α-MMC depended on 
various factors such as treatment time, reaction temperature and DNase 
buffer pH (Wang et al. 2013).  
These evidences suggest that RIPs have DNA nuclease activity towards 
variety of different forms of DNA, including supercoiled, covalently closed, 
circular plasmid DNA and single stranded phage DNA, along with rRNA N-
glycosidase and translation inhibitory activity, suggesting its variant 
biological role within the cell. 
1.7.3 Lipase, chitinase and superoxide dismutase activity 
Besides nuclease activities, RIPs exhibit number of novel enzymatic 
activities, including phosphatase activity on lipids, chitinase and superoxide 
dismutase activity. However, there is limited evidence to support lipase, 
chitinase and superoxide dismutase activity of RIPs. RCA60 demonstrated a 
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phospholipase activity towards palmitoyl-oleoyl-glycerophosphatidylcholine. 
The nature of the hydrolysis products were analysed by thin-layer and gas 
chromatography which supported the conclusion that RCA60 exhibits 
phospholipase A1 and A2 activities (Helmy, Lombard & Pieroni 1999). 
TKC 15, TKC 28-I, and TKC 28-II purifed from the Trichosanthes kirilowii 
plant cell cultures possess both chitinase and RIP activity. Highly purified 
preparations of these proteins exhibited endochitolytic as well as the specific 
28S rRNA N-glycosidase activity (Shih et al. 1997). 
Camphorin, a type-I RIP isolated from the seeds of Cinnamomum camphora, 
exhibits superoxide dismutase activity along with RNA N-glycosidase and 
supercoiled dependent endonuclease activities (Li et al. 1997). A BLAST 
(NCBI) database sequence search studies revealed that a 15 amino acid 
internal polypeptide sequence of TRIP was identical with the internal 
sequence of the iron-superoxide dismutase (Fe-SOD) from wild tobacco, 
Arabidopsis, and potato. Also, purified TRIP showed SOD and RIP activity 
demonstrating it as a dual activity enzyme (Sharma et al. 2004). In contrast, 
pyrogallol autoxidation and NBT staining analysis revealed that MAP30 and 
α-MMC, simultaneously isolated from Momordica charantia L., did not 
exhibit superoxide dismutase activity (Meng et al. 2014). 
These evidences suggest that RIPs possess dual biochemical activities and 
have multiple biological roles, encouraging researchers to exploit RIPs in the 
field of therapeutics. The section below describes various therapeutic 
applications of RIPs with a major focus towards the use of RIPs in cancer 
treatment. 
1.8 Therapeutic function of RIPs 
RIPs are one class of pathogenesis-related proteins that could be used as 
antimicrobial agents. The section below describes some of the antimicrobial 
properties exhibited by RIPs. 
 
 1.8.1 Antibacterial activity 
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Antibacterial properties of RIPs are less frequently described compared to 
antitumor and antiviral activities. A number of RIPs have been shown to 
inhibit the growth of various human and plant bacterial pathogens. Tobacco 
RIP (TRIP) from Nicotiana tabacum possessed broad-spectrum antibacterial 
activity towards various bacterial pathogens including Pseudomonas 
solancearum, Erwinia amylovora, Shigella asonei, Salmonella typhimurium, 
Rhizobium leguminosarum, Enterobacter aerogenes, Agrobacterium 
radiobacter, Bacillus subtilis and Erwinia herbicola (Sharma et al. 2004). A 
RIP purified from Cucurbita moschata demonstrated growth inhibitory 
activity towards several phytopathogenic bacteria such as Phytophthora 
infestans, E. amylovora and P. solancearum (Barbieri et al. 2006). α-MMC 
from Momordica charantia exhibited antibacterial activity against E.coli, 
Pseudomonas aeruginosa, Staphylococcus aureus and B. subtilis. α-MMC 
was found to be active against P. aeruginosa, however, had little effect on 
E.coli, S. aureus and B. subtilis (Wang et al. 2012). This potential of RIPs has 
been exploited in the field of crop improvement to develop transgenic plants 
resistant to bacterial infections. 
1.8.2 Antiviral activity 
Apart from antibacterial properties, RIPs exhibit broad range antiviral 
properties against different viruses, including RNA and DNA viruses, 
infecting both plants and humans (Akkouh et al. 2015).  
Several RIPs have been reported to inhibit the growth of various plant 
viruses. PAP, a type-I RIP from Phytolacca americana exhibited antiviral 
activity against wide range of plant DNA and RNA viruses, including potato 
virus X and Y, tobacco mosaic virus, alfalfa mosaic virus, cucumber mosaic 
virus, cauliflower mosaic virus, african cassava mosaic virus and brome 
mosaic virus in a dose and time dependent manner (Chen et al. 1991; Di & 
Tumer 2015; Hudak, Wang & Tumer 2000; Taylor et al. 1994). α-MMC from 
Momordica charantia inhibited replication and growth of plant viruses such 
as chilli veinal mottle virus, tobacco mosaic virus and cucumber mosaic virus 
in the infected plants (Zhu et al. 2013). In the case of human viruses, 
specially human immunodeficiency virus (HIV), RIPs have been known to 
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target three main enzymes involved in the progression of HIV replication, 
namely, (i) Reverse Transcriptase, the enzyme involved in the synthesis of 
viral DNA from HIV-1 mRNA, (ii) Integrase, the enzyme that integrates viral 
DNA into host genome, and (iii) Viral proteins essential for virion synthesis 
and release from the host cell for the spread of HIV infection (Figure 1.4). 
Table 1.2 describes in detail the enzymes and viral proteins targeted by RIPs 
in the replication cycle of HIV.  
Besides human immunodeficiency virus (HIV-1), RIPs are also known to 
target various other human viruses (Kaur, Gupta & Puri 2011). PAP from 
Phytolacca americana exhibited antiviral activity against various human 
viruses including influenza virus, poliovirus, human T-cell leukemia virus-1 
(HTLV-1), herpes simplex virus (HSV), japanese encephalitis virus (JEV) 
and lymphocytic choriomeningitis virus (LCMV) (Domashevskiy & Goss 
2015; Ishag et al. 2013; Mansouri et al. 2009; Teltow, Irvin & Aron 1983; 
Uckun et al. 2005). MAP30 from Momordica charantia demonstrated 
inhibitory activity towards kaposi’s sarcoma-associated herpesvirus (KSHV) 
and retarded the proliferation of KSHV infected BL-2 cells with an EC50 
ranging between 0.3 to 0.6 nM. It was found that MAP-30 upregulated the 
genes involved in apoptosis (Bax, caspase-3, CRADD) and lowered the 
expression of cellular genes related to KSHV pathogenesis (Sun et al. 2001). 
Other RIPs such as gelonin (Gelonium multiflorum), Momordica charantia 
inhibitor (MCI) (Momordica charantia) and dianthin 32 (Dianthus 
caryophyllus) have shown inhibitory effect against HSV-1 and poliovirus. All 
proteins reduced viral replication, decreased plaque forming efficiency and 
inhibited protein synthesis in the virus infected cells (Foa-Tomasi et al. 
1982). 
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Figure 1.4: Schematic representations of targets of various RIPs in the life cycle of HIV-1. The RIP causes inhibition at various stages in 
the replication cycle and further represses its progress. 
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Table 1.2 Overview of RIPs targeting various enzymes and viral proteins involved in HIV replication. 
RIPs Source RIPs target Reference 
 
Balsamin 
 
Momordica balsamina (seeds) 
 
p55, p24, p41 
 
(Kaur et al. 2013) 
Bryodin 1 & 2 Bryonia cretica spp. dioica (roots) Reverse Transcriptase (Wachinger et al. 1993) 
TCS Trichosanthes kirilowii (root tubers) Reverse Transcriptase (Wang et al. 2002) 
p24 (Pan & Levy 1994) 
Gag budding sites (Zhao et al. 2009) 
Saporin Saponaria officinalis (seeds) HIV- Integrase (Au et al. 2000) 
GAP 31 Gelonium multiflorum (seeds) Reverse Transcriptase, p24 (Lee-Huang et al. 1991) 
HIV- Integrase (Lee-Huang et al. 1995a) 
Viral DNA-LTR (Li et al. 2010b) 
Luffin Luffa cylindrica (seeds) HIV- Integrase (Au et al. 2000) 
DAPs 30 & 32 Dianthus caryophyllus (leaves) Reverse Transcriptase, p24 (Lee-Huang et al. 1991) 
MAP 30 Momordica charantia (seeds & leaves) Reverse Transcriptase, (Lee-Huang et al. 1990) 
HIV- Integrase (Lee-Huang et al. 1995a) 
Viral DNA-LTR (Wang et al. 1999) 
PAP-S Phytolacca americana (seeds) Reverse Transcriptase (Olson, Ramakrishnan & Anand 1991) 
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RIPs Source RIPs target Reference 
 
Gelonin  
 
Gelonium multiflorum (seeds) 
 
HIV- Integrase 
 
(Au et al. 2000) 
LRIP-1 Luffa aegyptiaca (seeds) Reverse Transcriptase (Olson, Ramakrishnan & Anand 1991) 
 
Trichobitacin 
 
Trichosanthes kirilowii (root tubers) 
 
p24 
 
(Zheng, Ben & Jin 2000) 
α-MMC Momordica charantia (seeds) p24 (Zheng, Ben & Jin 1999) 
(Au et al. 2000) 
HIV- Integrase 
PAP isoforms    
(PAP-I, II & III) 
Phytolacca americana (leaves) HIV-1 mRNA (Rajamohan et al. 1999) 
β-MMC Momordica charantia (seeds) HIV- Integrase (Au et al. 2000) 
Luffin P1 Luffa cylindrica (seeds) p24, RRE (Ng et al. 2011) 
PAP Phytolacca americana (leaves) Gag protein, p24, p41, Nef, Env (Mansouri, Kutky & Hudak 2012) 
Luffaculin I Luffa acutangula (seeds) p24 (Long et al. 2008) 
HIV: human immunodeficiency virus; LTR: long terminal repeats; RRE: rev response element; Nef: negative regulatory factor; Env: envelope protein.
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1.8.3 Anti-tumor activity  
Type I RIPs from different plant sources have shown to have antitumor activity in 
both in vivo and in vitro studies (Zeng et al. 2015). Table 1.3 provides a detailed 
overview of Type I RIPs with antitumor activities including studies on cell lines and 
tumor models. 
1.8.3.1 Effect on breast cancer 
Type I RIPs such as TCS, MAP30, GAP31, saporin-6, gelonin, marmorin, α–MMC 
have been known to inhibit the growth of breast tumors in vitro and in vivo. The first 
RIP that demonstrated anti-breast activity was saporin-6, a plant RIP isolated from 
Saponaria officinalis. The protein at a concentration of 10-9 M was found to be 
highly toxic to breast cancer cells obtained from 27 patients bearing primary breast 
cancer (Gasperi-Campani et al. 1991). The conjugation of saporin to epithelial cell 
adhesion molecule (EpCAM) targeting monoclonal antibody, 3-17I demonstrated 
enhanced toxicity towards MCF-7 breast cancer cells in a light dependent manner 
after photochemical internalization of 3-17I (Lund et al. 2014). Several other RIPs 
have been reported as potent inhibitors of breast cancer. TCS exhibited 
antiproliferative activity and induced apoptosis in both MCF and MDA-MB-231 
cells in a dose dependent manner. The protein arrested cell cycle at G1 phase and 
stimulated apoptosis through caspase -3, -8 and -9 activation, PAP cleavage and 
DNA fragmentation. In vivo studies demonstrated that TCS could ablate tumor 
volume and tumor weight from the 6th day of treatment in nude mice bearing MDA-
MB-231 cells (Fang et al. 2012c). Other RIPs such as MAP30, GAP31 and α-luffin 
have also been found to possess antitumor activity against various breast cancer cell 
lines in a dose dependent manner (Lee-Huang et al. 1999; Liu et al. 2010; Rybak et 
al. 1994). MAP30 and GAP31 inhibited MDA-MB-231 cell proliferation by 
downregulating the expression of human epidermal growth factor receptor-2 (Her-
2), an oncogene that plays an important role in the development and progression of 
cancer. This gene is overexpressed in approximately 30% of all human breast 
cancer, and Her-2 expressing breast tumor cells are sensitive to chemotherapy, 
therefore, MAP-30 and GAP31 could represent an alternative therapeutic strategy 
for Her-2 expressing breast tumors (Rybak et al. 1994).  
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Table 1.3: Summary of RIPs antitumor activities, including in vivo and in vitro studies. 
RIP Tumor  Cell line (in vitro) Animal (in vivo) References 
 
TCS 
 
Breast cancer 
 
MCF-7, MDA-MB-231 
 
Nude mouse (transplanted) 
 
(Fang et al. 2012c) 
 Cervical cancer CaSki, HeLa  (Peng et al. 2011; Wang et al. 2009) 
 Choriocarcinoma JAR, H35, BeWo  (Chan, Huang & Tam 2003; Jiao & 
Liu 2010) 
   Kunming mouse U14 cells (Zhang, Huang & Wu 2009) 
 Colorectal cancer LoVo  (Gao et al. 2010) 
   Nude mice SW-1116 cells (Zhenwu, Yuxin & LingJi 1997) 
 Liver cancer HepG2, Hep A-H  (Dou & Li 2004; Li et al. 2010c) 
  H22 Balb/c mice with H22 cells (Zhang et al. 2011) 
 Prostate cancer RM-1  (Shi et al. 2009) 
 Lung cancer  Nude mouse with A549 cells (Li et al. 2010a) 
 Larynx cancer AMC-HN-8, HEp-2  (Zhang et al. 2015) 
 
α-MMC 
 
Breast cancer 
 
MCF-7, MDA-MB-231, EMT-6 
 
Nude mouse (transplanted) 
 
(Cao et al. 2015; Deng et al. 2016) 
 Choriocarcinoma JAR  (Ng et al. 1994) 
 Nasopharyngeal cancer  CNE-2, HONE-1  (Pan et al. 2014) 
 Lung cancer A549, COR-L23  (Fan et al. 2015; Manoharan, Jaiswal 
& Singh 2014) 
 Retinoblastoma WeriRb-1  (Manoharan, Jaiswal & Singh 2014) 
 Glioblastoma 1321N1, Gos-3, U-87MG  (Manoharan, Jaiswal & Singh 2014) 
 
MCP30 
 
Prostate cancer 
 
PIN, RWPE-1, PC-3, LNCaP 
 
Male mouse with PC-3 cells 
 
(Xiong et al. 2009) 
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RIP Tumor Cell lines (in vitro) Animal (in vivo) References 
 
β-MMC 
 
Lung cancer 
 
COR-L23 
  
(Manoharan, Jaiswal & Singh 2014) 
 Retinoblastoma WeriRb-1  (Manoharan, Jaiswal & Singh 2014) 
 Glioblastoma 1321N1, Gos-3, U-87MG  (Manoharan, Jaiswal & Singh 2014) 
 
MAP30 
 
Choriocarcinoma 
 
JAR 
  
(Meng et al. 2012) 
 Bladder cancer 5637  (Hao et al. 2014) 
 Colorectal cancer LoVo  (Fan et al. 2008) 
 Lung cancer A549  (Fan et al. 2015) 
 Breast cancer MDA-MB-231 Mouse with MDA-MB-231 
cells 
(Lee-Huang et al. 1999) 
 Liver cancer 
 
Melanoma 
 
Myeloma 
 
Neuroblastoma 
 
Prostate cancer 
HepG-2, Hep-3B 
 
Malme-3M 
 
U266 
 
SK-N-SH 
 
DU145 
 
HepG2 bearing mice 
 
 
(Fang et al. 2012b) 
 
(Lee-Huang et al. 1995b) 
 
(Lee-Huang et al. 1995b) 
 
(Lee-Huang et al. 1995b) 
 
(Lee-Huang et al. 1995b) 
 
 
Cucurmosin 
 
Myeloid leukemia 
 
K567 
  
(Xie et al. 2011) 
 Pancreatic cancer CFPAC-1, PANC-1, BxPC-3  (Wang et al. 2014; Xie et al. 2013; 
Zhang et al. 2012) 
 
Gelonin 
 
Bladder 
 
T-24 
  
(Zhou et al. 2011) 
 Adenocarcinoma CT26, LS174T  (Shin et al. 2013) 
 Prostate cancer PC-3  (Shin et al. 2013) 
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RIP Tumor Cell lines (in vitro) Animal (in vivo) References 
 
MCL 
 
Nasopharyngeal cancer 
 
CNE-1, CNE-2 
 
Nude mouse (transplanted) 
 
(Fang et al. 2012a) 
 
α-luffin 
 
Breast cancer 
 
MCF-7 
 
 
 
(Liu et al. 2010) 
 Choriocarcinoma JEG-3  (Liu et al. 2010) 
 Liver cancer HepG2  (Liu et al. 2010) 
 
Saporin 
 
Breast cancer 
 
MCF-7 
  
(Gasperi-Campani et al. 1991) 
 Prostate cancer LNCaP, CWR22Rv1  (Kuroda et al. 2010) 
 Pancreatic cancer BxPC-3  (Lund et al. 2014) 
 Colon cancer WiDr  (Lund et al. 2014) 
 
Trichomislin 
 
Choriocarcinoma 
 
JAR 
  
(Mi et al. 2005) 
 
GAP31 
 
Breast cancer 
 
MDA-MB-231 
 
Mouse with MDA-MB-231 
cells 
 
(Lee-Huang et al. 1999) 
 
Cochinin B 
 
Cervical cancer 
 
Lung cancer 
 
HeLa 
 
NCI-H187 
  
(Chuethong et al. 2007) 
 
(Chuethong et al. 2007) 
 
Diocin-2 
 
Cervical cancer 
 
Choriocarcinoma 
 
HeLa 
 
CoLo320 
  
(Iglesias et al. 2016) 
 
(Iglesias et al. 2016) 
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Many cell membrane receptors are expressed at a very low level in normal cells but 
are overexpressed in the tumor cells. Estrogen receptor α (ERα) is a membrane 
receptor that plays an important role in breast carcinogenesis as more than 70% of 
breast cancer tissues express elevated levels of ERα compared to normal breast tissue 
(Ali & Coombes 2000). Number of drugs has been known that target ERα expressed 
on breast tumor tissue. Marmorin, type I RIP, from Hypsizigus marmoreus suppressed 
in vivo and in vitro growth of breast tumors. It induced apoptosis in mice bearing 
MDA-MB-231 tumor xenografts by suppressing the expression of ERα, inducing 
endoplasmic reticulum (ER) stress and activating mitochondrial and death receptor-
mediated apoptotic pathway. In addition, marmorin also inhibited angiogenesis by 
reducing the viability of human umbilical vein endothelial cells, suggesting that it has 
an anti-angiogenic and anti-metastatic potential (Pan et al. 2013). All these studies 
demonstrated that RIPs exhibit potential toxicity on breast tumor cells; however, none 
of these studies reported about the toxicity of RIPs on normal cells, which is 
considered as an important aspect before any therapeutic agent is considered for 
clinical trials. In one of the recent studies, it was demonstrated that α-MMC, a type I 
RIP exerts toxic effects on Balb/c mice. These studies revealed that α-MMC inhibited 
cell viability and induced apoptosis in breast cancer cells through cell cycle arrest and 
caspase-3 activation. In the xenograft tumor models, α-MMC demonstrated significant 
decrease in the tumor growth at a dose of 1.2 mg/kg and 0.8 mg/kg. However, further, 
in vivo toxicity experiments revealed that at a dose above 1.2 mg/kg, balb/c mice 
began to show signs of toxicity such as loss of body weight and changes in serum 
biochemical parameters, suggesting that α-MMC has a narrow therapeutic window in 
vivo, which could limits its use in clinical applications (Cao et al. 2015). Therefore, to 
reduce the toxic effects and achieve improved therapeutic efficacy, researchers 
modified α–MMC with polyethylene glycol (PEG) and investigated its anti-tumor 
efficacy in MDA-MB-231 transplanted tumor mouse models. They demonstrated that 
PEGylation increased plasma life and improved anti-tumor efficacy of α–MMC and 
mitigated non-specific toxicity, suggesting an alternative approach to reduce toxicity 
of RIPs on normal cells and improving the effectiveness of RIPs towards breast cancer 
treatment (Deng et al. 2016). 
 
Chapter 1 
32 
1.8.3.2 Effect on liver cancer 
RIPs from plants have also expressed in vivo and in vitro growth inhibitory activity 
towards liver cancer cells. MAP30 exerted both cytostatic and cytotoxic effects on 
human hepatocellular carcinoma HepG2 cells where the upregulation in the 
expression level of caspase-8, -9 and -3, and PARP after MAP30 treatment suggested 
that caspase-8 regulated extrinsic and caspase-9 regulated intrinsic cell death 
pathways were involved in MAP30 induced HepG2 cell apoptosis. Moreover, 
treatment of HepG2 cells with MAP30 resulted in activation of a serine/threonine 
kinase (Akt), p38 mitogen activated protein kinase (p38MAPK) and extracellular 
signal-regulated kinase (ERK), however, it did not had significant effect on JNK 
activation, suggesting that MAP30 induced apoptosis involves activation of Akt and 
MAPK/ERK signaling pathway, but not JNK signaling pathway in HepG2 cells. 
Further, MAP30 induced apoptosis resulted in reduction of tumor volume in HepG2 
bearing mice, which merits clinical trials of MAP30 in the management of liver cancer 
(Fang et al. 2012b). Similar studies showed that α-luffin could inhibit the growth and 
induce apoptosis in HepG2 cells in a dose dependent manner with an IC50 value 
7.03±1.03 µg/ml (Liu et al. 2010). Further, cucurmosin from Cucrubita moschata 
induced G0/G1 phase cell cycle arrest and apoptosis by increasing Bax protein 
expression and decreasing Bcl-2 and pro-caspase 3 expressions in HepG2 cells. In vivo 
studies demonstrated that cucurmosin significantly reduced tumor weight with an 
inhibitory rate of 78.4% observed in HepG2 bearing mice treated with 1 mg/kg 
cucurmosin (Xie et al. 2011). 
Dexamethosane is a drug used to treat various cancers. It was reported that 
dexamethosane could enhance TCS induced apoptosis in HepG2 cells. 
Dexamethosane may inhibit dissociation of nuclear factor kappa-light chain enhancer 
of activated B cells (NF-κB) in the cytoplasm and transcription of the IκB-α gene 
leading to suppression of NF-κB activation and enhanced TCS induced anti-tumor 
effect (Li et al. 2010c). Flow cytometry and chorioallantoic membrane assay studies 
showed that TCS could inhibit tumor growth and angiogenesis in BALB/c mice 
bearing H22 cells (Zhang et al. 2011). 
Not much has been reported about the potential cytotoxicity of RIPs on liver cancer 
cells, but based on these evidences, it could be anticipated that RIPs possibly have a 
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potential anticancer properties against human hepatoma. However, these studies 
further warrants detailed investigation of RIPs in the management of liver cancer. 
1.8.3.3 Effect on other cancer cells 
RIPs from plants have been effective against various other tumors including lung 
cancer, prostate cancer, choriocarcinoma, bladder cancer, cervical cancer, leukemia, 
colorectal cancer, pancreatic cancer and nasal pharyngeal cancer.  
Some early studies in the 20th century showed that TCS exerts significant inhibitory 
effects on HeLa cells (Dou & Li 2004). TCS induced apoptosis of HeLa cells through 
S phase cell cycle arrest and activation of caspase family mediated apoptosis that 
critically involved caspase-3, -8, and -9 (He & Li 2006). Other studies showed that 
TCS mediates apoptosis in HeLa cells by interfering with the PKC/MAPK and ER-
stress signaling pathway (Huang et al. 2010; Wang et al. 2009). Further investigations 
revealed that cAMP response element binding (CREB) protein plays an important role 
in TCS induced apoptosis in HeLa cells. CREB is involved in the regulation of Bcl-2 
expression. Usually, phosphorylation of CREB increases the expression of Bcl-2. 
However, TCS treatment decreased the phosphorylated CREB protein level and Bcl-2 
expression resulting in HeLa cell apoptosis (Wang, Xu & Zhang 2010). Interestingly, 
increased cytosolic calcium was also stimulated in TCS induced apoptosis that 
inhibited cAMP levels through suppression of adenylyl cyclase activity in HeLa cells 
(Jiang et al. 2011). In CaSki cervical cells, TCS arrested cell cycle at G1/G2 phase and 
upregulated Smac, a mitochondrial protein that promotes caspase activation in the 
caspase-9 apoptotic pathway (Cui et al. 2015; Peng et al. 2011). TCS also exerted 
antiproliferative activity in colorectal carcinoma LoVo cells in vitro (Gao et al. 2010). 
Further, the antitumor and immunomodulatory effect of TCS was studied in a murine 
lewis lung cancer model. The studies revealed that TCS inhibited cell proliferation, 
induced apoptosis and retarded tumor growth in the 3LL tumor model. The level of 
IFN-γ producing CD4+ and CD8+ T cells increased in tumor bearing mice. Moreover, 
TCS upregulated the expression of tumor suppressor lung cancer 1 (TSLC-1) and 
class-I restricted T cells associated molecule (CRTAM). It was further elucidated that 
TCS treatment enhanced antitumor immunity through TSLC-1 and CRTAM 
interaction, as blocking TSLC-1 expression with siRNA completely eliminated the 
effect of TCS on effector T cells (Cai et al. 2011). In vivo studies on Swiss-Df strain 
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nude mice transplanted with colorectal adenocarcinoma SW-1116 cells in subrenal 
capsules showed that TCS at a dose of 0.05 mg/kg was effective enough to inhibit the 
growth of tumor by 27.5% in this model (Zhenwu, Yuxin & LingJi 1997). Further, 
low concentration of TCS induced apoptosis in human epithelial type 2 (HEp-2) and 
AMC-HN-8 human laryngeal epidermoid carcinoma cells via activation of 
JNK/MAPK signaling pathway and S phase cell cycle arrest (Zhang et al. 2015).  
Interestingly, researchers have also attempted to explore the mechanism by which 
TCS enters inside the cancer cells. Dai and co-workers conjugated colloidal gold to 
TCS and found that TCS specifically enters cultured choriocarinoma JAR cells 
through receptor mediated endocytosis that enables rapid transport and accumulation 
of TCS in the JAR cells (Dai et al. 1993). Further in depth studies by other group 
confirmed that LDL receptor family members, LRP and megalin, mediate the entry of 
TCS in the cells (Chan et al. 2000; Chan, Huang & Tam 2003). Jiao and co-workers 
elaborated that LDL receptor related protein 1 (LRP1) is an essential receptor that is 
responsible for binding and internalization of TCS into JAR cells, which might be the 
molecular basis of the abortifacient and anti-choriocarcinoma activity of TCS. The 
results were further verified by silencing the LRP1 gene in the cells which ultimately 
blocked the binding and endocytosis of TCS (Jiao & Liu 2010). However, Xia and 
colleagues contradicted the above findings and reported that TCS has specificity for 
two proteins found on the surface of JAR cell and these proteins are neither LRP and 
megalin nor CCR5 (Xia et al. 2006). Production of ROS and influx of calcium were 
also stimulated in TCS induced apoptosis of human choriocarcinoma cells suggesting 
that generation of ROS is a calcium dependent process and is involved in TCS 
induced apoptosis in JAR cells (Chun-Yang et al. 2000; Zhang et al. 2001). Similarly, 
trichomislin from Trichosanthes kirilowii could also bind and enter JAR cells and 
induce apoptosis by releasing cyt-c from mitochondria and stimulating a cascade of 
caspases in JAR cells (Mi et al. 2005). Based on these evidences, it could be 
concluded that TCS has specificity for the receptors expressed on the surface of cancer 
cells, however, detailed investigation is required to identify precise mechanism by 
which TCS enters inside the choriocarcinoma cells. 
RIPs from Momordica charantia have also demonstrated to exhibit antitumor activity 
against various cancers. α-MMC and MAP30 from Momordica charantia could 
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inhibit the proliferation of human lung adenocarcinoma epithelial A549 cells. Cell 
cycle arrest at S phase and DNA fragmentation were the main apoptosis 
characteristics observed in α-MMC and MAP30 treated cells. However, MAP30 was 
found to be more potent in inhibiting tumor growth compared to α-MMC (Chuethong 
et al. 2007; Fan et al. 2015). In choriocarcinoma cells, α-MMC exhibited 
antiproliferative activity on JAR (human placental choriocarcinoma) cells (Ng et al. 
1994). The analysis of the effect of PEGylated and unPEGylated α-MMC and MAP30 
on JAR cells showed that PEGylated α-MMC and MAP30 were 21% and 25% more 
effective in inhibiting cell proliferation at the highest concentration tested compared to 
their native forms (Meng et al. 2012). In similar studies, α-MMC supressed the growth 
of normoxic and hypoxic nasopharyngeal carcinoma (NPC) by blocking the 
expression of growth factors (e.g. HIF1 α, VEGF and UPR) involved in survival 
signaling and stimulating apoptotic pathways mediated by mitochondria or death 
receptors (Pan et al. 2014). Interestingly, α- and β- MMC have also been found to be 
effective against various other tumors including glioblastoma, retinoblastoma, lung 
cancer and melanoma (Manoharan, Jaiswal & Singh 2014).   
Several other RIPs have also been reported to exhibit anti-tumor activity against 
various cancer cells. Cochinin B from Momordica cochinchinensis exerted strong 
antiproliferative activity on a human small lung cancer cell line (NCI-H187) with IC50 
of 574 mM (Chuethong et al. 2007). Li and colleagues demonstrated that TH-R 
(tianhua) extracted from Trichosanthes kirilowii inhibited proliferation of lung cancer 
cells. The protein inhibited cell growth and induced apoptosis via G0/G1 cell cycle 
arrest. Telomerase activation is an indication of carcinogenesis. Interestingly, it was 
found that TH-R could supress the telomerase activity in A549 cells, inhibiting the 
process of lung tumorgenesis (Li et al. 2010a). Similarly, the effect of cucurmosin, 
from Cucurbita moschata, was examined on chronic myeloid leukemia K562 cells. 
The cells treated with cucurmosin demonstrated cell shrinkage, cell cycle arrest, DNA 
fragmentation, activation of the caspase-3 cascade and decreased Bcl-2/Bax ratio that 
induced apoptosis in K562 cells (Xie et al. 2011). Nevertheless, the protein also 
triggered programmed cell death in human pancreatic cancer BxPC-3 and PANC-1 
cells by blocking epidermal growth factor receptor (EGFR) signaling pathway (Wang 
et al. 2014; Zhang et al. 2012). In addition, curcumosin downregulated the expression 
of proteins (e.g. PI3K, Akt, p-Akt, mTOR, p-mTOR, P70S6K-a, p-P70S6K-a, 4E-BP1 
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and p-4E-BP1) involved in P13K/Akt/mTOR signaling pathway resulting in apoptosis 
of human pancreatic cancer CFPAC-1 cells (Xie et al. 2013). 
HDAC (histone deacetylases) are a class of enzymes that catalyse the removal of 
acetyl groups from N-termini of histones resulting in chromatin condensation and 
transcriptional repression. HDAC1 is usually overexpressed in human premalignant 
and malignant lesions. HDAC inhibitors selectively induce apoptosis in neoplastic 
cells and are therefore recognized as a class of antitumor compounds. Recent studies 
showed that type I RIPs from plants also acts as HDAC inhibitors and can be 
employed in the treatment of prostate cancer. Momordica charantia protein 30 
(MCP30) isolated from bitter melon seeds has been shown to induce apoptosis in PIN 
and PCa cell lines in vitro. MCP30 inhibited HDAC1 activity and promoted histone 3 
and 4 protein acetylation. Interestingly, MCP30 also inhibited Akt phosphorylation, an 
essential step in the Akt signaling pathway that promotes survival and growth of 
cancer cells. The Akt pathway regulates Wnt signaling. MCP30 inhibited Wnt 
signaling activity through reduction of nuclear accumulation of β-catenin and 
decreased levels of c-Myc and cyclin-D1 (Xiong et al. 2009). These finding suggest 
that RIPs can also induce apoptosis by inhibiting HDAC apart from activating other 
protein kinases such as Akt, p38MAPK and ERK within the cancer cells, which could 
enhance its importance as a potent anticancer agent, however, side effect and toxicity 
of RIPs on normal cells remains a challenge. The section below describes various 
strategies employed to overcome these problems. 
1.9 RIPs from bioconjugates to nanoconstructs for cancer therapeutics 
RIPs exhibit anti-proliferative activity towards various cancer cells and the 
mechanism of apoptosis varies with the cancer cell type. Although several 
mechanisms involved in RIP-induced apoptosis have been elucidated, determination 
of optimal dose of RIPs and precise mechanism is necessary to establish the scientific 
basis for the potential application of RIPs in the treatment of cancer. Also, it becomes 
necessary to develop strategies that can enable selective targeting of RIPs to malignant 
cells in order to minimize its effects on normal biochemical events in the mammalian 
system.   
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Monoclonal antibody targeted therapy is one such approach that has been exploited 
for the treatment of cancer and involves combining monoclonal antibody to RIP to 
develop chimera with superior antigen binding and pharmacokinetic properties.  
Kuroda and his co-workers developed an immunotoxin by conjugating humanized 
anti-PSMA monoclonal antibody (hj591) to saporin. The treatment of prostate-specific 
membrane antigen (PSMA) positive cell lines, LNCaP and CWR22Rv1, with 
immunotoxin inhibited the growth of cells with IC50 of 0.14 nM and 1.99 nM, 
respectively. The population of apoptotic cells were found to be 60.29% and 40.73% 
in LNCaP and CWR22Rv1 cell lines, respectively. However, no such effect was 
observed in the PSMA negative cell line, PC-3. Also, hj591 coupled with streptavidin-
saporin (SAZAP), named as hj591-SAZAP immunotoxin, exhibited potent antitumor 
activity in LNCaP xenograft model (Kuroda et al. 2010), suggesting that conjugation 
of monoclonal antibody with RIPs could be an improved and effective therapy for 
cancer. Nevertheless, many problems such as competition between free antibodies and 
immunoconjugates in the recognition of target sites; decrease of intracellular cytotoxic 
RIPs and increase of side effects on several organs are associated with this approach. 
Protein or peptide conjugated RIPs is another strategy that has been employed to 
improve therapeutic application of RIPs. This approach involves fusion of RIPs with 
carriers such as cell binding ligands, hormones, protease inhibtors, etc, to develop a 
bifunctional cytotoxic agent that binds to specific receptors expressed on the surface 
of tumor cells. Transferrin receptor is widely distributed in different cell types and 
usually overexpressed in malignant cells. A transferrin receptor peptide (TfRBP) was 
fused to curcin, a type I RIP, to develop a conjugate that selectively inhibited the 
growth of HepG2 cells overexpressing transferrin receptor. Interestingly, this 
conjugate demonstrated low inhibitory effect on SKBR-3 cells expressing low levels 
of transferrin receptors (Zheng et al. 2013). MAP30 expressed in an E.coli 
BL21(DE3) strain demonstrated growth inhibitory effects and induce apoptosis in 
bladder cancer 5637 cells in a dose and time dependent manner (Hao et al. 2014). 
However, low efficiency of rMAP30 to penetrate into tumor cells restricted its 
tumoricidial effects. In recent studies, rMAP30 fused with human derived cell 
penetrating peptide (HBD) exhibited significant improvement in the cytotoxic activity 
of rMAP30 in tested cancer cell lines, HeLa, MCF-7, 5637, MGC 803, SMMC-7721 
and B16, compared to rMAP without HBD (Lv et al. 2015), suggesting that this could 
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be an alternative approach to increase the effectiveness of RIPs towards cancer cells, 
however, stability of peptide is a major issue that needs to addressed before this 
approach can be employed in the treatment of cancer. 
In recent years, considerable efforts have been made to develop nanoparticle based 
RIP delivery system. Apart from greater stability, greater surface area and ease of 
modification, this system renders intriguing features such as size, shape and 
biocompatibility. In a recent study, a type I RIP from Mirabilis jalapa L. leaves was 
incorporated into a nanoparticle conjugated with Anti-EpCAM antibodies. 
Nanoparticles were obtained by polyelectrolyte complexation of chitosan and alginate 
and then chemically conjugating with Anti-EpCAM antibody by carbodiimide 
reaction. The RIP nanoconjugate demonstrated selective cytotoxicity against T47D 
breast cancer cells with no cytotoxic effect on normal cells (Wicaksono et al. 2016). In 
other study, curcin, a type I RIP was incorporated into gold nanoparticles (AuNPs) 
conjugated with folate and anti-transferrin antibody to achieve nanoconjugate that had 
the ability to selectively target glioma cells with minimal non-specific systemic 
toxicity during circulation (Mohamed et al. 2014; Pizzo and Di Maro 2016)).  
Progressive development towards RIP based nanoconjugate system represents an 
innovative approach aimed to mitigate toxicity associated with the use of RIPs in 
cancer therapy. 
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1.10 Research objectives 
Keeping in view the therapeutic and agricultural applications of RIPs, the purification 
of RIPs from plants carries a great importance. Momordica balsamina is a medicinal 
and nutraceutical plant advocated for health care management, however it has not 
received major international attention (Puri 2010). This plant comprises tendril 
bearing high climbing vines. The leaves, seeds, bark and fruits of the plant contain 
large number of medicinal compounds such as phytochemicals (alkaloids, saponins, 
flavonoids, glycosides and terpenes) and type I RIP. These compounds contribute 
towards medicinal and nutritional properties, including anti-plasmodial, anti-
inflammatory, anti-diarrheal, anti-HIV, antioxidant, antimicrobial and 
hepatoprotective properties, of the plant (Thakur et al. 2009). Balsamin, a type-I RIP, 
isolated from Momordica balsamina constitute up to 15% of the total protein content 
in mature dry seeds (Kaur et al. 2012). Previous studies from our group have 
demonstrated that balsamin possesses potent anti-HIV activity and inhibits the 
translation step occurring prior to viral budding and release in the HIV-1 replication 
cycle (Kaur et al. 2013). In the present study, we extended the therapeutic application 
of balsamin from HIV to cancer with the following research objectives: 
1. Purification and functional analysis of natural balsamin (nBalsamin) from 
Momordica balsamina. 
2. Evaluation of cytotoxic effects of nBalsamin on liver and breast cancer cells. 
3. Molecular cloning, expression and functional analysis of recombinant balsamin 
(rBalsamin) from Momordica balsamina. 
4. Determination of anti-tumor activity of rBalsamin on liver and breast cancer cells. 
5. Evaluation of in vitro cytotoxicity of nBalsamin-flavonoids combination on liver 
and breast cancer cells. 
The studies carried out in this thesis are outlined in Figure 1.5. 
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Figure 1.5 Research outline and the corresponding chapters shown in the thesis. 
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Chapter 2: Purification and functional analysis of natural balsamin 
(nBalsamin) from Momordica balsamina.1
                                                          
1 This chapter has been published in the form of a research article in the Plant Foods 
for Human Nutrition journal. I exclusively conducted this work with the guidance of 
Prof. Munish Puri and Prof. Ken Walder. 
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Plant Foods for Human Nutrition 
 
Supplementary information 
 
 
 
Supplementary Figure 1: DPPH scavenging activity of ascorbic acid. All values 
are mean ± SD. SD, standard deviation; n = 3; *P = 0.002, Kruskal-Wallis test. 
 
 
 
Supplementary Figure 2: Superoxide radical scavenging activity of ascorbic 
acid. All values are mean ± SD. SD, standard deviation; n = 3; *P < 0.001, 
Kruskal-Wallis test. 
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Supplementary Figure 3: Reducing power ability of ascorbic acid. All values 
are mean ± SD. SD, standard deviation; n = 3; *P = 0.001, Kruskal-Wallis test. 
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Supplementary Figure 4: Antibacterial activity of different dilutions of 
balsamin against Staphylococcus aureus ATCC 25923 (A), Pseudomonas 
aeruginosa ATCC 27853 (B), Escherichia coli ATCC 2348 (C), Staphylococcus 
epidermidis ATCC 12228 (D), Salmonella enterica ATCC 43971 (E), Entercoccus 
faecalis ATCC 10100 (F). Disc 1, 2, 3 contains 50 μg/ml, 100 μg/ml, and 200 
μg/ml of balsamin respectively; disc 4 contains control PBS in each plate. 
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Supplementary Figure 5: Dose dependent inhibition of Staphylococcus aureus 
(A), Pseudomonas aeruginosa (B), Escherichia coli (C), Staphylococcus 
epidermidis (D), Salmonella enterica (E) and Enterococcus faecalis (F) with 
balsamin. All values are mean ± SD. SD, standard deviation; n = 3; *P < 0.05. 
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Additional information for Chapter 2: 
Methodology: 
Purification of natural balsamin (nBalsamin) from Momordica balsamina: 
Purification was performed according to Kaur et al. (2012) as shown in 
Supplementary Figure 6. Momordica balsamina seeds (10 g) were grounded into 
fine powder using a motor and pestle and homogenized in 50 ml of 150 mM NaCl. 
The slurry obtained was centrifuged at 12,000 X g for 20 min at 4°C. Following 
centrifugation, the proteins were precipitated from the supernatant with the addition 
of ammonium sulphate. The precipitate obtained after centrifugation was dissolved 
in 10 mM phosphate buffer (PB), pH 6.5 and dialysed against the same buffer. 
Following equilibration of a CM-Sepharose column with PB, pH 6.5, the dialysed 
sample was loaded onto the column and elution of unbound protein was carried out 
with PB, pH 6.5. The bound proteins were eluted using linear gradient of NaCl (0.1-
0.4 M) in PB, pH 6.5. The peak fractions containing the protein of interest (analysed 
by SDS-PAGE) were pooled, concentrated and loaded onto a Hi LoadTM 26/60 
SuperdexTM 75 prepacked column equilibrated with PB, pH 6.5. The eluted fractions 
with the desired protein were pooled, concentrated and further used to determine 
various enzymatic and biological activities.  
Protein concentrations were determined using bovine serum albumin as standard. 
The molecular weight of the purified protein was determined by SDS-PAGE using a 
12% separating gel. After electrophoresis, the gel was stained with Coomassie 
brilliant blue R-250 (CBB). 
Assay for RNA N- glycosidase activity 
The assay was performed as per Bagga et al. (2003). nBalsamin was incubated with 
rabbit reticulocyte lysate at 30°C for 30 min. 10% SDS (w/v) was added to terminate 
the reaction and total rRNA was extracted using an Ambion RNAqueous® Kit. The 
RNA obtained was divided into two parts where one part was treated with aniline 
acetate (pH 4.5) and the other part was left untreated. The samples were incubated at 
60°C for 3 min. The treated and untreated samples were analyzed on a 2% agarose 
gel and visualized using a Gel Doc™ XRS+ system (Bio-Rad, Hercules, CA, USA). 
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Supplementary Figure 6: Diagrammatic representations of purification 
strategy. 
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Biophysical characterization of nBalsamin 
Electrospray ionization- Time of flight (ESI-TOF) mass spectrometry 
ESI-TOF mass spectrometric analysis was carried out to determine the molecular 
weight of nBalsamin. All analyses were done on an Agilent 6220 ESI-TOF LC/MS 
mass spectrometer coupled to an Agilent 1200 LC system (Agilent, Palo Alto, CA) 
with the following experimental conditions: 
• Ionisation mode: Electrospray Ionisation 
• Drying gas flow: 7 L/min; 
• Nebuliser: 35 psi; 
• Drying gas temperature: 325°C; 
• Capillary Voltage (Vcap): 4000 V; 
• Fragmentor: 250 V; 
• Skimmer: 65 V; 
• OCT RFV: 250 V; 
• Scan range acquired: 100–3200 m/z 
• Internal Reference ions: Positive Ion Mode = m/z = 121.050873 & 922.009798 
• Chromatographic separation was performed using an Phenomenex Aeris 
Widepore-C4 2.1 x 150 mm, 3.6μm column (Phenomenex, NSW, Australia) 
using an acetonitrile gradient (5% (v/v) to 75% (v/v)) over 15 min at 0.25 
mL/min. 
• Solvent A = aqueous 0.1% (v/v) formic Acid 
• Solvent B = acetonitrile/0.1% (v/v) formic Acid 
All data were acquired and reference mass corrected via a dual-spray electrospray 
ionisation (ESI) source. Mass spectra were created by averaging the scans across 
each peak and background subtracted against the first 10 seconds of the TIC. 
Acquisition was performed using the Agilent Mass Hunter Acquisition software 
version B.02.01 (B2116.30) and analysis was performed using Mass Hunter version 
B.03.01. 
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Circular dichroism (CD) spectroscopy 
CD analysis of nBalsamin (450 μg/ml in 10 mM phosphate buffer, pH 6.5) was 
carried out on Jasco J-815 CD spectrometer (Jasco Inc., Easton, MD, US). Spectra in 
the far UV range (190-260 nm) were recorded at a scanning speed of 100 nm/min in 
1 mm path length cells. The analysis of CD spectrum was performed using Spectra 
managerTM software (Jasco). 
Fourier transform infrared (FTIR) spectroscopy 
The FTIR analysis of nBalsamin was performed to determine the functional groups 
present in the protein. FTIR measurements were performed using an Alpha FTIR 
spectrometer (Bruker Optik GmbH, Ettlingen, Germany). The FTIR spectra were 
acquired at 4 cm-1 spectral resolutions with 24 scans. Blackman-Harris 3-Term 
apodization, PowerSpectrum phase correction, and zero-filling factor of 2 were set 
as default acquisition parameters using the OPUS 7.0 software suite. Background 
spectra of a clean attenuated total reflection (ATR) surface and PB (pH 6.5) were 
acquired prior to sample measurement using the same acquisition parameters. 
Results and discussion 
Purification of nBalsamin 
nBalsamin was extracted from the seeds of Momordica balsamina as described by 
Kaur et al. 2012. Most of the protein precipitated at 60% ammonium sulphate 
saturation. After dialysis, the sample was subjected to CM-Sepharose column 
equilibrated with phosphate buffer (10 mM PB, pH 6.5). Most of the protein retained 
on CM-Sepharose column indicating that proteins collected is mainly basic in 
nature. Two peaks (BI and BII) were obtained using NaCl linear gradient (0.1-0.4 
M) (Supplementary Figure 7a). SDS-PAGE analysis revealed that peak BII 
contained nBalsamin (Supplementary Figure 7b). Peak BI fractions were pooled, 
concentrated and further purified using a Superdex 75 gel-filtration column. Two 
peaks (PI and PII) were obtained (Supplementary Figure 8a) and analysed by SDS-
PAGE (Supplementary Figure 8b). Peak PI fractions containing nBalsamin were 
pooled, concentrated and stored at -20°C until further analysis. The purified 
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nBalsamin showed a single band with a molecular weight corresponding to ~28 kDa 
by 12% SDS-PAGE (Supplementary Figure 8c). Multiple forms of RIPs from 
Momordica charantia, namely, α- MMC, β- MMC, γ- MMC, δ-MMC and ε-MMC 
and MAP30 have been reported (Kaur et al. 2012). Most of the RIPs possess 
molecular mass in the range of 24–30 kDa (Puri et al. 2009), indicating that the 
molecular weight of nBalsamin (28 kDa) is in agreement with the published data. 
 
Supplementary Figure 7: a) Profile of ion exchange chromatography of 
nBalsamin. Fractions corresponding to the peaks were pooled separately and 
denoted as BI and BII. b) SDS-PAGE of BI and BII fractions. Lane 1: marker, 
Lane 2: flow through, Lane 3-5: fractions from peak BI and Lane 6-9: fractions 
from peak BII. The arrow points to the nBalsamin. 
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Supplementary Figure 8: a) Profile of Superdex-75 gel filtration 
chromatography of nBalsamin. Fractions corresponding to the peaks were 
pooled separately and denoted as PI and PII. b) SDS-PAGE of PI and PII 
fractions. Lane 1 & 2: marker, Lane 3-6: fractions from peak PI and Lane 7-10: 
fractions from peak PII. c) SDS-PAGE of concentrated nBalsamin. Lane 1: 
marker, Lane 2: concentrated nBalsamin. The arrow points to the nBalsamin. 
ESI-TOF mass spectrometric analysis 
ESI-TOF mass spectrometric analysis was carried out to determine the molecular 
weight of nBalsamin. All analyses were done on an Agilent 6220 ESI-TOF LC/MS 
mass spectrometer coupled to an Agilent 1200 LC system (Agilent, Palo Alto, CA). 
The results revealed that the molecular weight of nBalsamin is 28.26 kDa, in 
agreement with the predicted molecular mass of nBalsamin by SDS-PAGE 
(Supplementary Figure 9) and the published data (Kaur et al. 2012).  
SDS-PAGE (Supplementary Figure 8c) and ESI-TOF mass spectrometric analysis 
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(Supplementary Figure 9) indicates that nBalsamin with greater than 95% purity was 
obtained through purification process. 
 
Supplementary Figure 9: ESI-TOF mass spectrometric analysis of nBalsamin. 
CD spectroscopic analysis 
CD spectroscopic analysis was carried out to determine the secondary structure of 
nBalsamin. CD spectra of nBalsamin indicated the presence of predominantly α-
helices and random coils. nBalsamin exhibited 35.2% α-helix, 19.6% β-sheet, 12.5% 
turn and 32.2% random coils at 25°C (Supplementary Figure 10), which was in 
agreement with the published data (Kaur et al. 2012). 
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Supplementary Figure 10: CD spectroscopic analysis of nBalsamin. 
FTIR spectroscopic analysis 
The functional groups present in the nBalsamin were identified by FTIR 
spectroscopy. Peaks recorded between 3000 and 3500 cm-1 were expected to be due to 
vibration modes of O-H and –NH groups present in the protein. Peak around 2971 cm-
1 depicted N-CH3 stretching. Peaks recorded around 1650 cm-1 arises mainly from -
C=O stretching vibration with minor modification from the out-of-phase C-N 
stretching vibration, the C-C-N deformation and the NH in-phase bend, and depicts 
amide I of the protein. Peaks recorded around 1542 cm-1 arises from out of phase 
combination of the -NH in plane bend and the C-N stretching vibration with minor 
contribution from the -C=O in plane bend and the C-C and N-C stretching vibrations, 
and depicts amide II of the protein (Supplementary Figure 11).  
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Supplementary Figure 11: FTIR spectroscopic analysis of nBalsamin. 
RNA N-glycosidase activity 
RNA N-glycosidase activity is a unique characteristic exhibited by RIPs. The activity 
was performed as described by Kaur et al. 2012. nBalsamin produced a specific RNA 
fragment of about 400 nucleotides, named Endo-fragment. The treatment of rRNA 
with nBalsamin resulted in removal of adenine thereby weakening the phosphodiester 
bond. Therefore no fragment appeared at this stage on a 2% agarose gel. Only after 
the treatment of rRNA with aniline was the bond cleaved resulting in generation of an 
Endo fragment (Supplementary Figure 12). These results were in agreement with 
previous reports on RIPs from different plant species (Choudhary, Yadav & Lodha 
2008; Sharma et al. 2004) confirming that nBalsamin extracted from Momordica 
balsamina belong to a family of ribosome inactivating proteins. 
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Supplementary Figure 12: RNA N-glycosidase activity of nBalsamin. rRNA was 
treated (+) with or without aniline (-) and analysed on a 2% agarose gel. The 
Endo-fragment generated after nBalsamin treatment is denoted with an arrow. 
Besides RNA N-glycosidase activity, nBalsamin demonstrated DNase-like activity 
in a concentration dependent manner. The DNase-like activity of nBalsamin was 
found to be temperature dependent with the complete conversion of the supercoiled 
form of plasmid to open circular and linear conformation observed in the 
temperature range of 35-45°C. However, below 35°C and above 45°C, partial 
conversion in the supercoiled form of plasmid was observed. It could be anticipated 
that increasing and decreasing the temperature outside the tolerable range might 
cause conformational changes and affect the chemical bonds in the active site of 
nBalsamin decreasing their specificity towards DNA. Further, the DNase-like 
activity of nBalsamin was found to be pH dependent with the pH range of 6.5-7.5 
observed to be optimum. The possible reason could be that the isoelectric focusing 
point (pI) of nBalsamin is 9.43. At pH below pI, nBalsamin establishes a net positive 
charge thereby increasing its specificity towards negatively charged DNA. However, 
lowering the pH outside the optimal range causes nBalsamin to denature resulting in 
loss of DNase-like activity.  
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Many enzymes require divalent metal ions for nuclease activity. It was found that 
the DNase-like activity of nBalsamin was dependent on Mg2+ as the exclusion of 
Mg2+ from the assay buffer completely inhibited balsamin activity. However, the 
activity was restored by the addititon of Mg2+, suggesting that divalent metal binding 
site(s) could be present in the DNA cleavage domain of nBalsamin. RIPs are known 
to depurinate adenine from highly conserved (GAGA) sequence in the stem loop 
region in 28S rRNA, resulting in inhibition of protein synthesis (Endo et al. 1987). 
Similarly, it is assumed that the DNase-like activity of nBalsamin possibly involves 
recognition and binding of DNA cleavage domain of nBalsamin to specific sequence 
in the DNA, and depurination of adenine from this sequence results in DNA 
damage. Nevertheless, further studies are required to understand the precise 
mechanism of DNase-like of nBalsamin and its possible involvement in biological 
proceeses. 
Besides enzymatic activities, nBalsamin exhibited antibacterial activity against 
various pathogens including S. aureus, S.enterica, S.epidermidis and E.coli. Further, 
the protein demonstrated free radical and superoxide radical scavenging activity in a 
dose dependent manner. Based on these findings, it can be inferred that nBalsamin 
with multifunctional properties could be considered as a nutraceutical or functional 
food ingredient that could find significant importance in preventing and slowing 
down the progress of various human diseases and bacterial infections. However, 
further investigation of the cytotoxicity of nBalsamin on diseased cells would be 
beneficial to explore its potential use in the field of therapeutics. 
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Chapter 3: Cytotoxic effects of nBalsamin from Momordica 
balsamina on liver and breast cancer cells. 
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3.1 Introduction 
RIPs are RNA N-glycosidases that have gained attention as potential therapeutic 
agents. A number of RIPs have been reported to inhibit tumor cell proliferation via 
inducing apoptosis in a variety of cancers, such as hepatoma, breast carcinoma and 
leukemia (Zeng et al. 2015). Some studies have also unveiled the mechanisms and 
pathways involved in RIP-induced apoptosis in tumor cells. MAP30 induced 
apoptosis in liver cancer cells via activation of both caspase-8 regulated extrinsic 
and caspase-9 regulated intrinsic apoptotic cascades (Fang et al. 2012b). α-MMC 
induced apoptosis in human breast cancer cells in vivo and in vitro by activating 
caspase-3 and arresting cell cycle at G0/G1 phase or G2/M phase (Cao et al. 2015). 
MCP30 evoked apoptosis in prostate cancer cells by inhibiting histone deacetylase 
and Wnt signaling activity (Xiong et al. 2009). Pan et al. (2013) demonstrated that 
marmorin activated the extrinsic apoptotic pathway and ER-stress induced apoptosis 
in both MCF-7 and MDA-MB-231 breast cancer cells (Pan et al. 2013). Cucurmosin 
downregulated the expression of PDGFR-β at the protein level and activated the 
PI3K/Akt/mTOR signaling pathway in cystic fibrosis pancreatic adenocarcinoma 
cells leading to apoptosis (Xie et al. 2013). TCS generated reactive oxygen species 
(ROS) and induced nitric oxide mediated apoptosis in human choriocarcinoma cells 
(Zhang et al. 2001). Thus, it is suggested that RIPs do not target a specific signaling 
pathway to induce apoptosis; rather the pathway varies with the type of RIP and 
tumor cell type. 
Balsamin, a type-I RIP, has been extracted from Momordica balsamina (Kaur et al. 
2012) (mentioned in Chapter 2, named nBalsamin). Studies have demonstrated that 
nBalsamin exhibited potent anti-HIV activity and inhibited the translation step 
occurring prior to viral budding and release in the HIV-1 replication cycle (Kaur et 
al. 2013). In our previous study, we reported that nBalsamin exhibits antioxidant, 
DNase-like and broad-spectrum antimicrobial activity (Ajji, Walder & Puri 2016). 
To further investigate its role as a potential therapeutic agent, we evaluated the 
cytotoxicity of nBalsamin on liver (HepG2 and H4IIE) and breast cancer (MCF-7 
and BT549) cells. 
Liver cancer is the sixth most common cancer and the third leading cause of cancer 
related deaths worldwide. Hepatocellular carcinoma (HCC) is one of the most 
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common forms of liver cancer. Around 6% of all types of cancer in men and 3% in 
women are HCC (Venook et al. 2010). Risk factors include cirrhosis, hepatitis B and 
C infections, aflatoxin, gender, hormones and obesity (Curry & Beattie 1996). Most 
cases of HCC (around 80%) are associated with chronic hepatitis B virus (HBV) or 
hepatitis C virus (HCV) infections. Approximately 5% of the world’s population is 
chronically infected with HBV and 2% with HCV (El-Serag 2012). The only therapy 
for HCC remains surgery that includes liver transplantation and partial liver 
resection. Although liver transplantation is considered the most efficient treatment in 
patients with small HCC (< 3cm), less than 30% of the patients are eligible for this 
treatment due to donor shortage, the expense of the procedure, tumor size and 
localization. For large HCC, liver resection is the preferred treatment, however, the 
treatment involves a high risk of deterioration in liver function after the operation 
(Belghiti & Kianmanesh 2005). Non-surgical therapies such as percutaneous ethanol 
injection and radiofrequency ablations are alternatives, but are not suitable for large 
peripheral lesions (>3cm in diameter) and moreover data on efficacy are limited. In 
addition, HCC has high resistance to conventional chemotherapy (Ryder 2003). All 
of these therapies have limitations associated with their use. Therefore, in this study, 
we investigated the efficacy of nBalsamin on HepG2 and H4IIE liver cancer cells.  
Breast cancer is also one of the most prevalent and severe health problems in women 
worldwide with an estimated 1.67 million new cancer cases diagnosed in 2012 (25% 
of all cancers). Since 2008, the worldwide incidence of breast cancer has increased 
by more than 20% with the death rate increased by 14% (www.bcrfcure.org/breast-
cancer-statistics).  Despite novel drugs being developed as first-line therapies for 
breast cancer, drawbacks such as metastasis and relapse make breast cancer a major 
challenge (Kretowski et al. 2016; Qu et al. 2014).  
Keeping in view the limitations involved in the treatment of cancer, identification 
and development of a single natural plant product that can be used to treat various 
cancers is highly desirable. Therefore, in this study, we investigate the antitumor 
potential of nBalsamin on two different cancer cell types, liver (HepG2 and H4IIE) 
and breast (MCF-7 and BT549) cancer cells.   
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3.2 Materials and methods 
3.2.1 Chemicals, reagents and kits 
RPMI, DMEM media and FBS were purchased from Life Technologies Corporation 
(California, USA). Trypsin, In vitro toxicology assay kit, Caspase-3 assay kit and 
Caspase-8 assay kit were purchased from Sigma-Aldrich (USA). DNeasy and total 
RNA isolation kit were purchased from Qiagen (Hilden, Germany). Propidium 
iodide (PI) flow cytometry kit was procured from BD Biosciences (San Jose, CA). 
Reagents for electrophoresis were procured from Bio-Rad Laboratories (California, 
USA). All other reagents were purchased from either Sigma-Aldrich (USA) or Bio-
Rad Laboratories (California, USA) and were of analytical grade. 
3.2.2 Cell lines and cell culture 
Liver (HepG2 and H4IIE) and breast (MCF-7 and BT549) cancer cells used were 
obtained from the American Type Culture Collection (ATCC) (Rockville, MD). 
HepG2 and H4IIE cells were maintained in RPMI medium supplemented with 10% 
FBS, in an atmosphere of 5% CO2 at 37°C. The cells were grown in T-25 flasks until 
80% confluence and split 1:10 in culture dishes before assays were performed. 
MCF-7 and BT549 cells were maintained in DMEM supplemented with 10% FBS, 
in an atmosphere of 5% CO2 at 37°C. The cells were grown in T-25 flasks until 80% 
confluence and split 1:4 in culture dishes before assays were performed. 
3.2.3 Cell viability/proliferation assay  
Liver (HepG2 and H4IIE) and breast (MCF-7 and BT549) cancer cells were seeded 
in a 6-well plate at a density of 1 X 105 cells per well and incubated overnight at 
37°C in 5% CO2. After incubation, the media was aspirated and fresh media was 
added to each well. The cells were treated with increasing concentrations (3.125-200 
µg/ml) of nBalsamin and PBS (control) for 24 h, 48 h and 72 h. After incubation, the 
media was discarded and cell viability was determined using an In vitro toxicology 
(MTT based) assay kit. For this, 45 µl media and 5 µl of MTT reagent was added in 
each well. The plates were incubated at 37°C for 2 h. After incubation, the resulting 
formazan crystals were dissolved in 50 µl of MTT solubilisation reagent. 
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Absorbance was measured at 570 nm and 690 nm. The background absorbance of 
each well at 690 nm was subtracted from the 570 nm measurements. The % 
inhibition of cell viability was calculated with the formula: 
% inhibition of cell viability = (1- Absample - Abblank / Abcontrol – Abblank) X 100 
Results were expressed as mean ± standard deviation. Each experiment was 
performed in triplicate. 
For the cell proliferation assay, counting of total cell number was performed using a 
haemocytometer after treatment of cells with nBalsamin (3.125-200 µg/ml) and PBS 
(control). Results were expressed as mean ± standard deviation. Each experiment 
was performed in triplicate. 
3.2.4 DNA fragmentation assay 
Liver (HepG2 and H4IIE) and breast (MCF-7 and BT549) cancer cells were seeded 
in a 6-well plate at a density of 1 X 105 cells per well and incubated overnight at 
37°C in 5% CO2. The cells were then treated with nBalsamin at a final concentration 
of 6.25 µg/ml, 25 µg/ml or 100 µg/ml for 48 h, and harvested for genomic DNA 
extraction using DNeasy kits (Qiagen). Briefly, the cells were suspended in 200 µl 
of 1X PBS and 0.6 U/µl proteinase K. To this, 200 µl of Buffer AL was added. The 
suspension was vortexed and incubated at 56°C for 10 min. After incubation, 200 µl 
of 100% ethanol was added to the suspension. The suspension was then applied to 
the spin column and centrifuged at 10,000 X g for 1 min. The flow through was 
discarded and the column was washed with 500 µl of Buffer AW1 and 500 µl of 
Buffer AW2. Finally, 30 µl of nuclease free water was added to the column and 
DNA was eluted by centrifugation at 10,000 X g for 1 min. DNA was analysed on 
1.5% agarose gel and the image of the gel was captured in a Gel Doc™ XRS+ 
system (Bio-Rad, Hercules, CA, USA). 
3.2.5 Cell cycle analysis 
Cell cycle analysis was performed according to the manufacturer’s instructions (BD 
Biosciences, San Jose, CA). Briefly, liver (HepG2 and H4IIE) and breast (MCF-7 
and BT549) cancer cells were seeded in 6-well plates at a density of 2 X 105 cells per 
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well and incubated overnight at 37°C in 5% CO2. The cells were then treated with 
6.25 µg/ml, 25 µg/ml or 100 µg/ml of nBalsamin and PBS (control) for 48 h. After 
48 h, the cells were harvested by centrifugation at 500 X g for 5 min and fixed in 1 
ml of 66% ice-cold ethanol for 2 h. After incubation, the cells were centrifuged at 
500 X g for 5 min to remove the ethanol and washed twice with PBS. The cells were 
then stained with propidium iodide (PI) medium (50 µg/ml PI in PBS, containing 10 
µg/ml RNase A) and incubated at 37°C in the dark for 20-30 min before analysis. 
Finally, the cells were analyzed on a FACSCantoTM II (BD Biosciences, US) and PI 
fluorescence was collected. The data was analyzed using FCS Express 4 software. 
3.2.6 Caspase-3 and -8 activity assay 
Caspase-3 and -8 activity was measured according to the manufacturer’s instructions 
(Sigma-Aldrich, USA). Liver (HepG2 and H4IIE) and breast (MCF-7 and BT549) 
cancer cells were seeded in a 24-well plate at a density of 6 X 104 cells per well. The 
plates were placed overnight at 37°C in 5% CO2. After incubation, the cells were 
treated with 6.25 µg/ml, 25 µg/ml or 100 µg/ml of nBalsamin and PBS (control) for 
48 h. Media was aspirated from each well and 100 µl of 1X lysis buffer (50 mM 
HEPES, pH 7.4, 5 mM CHAPS and 5 mM DTT) was added. The cells were 
incubated on ice for 20 min and scraped from the surface to ensure proper lysis. The 
suspension was then transferred in an eppendorf tube and centrifuged at 16,000 X g 
for 15 min at 4°C. The supernatant was transferred into fresh tubes and stored at - 
80°C for further analysis. 
The caspase-3 activity assay was carried out in 96 well plates. To 5 µl of cell lysate 
from each treatment or caspase-3 positive control, 85 µl of 1X assay buffer (20 mM 
HEPES, pH 7.4, 0.1% CHAPS, 5 mM DTT and 2 mM EDTA) was added. The 
reaction was initiated by adding 10 µl of 2 mM caspase-3 substrate (acetyl-Asp-Glu-
Val-Asp p-nitroanilide) to each well. The plates were covered and incubated at 37°C 
for 2 h. After incubation, absorbance was measured at 405 nm. The caspase-3 
activity was calculated as µmol of p-nitroaniline (pNA) released (obtained from 
pNA calibration curve) per min per ml of cell lysate or positive control based on the 
formula: 
Caspase-3 activity, µmol pNA/min/ml = µmol pNA x d / t x v 
where: 
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v - volume of sample in ml 
d - dilution factor 
t - reaction time in minutes 
The caspase-8 activity assay was performed in 96 well plates. To 10 µl of cell lysate 
from each treatment or caspase-8 positive control, 80 µl of 1X assay buffer (20 mM 
HEPES, pH 7.4, 0.1% CHAPS, 5 mM DTT, 2 mM EDTA and 5% sucrose) was 
added. The reaction was initiated by adding 10 µl of 2 mM caspase-8 substrate 
(Acetyl-Ile-Glu-Thr-Asp p-nitroaniline) to each well. Absorbance was measured at 
405 nm (t = 0). The plates were then placed at 37°C for 30 min. After incubation, 
absorbance was measured at 405 nm (t = 35 min). The caspase-8 activity was 
calculated as nmoles of pNA released (obtained from pNA calibration curve) per 
minute per ml of cell lysate or positive control based on the formula: 
Caspase-8 activity (nmole/min/ml) = (At – A0) x d / (A1 nmole) x t x v 
where: 
v = volume of sample in ml 
d = dilution factor 
t = reaction time in minutes 
A1 nmol = absorbance of 1 nmole of pNA in the well 
At = absorbance at time t minutes 
A0 = absorbance at zero time 
3.2.7 RNA extraction and RT-PCR 
Liver (HepG2 and H4IIE) and breast (MCF-7 and BT549) cancer cells were seeded 
in 24 well-plates at a seeding density of 6 X 104 cells per well and incubated 
overnight at 37°C in 5% CO2. After incubation, the cells were treated with 6.25, 25 
or 100 µg/ml of nBalsamin and PBS (negative control) for 48 h. After treatment, the 
media was removed and the cells were washed with PBS. The total RNA from each 
sample was extracted using a Total RNA isolation kit based on the manufacturer’s 
protocol. For this, 400 µl of RLT buffer was added to each well. The lysate was 
collected in the centrifuge tube and centrifuged at 16,000 X g for 3 min to remove 
debris. An equal volume of 64% ethanol was then added to the supernatant. The 
suspension was applied to the mini-isolation column and centrifuged at 16,000 X g 
for 30 sec. The flow through was discarded and the column was washed with 700 µl 
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of RW1 buffer and twice with 500 µl RPE buffer. Finally, the spin column was dried 
by centrifugation at 16,000 X g for 30 sec. The spin column was then transferred to a 
fresh collection tube for RNA elution. 30 μl of nuclease free water was added to the 
column, incubated for 1 min and then centrifuged at 16,000 X g for 1 min.   
RNA of each sample was subjected to first strand complementary DNA (cDNA) 
synthesis using a Maxima H minus first strand cDNA synthesis kit in a total volume 
of 20 µl. Reverse transcription reaction was performed at 50°C for 30 min, followed 
by 85°C for 5 min and 4°C for 5 min. PCR amplification of the newly synthesised 
cDNA was performed using the primers listed in Table 3.1. PCR, in a total volume 
of 10 µl, was carried out at 95°C for 7 min, 40 cycles at 95°C for 30 s and 60°C for 
1 min, 60°C for 60 s, 55°C-95°C (hold time: 1 s, temperature increment after hold: 
0.2°C) and 20°C for 10 s. Results were expressed as mean ± standard deviation with 
each sample tested in replicates of six. 
Table 3.1: Primers used for qRT-PCR 
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3.2.8 Statistical analysis 
Data was analysed using SPSS Statistics software version 22.0. Data was assessed 
for normality using Kolmogorov-Smirnov test. Two-way analysis of variance was 
used to compare the mean difference between groups that have been separated on 
two independent factors. One-way analysis of variance (ANOVA) was used to 
compare the mean difference among multiple groups and repeated measurements 
within one group. Probability values less than 0.05 were considered statistically 
significant. 
3.3 Results and discussion 
3.3.1 nBalsamin inhibits liver and breast cancer cell proliferation and viability 
Recent statistics revealed that cancer is one of the leading causes of deaths 
worldwide. In Australia, 130,466 new cancer cases and 46,880 cancer deaths are 
expected to occur in Australia in the current year (http://www.aihw.gov.au/). The 
most common treatment available is chemotherapy that involves the use of anti-
cancer drugs to weaken and destroy cancer cells. However, drawbacks such as toxic 
side effects and development of resistance to chemical agents limit its effectiveness 
(Chabner & Roberts 2005). Thus, the development of naturally occurring therapeutic 
agents is highly desirable. In recent years, RIPs have gained increasing attention as 
they target conserved host protein synthesis machinery, which makes it difficult to 
develop drug resistance, a common problem observed during chemotherapy. 
Moreover, it has been reported that RIPs exhibit low or no detectable side effect on 
normal cells as they recognize specific receptors expressed on the surface of tumor 
cells, which makes them a promising tool for cancer therapeutics (Fang et al. 
2012b). RIPs from many plants have shown antitumor activity (Akkouh et al. 2015; 
Fan et al. 2008; Lee-Huang et al. 1999). TCS, a type-I RIP exhibits anti-tumor 
activity against various tumor cell lines including cervical carcinoma, breast 
carcinoma, hepatoma, colon carcinoma, choriocarcinoma, melanoma, prostate 
carcinoma, lung carcinoma and stomach adenocarcinoma (Sha et al. 2013). α-MMC 
possesses anti-tumor activity against breast cancer, lung carcinoma, nasopharyngeal 
cancer, retinoblastoma and glioblastoma (Akkouh et al. 2015; Cao et al. 2015; 
Manoharan, Jaiswal & Singh 2014). However, this is the first study carried out to 
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investigate the anti-tumor effects of nBalsamin on liver (HepG2 and H4IIE) and 
breast (MCF-7 and BT549) cancer cells.  
To determine the potential cytotoxicity of nBalsamin on these cancer cell lines, the 
growth inhibitory effects of nBalsamin were evaluated. The results showed that 
nBalsamin inhibited the growth of HepG2, H4IIE, MCF-7 and BT549 cells in a 
dose-dependent manner with a maximum effect observed on MCF-7 cells (Figure 
3.1). Based on this, we further evaluated the cytotoxicity of nBalsamin on these cell 
lines using an In vitro toxicology assay kit. 
 
Figure 3.1: Effect of different concentrations of nBalsamin on the growth of 
HepG2 (a), H4IIE (b), MCF-7 (c) and BT549 (d) cells after 48 h treatment. All 
values are mean ± SD. SD, standard deviation; n = 3. 
The results showed that nBalsamin exhibited the potential to inhibit cell viability in 
all the four cell lines in a time and dose dependent manner (Figure 3.2). After 24 h 
treatment with nBalsamin, the IC50s for the HepG2, H4IIE, MCF-7 and BT549 
cancer cell lines were 183.09 µg/ml, 372.41 µg/ml, 179.47 µg/ml and 399.41 µg/ml 
respectively. After treatment with nBalsamin for 48 h, the IC50s for the HepG2, 
H4IIE, MCF-7 and BT549 cancer cells were 60.95 µg/ml, 72.97 µg/ml, 49.40 µg/ml 
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and 103.54 µg/ml respectively. To further investigate the effect of treatment time on 
cell viability, cell viability was determined after 72 h of treatment. The IC50s 
observed were 33.12 µg/ml, 28.50 µg/ml, 24.53 µg/ml and 32.79 µg/ml for HepG2, 
H4IIE, MCF-7 and BT549 cells, respectively (Figure 3.2), suggesting that 
nBalsamin exhibits significant antiproliferative effects on HepG2, H4IIE, MCF-7 
and BT549 cells, however, the degree of cytotoxicity varies with cancer cell type. 
Based on this, we further attempted to explore the main cause of death in these cells, 
which could be apoptosis, necrosis or autophagy. Since RIPs are known to cause cell 
death through apoptosis, we decided to further align our studies towards 
investigating the key hallmarks of apoptosis in nBalsamin treated liver and breast 
cancer cells.  
 
Figure 3.2: Effect of different concentrations of nBalsamin on the viability of 
HepG2 (a), H4IIE (b), MCF-7 (c) and BT549 (d) cells after 24 h, 48 h and 72 h 
treatment. All values are mean ± SD. SD, standard deviation; n = 3; *P < 0.001, 
main effect of protein concentration; main effect of time; interaction between 
nBalsamin and time, Two-way ANOVA. 
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3.3.2 nBalsamin induces changes in apoptotic morphology and causes DNA 
fragmentation in liver and breast cancer cells.  
Apoptosis is characterized by a series of morphological changes in the cell (Saraste 
& Pulkki 2000). Therefore, we examined the morphology of HepG2, H4IIE, MCF-7 
and BT549 cells after nBalsamin treatment. Brightfield microscopy showed that the 
cells in the negative control (PBS) grew well, and were in dense and uniform 
arrangement. However, after treatment with 6.25, 25 or 100 µg/ml of nBalsamin, the 
number of cells decreased significantly with increasing nBalsamin concentration. 
Cells treated with nBalsamin-exhibited characteristics of apoptosis, including cell 
shrinkage, cavitation and a decrease in cell connections. More dead cells and less 
adherent cells were observed in treated cells compared to untreated cells (Figure 
3.3). 
 
Figure 3.3: Morphology of HepG2, H4IIE, MCF-7 and BT549 cells treated with 
different concentrations of nBalsamin (6.25, 25 and 100 µg/ml) for 48 h.  
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In addition, DNA fragmentation into different size fragments is one of the 
biochemical hallmarks of apoptosis (Zhang & Ming 2000). Therefore, the genomic 
DNA of HepG2, H4IIE, MCF-7 and BT549 cells, treated with 6.25, 25 or 100 µg/ml 
of nBalsamin and PBS (control) was extracted and analysed on a 1.5% agarose gel. 
As shown in Figure 3.4, cells treated with different concentrations (6.25, 25 or 100 
µg/ml) of nBalsamin for 48 h resulted in degradation of DNA into small 
oligonucleosomal fragments. Treated cells showed characteristic DNA laddering 
with a significant amount of DNA fragments appearing around the 180-200 bp 
interval on an agarose gel compared to untreated cells with intact DNA (Figure 3.4, 
Lane C), suggesting that DNA damage could be one reason for apoptosis in 
nBalsamin treated liver and breast cancer cells. 
 
Figure 3.4: DNA fragmentation in HepG2 (a), H4IIE (b), MCF-7 (c) and BT549 
(d) cells treated with different concentrations of nBalsamin for 48 h. M and C 
denotes marker (1 KB DNA ladder) and control, respectively. 
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3.3.3 nBalsamin induces cell cycle arrest in liver and breast cancer cells  
Cell cycle is a key regulator of processes crucial to cell survival, including the 
detection and repair of DNA damage, cell proliferation and cell migration. The 
molecular events that regulate the cell cycle are ordered and directional. Any 
dysregulation of cell cycle machinery can lead to the development of cancer (Boehm 
& Nabel 2001). The induction of cell cycle arrest leading to apoptosis is a common 
mechanism through which a number of anticancer drugs inhibit tumor growth (Gerl 
& Vaux 2005). It has been reported that a variety of natural occurring plant proteins 
can arrest cell cycle in G0/G1, S or G2/M phase and then induce apoptosis of cancer 
cells (Zeng et al. 2015).  Therefore, we determined the proportion of nBasamin-
treated HepG2, H4IIE cells, MCF-7 and BT549 cells in different phases of the cell 
cycle. Cell cycle analysis revealed that nBalsamin arrested HepG2 cells in G phase 
as a significant dose dependent increase in the cell number was observed in G phase, 
after 48 h of treatment. Arrest of G phase was accompanied by a dose dependent 
decrease in the number of HepG2 cells in S phase, with no significant changes 
observed in M phase (Figure 3.5a). Compared to HepG2 cells, H4IIE, MCF-7 and 
BT549 cells had increased cell numbers in S phase in a dose dependent manner and 
decreased in G phase, which indicated that nBalsamin induced S phase cell cycle 
arrest in these cells after 48 h of nBalsamin treatment (Figure 3.5b, 3.6a and b).  
Furthermore, an increase in the proportion of apoptotic cells was observed in 
nBalsamin treated HepG2, H4IIE, MCF-7 and BT549 cells compared to untreated 
cells, suggesting that nBalsamin induces apoptosis in these cells, however, the extent 
of apoptosis and the phase of cell cycle arrest varies with different cell types. Similar 
evidence has been reported with other RIPs. α-MMC from Momordica charantia 
blocks cell cycle at G phase in MDA-MB-231 cells and M phase in MDA-MB-453 
and MCF-7 breast cancer cells (Cao et al. 2015). While in lung (A549) cancer cells, 
α-MMC induces cell cycle arrest at S phase (Fan et al. 2015), suggesting that the 
mode of action of RIPs could vary in different cancer cell types.  
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Figure 3.5: Cell cycle analysis of HepG2 (a) and H4IIE (b) cells treated with 
different concentrations of nBalsamin for 48 h. All values are mean ± SD. SD, 
standard deviation; n = 3; *P < 0.007; **P < 0.05, One-way ANOVA. 
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Figure 3.6: Cell cycle analysis of MCF-7 (a) and BT549 (b) cells treated with 
different concentrations of nBalsamin for 48 h. All values are mean ± SD. SD, 
standard deviation; n = 3; *P < 0.001; **P = 0.001, One-way ANOVA. 
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3.3.4 nBalsamin induced apoptosis involves activation of caspases in liver and 
breast cancer cells. 
Apoptosis, also known as programmed cell death, is one of the most fundamental 
biological processes that occurs in response to external stimuli. Apoptosis can occur 
via caspase dependent and caspase independent mechanisms. Caspase-3, a key 
effector that is activated by several initiator caspases, such as caspase-8, is activated 
in apoptotic cells by the extrinsic (death ligand) pathway, and caspase-9 is activated 
in apoptotic cells by the intrinsic (mitochondrial) pathway, resulting in apoptosis 
(McIlwain, Berger & Mak 2013; Porter & Jänicke 1999). Since RIPs have been 
reported to induce caspase-mediated apoptosis in cancer cells, we determined the 
activity of caspase-3 and -8 in nBalsamin treated liver and breast cancer cells.  
nBalsamin significantly increased the activity of caspase-3 (P < 0.001) in HepG2, 
H4IIE, MCF-7 and BT549 cells in a dose dependent manner. The effect appeared to 
be more pronounced in H4IIE cells compared to HepG2, MCF-7 and BT549 cells 
(Figure 3.7a). Furthermore, nBalsamin significantly increased the activity of 
caspase-8 (P < 0.001) in HepG2, H4IIE, MCF-7 and BT549 cells in a dose 
dependent manner. The effect was similar and appeared to be more pronounced in 
liver (HepG2 and H4IIE) cancer cells compared to breast (MCF-7 and BT549) 
cancer cells (Figure 3.7b). An increase in the activity of caspase-8 coupled with an 
up-regulation of caspase-3 suggested that nBalsamin induced the death receptor 
(extrinsic) apoptotic pathway in liver and breast cancer cells. However, activation of 
caspase-3 can also be due to activation of a cascade of caspases or regulation of 
genes involved in the mitochondrial (intrinsic) cell death pathway. Therefore, to 
discover whether nBalsamin activates the mitochondrial apoptotic pathway in liver 
and breast cancer cells, we investigated the expression of pro-apoptotic and anti-
apoptotic genes involved in the mitochondrial cell death pathway. 
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Figure 3.7: Effect of different concentrations of nBalsamin on caspase-3 (a) and 
caspase-8 (b) activity in HepG2, H4IIE, MCF-7 and BT549 cells after 48 h 
treatment. All values are mean ± SD. SD, standard deviation; n = 3; *P < 0.001, 
One-way ANOVA. 
3.3.5 nBalsamin regulates the expression of various apoptotic genes involved in 
the mitochondrial cell death pathway 
The tumor suppressor gene p53 plays a significant role in the regulation of 
apoptosis. It has been reported that DNA damage can lead to activation of p53. p53 
normally exists in inactive form that does not have the ability to bind to DNA and 
activate transcription. In response to DNA damage, the ability of p53 to bind to 
DNA increases leading to activation of genes that initiate apoptosis (Lakin & 
Jackson 1999). Our studies showed that nBalsamin damages DNA, therefore, we 
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further investigated if this damage could activate p53 expression in nBalsamin 
treated liver and breast cancer cells. The qRT-PCR results showed the expression of 
p53 significantly increased in HepG2 (P < 0.007), H4IIE (P < 0.05), MCF-7 (P < 
0.007) and BT549 (P < 0.007) cells in a dose dependent manner with the effect 
appearing to be more pronounced in liver cancer cells compared to breast cancer 
cells (Figure 3.8a). 
Caspase-8 is a major activator of Bid, cleaving Bid to an active form called tBid, that 
initiates the transcription of genes involved in mitochondrial cell death pathway 
(Kantari & Walczak 2011; Wei et al. 2000). In addition, it has been reported that 
p53-mediated apoptosis can also lead to an increase in the expression of Bid (Sax et 
al. 2002). Therefore, we further determined the expression of Bid in nBalsamin 
treated liver and breast cancer cells. The qRT-PCR results showed that nBalsamin 
significantly increased the expression of Bid in HepG2 (P < 0.007), H4IIE (P < 
0.05), MCF-7 (P < 0.007) and BT549 (P < 0.007) cells in a dose dependent manner. 
The effect appeared to be more pronounced in HepG2 cells compared to other cell 
lines (Figure 3.8b). 
Apart from p53 and Bid, Bcl-2 family genes also regulate the process of apoptosis. 
The genes associated with the Bcl-2 family can be either pro-apoptotic (Bax, Bak 
and Bok) or anti-apoptotic (including Bcl-2, Bcl-XL, and Bcl-W) and govern 
mitochondrial outer membrane permeabilization, which is a key indicator of the 
mitochondrial cell death pathway (Czabotar et al. 2014; Hong, Park & Lyu 2014). 
Therefore, we determined the expression of pro-apoptotic and anti-apoptotic markers 
in nBalsamin treated liver and breast cancer cells. The results showed that 
nBalsamin significantly increased the expression of Bax in HepG2 (P < 0.007), 
H4IIE (P < 0.007), MCF-7 (P < 0.007) and BT549 (P < 0.007) cells in a dose 
dependent manner. The effect appeared to be more pronounced in HepG2, H4IIE 
and BT549 compared to MCF-7 cells (Figure 3.9a). Further, the expression of Bad 
was also observed to increase significantly in HepG2 (P < 0.007), MCF-7 (P < 
0.007) and BT549 (P < 0.007) cells in a dose dependent manner. The expression 
tended to increase in H4IIE cells, however, the results were not significant 
demonstrating that nBalsamin does not activate Bad in H4IIE cells (Figure 3.9b).  
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Figure 3.8: Expression of p53 (a) and Bid (b) genes in HepG2, H4IIE, MCF-7 
and BT549 cells treated with different concentrations of nBalsamin for 48 h. All 
values are mean ± SD. SD, standard deviation; n = 3; *P < 0.007; **P < 0.05, 
One-way ANOVA. 
In addition, we also evaluated the expression of anti-apoptotic genes (Bcl-2 and Bcl-
XL) involved in the mitochondrial cell death pathway. The qRT-PCR results showed 
that nBalsamin significantly decreased the expression of Bcl-2 and Bcl-XL in MCF-7 
(P < 0.007) and BT549 (P < 0.007) cells in a dose dependent manner with the 
similar effects observed in both cell lines (Figure 3.10a and b).  
However, in the case of liver cancer cells, the level of Bcl-2 expression tended to 
decrease in nBalsamin treated HepG2 and H4IIE cells compared to control (Figure 
3.10a). A trend for an increase in the expression of Bcl-XL was observed in 
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nBalsamin treated H4IIE cells, however, it appeared opposite in HepG2 cells (Figure 
3.10b). However, none of these results were statistically significant. Based on these 
findings, it can be concluded that nBalsamin regulates the expression of anti-
apoptotic genes in breast (MCF-7 and BT549) cancer cells but not in liver (HepG2 
and H4IIE) cancer cells. 
 
Figure 3.9: Expression of Bax (a) and Bad (b) genes in HepG2, H4IIE, MCF-7 
and BT549 cells treated with different concentrations of nBalsamin for 48 h. All 
values are mean ± SD. SD, standard deviation; n = 3; *P < 0.007; **P < 0.05, 
One-way ANOVA. 
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Figure 3.10: Expression of anti-apoptotic genes, Bcl-2 (a) and Bcl-XL (b), in 
HepG2, H4IIE, MCF-7 and BT549 cells treated with different concentrations of 
nBalsamin for 48 h. All values are mean ± SD. SD, standard deviation; n = 3; 
*P < 0.007, One-way ANOVA. 
3.3.6 nBalsamin induces ER-stress mediated apoptosis in liver cancer cells but 
not in breast cancer cells. 
The endoplasmic reticulum (ER) is a cell organelle that plays a significant role in 
cell function, including the synthesis, post-translational modification and proper 
folding of proteins, and transport of newly synthesised proteins to the Golgi 
apparatus (Shiraishi et al. 2006). Several ER chaperone proteins, such as Hsp70 
family members GRP78, protein disulphide isomerase (PDI) and the peptidylpropyl 
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isomerase family are involved in the correct folding of newly synthesised proteins. 
However, perturbations in ER function, such as viral infection, redox dysregulation, 
nutrient deprivation and calcium dysregulation or over-expression of proteins, can 
lead to ER stress (Kober, Zehe & Bode 2012). When ER function is severely 
affected, the organelle evokes apoptotic signals. One of the most important 
mediators in ER-stress mediated apoptosis is C/EBP homologous protein (CHOP), 
also known as DNA damage-inducible gene 153 (GADD153). CHOP forms a 
heterodimer with various other C/EBP family members and acts as a dominant 
negative inhibitor of transcription. CHOP is usually expressed at undetectable levels, 
however, its expression is induced by cellular stress (Bento, Andersson & Aman 
2009). The 78-kDa glucose regulated protein (GRP78), also known as BiP, is a 
major regulator of ER function, as it forms complex with heterologous proteins that 
are processed through the ER. It is involved in protein folding and assembly, 
targeting misfolded proteins for degradation and regulating the activation of ER 
stress signals. In response to ER stress, GRP78 expression is upregulated to assist 
proper protein folding and it is considered to be an important component involved in 
ER-stress induced apoptosis (Li & Lee 2006). 
In order to assess whether nBalsamin induces ER-stress mediated apoptosis in liver 
and breast cancer cells, we determined the expression of CHOP and GRP78 in 
nBalsamin treated cells. The qRT-PCR results confirmed that nBalsamin 
significantly increased the expression of both GRP78 and CHOP in a dose 
dependent manner in liver cancer, HepG2 (P < 0.001) and H4IIE (P < 0.001), cells. 
However, nBalsamin neither affected the expression of GRP78 nor CHOP in breast 
cancer, MCF-7 and BT549, cells (Figure 3.11 a and b). These results suggest that, in 
addition to activation of intrinsic and extrinsic apoptotic pathways, nBalsamin-
induced apoptosis also involves activation of an ER stress-mediated pathway in liver 
cancer cells but not in breast cancer cells. Overexpression of CHOP has been 
reported to lead to a decrease in the levels of Bcl-2. Moreover, increased levels of 
CHOP leads to translocation of Bax protein from the cytoplasm to the mitochondria. 
Thus, CHOP mediated apoptotic signals are finally transmitted to the mitochondria, 
which act as an amplifier and integrator of apoptosis (Oyadomari & Mori 2004; 
Shiraishi et al. 2006). Hence, it could be anticipated that overexpression of CHOP is 
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linked to activation of the mitochondrial cell death pathway in nBalsamin treated 
liver cancer, HepG2 and H4IIE, cells. 
 
Figure 3.11: Expression of genes involved in ER-stress mediated apoptosis, 
GRP78 (a) and CHOP (b), in HepG2, H4IIE, MCF-7 and BT549 cells treated 
with different concentrations of nBalsamin for 48 h. All values are mean ± SD. 
SD, standard deviation; n = 3; *P < 0.001, One-way ANOVA. 
Although several RIPs are known to exhibit anti-proliferative activity and induce 
apoptosis in cancer cells by activating various apoptotic pathways, however, toxicity 
and side effect of RIPs to normal cells remains a challenge (Zeng et al. 2015). This 
could also be one possible problem associated with the use of nBalsamin in cancer 
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therapy. Various strategies have been employed to tune the selectivity of RIPs to 
cancer cells. Antibody targeted therapy is one such approach that has been used to 
develop RIP immunotoxin and involves conjugation of RIP to monoclonal antibody 
that specifically binds to the antigen expressed on the surface of cancer cells. 
Humanized anti-PSMA monoclonal antibody (hj591) was fused with saporin, a type 
I RIP, to develop immuntoxin that had specificity towards PSMA positive LNCaP 
and CWR22Rv1 cell lines and not towards PSMA negative cell line, PC-3 (Kuroda 
et al. 2010).  Nevertheless, problems such as generation of immune response, 
decrease of intracellular cytotoxic RIPs and increase of side effects on several 
organs are associated with this approach. 
Protein or peptide conjugated RIPs is another approach that has been used to 
improve therapeutic applications of RIPs. This strategy involves fusion of RIPs with 
carrier such as cell binding ligands, hormones and protease inhibitors to develop a 
bifunctional cytotoxic agent that binds to specific receptors expressed on the surface 
of tumor cells. A transferrin receptor peptide (TfRBP) was fused to curcin, a type I 
RIP, to develop a conjugate with improved selectivity towards HepG2 cells 
overexpressing transferrin receptors. This conjugate demonstrated low inhibitory 
effect on SKBR-3 cells expressing low levels of transferrin receptors (Zheng et al. 
2013). Nonetheless, stability of peptide is a major issue that restricts the use of this 
approach. 
Similiar strategies could be employed to tune the selectivity of nBalsamin to cancer 
cells. However, drawbacks associated with these approaches might limit the use of 
nBalsamin in cancer therapeutics. In recent years, efforts have been made to develop 
nanoparticle based RIP delivery system. Apart from greater stability, greater surface 
area and ease of modification, this system renders intriguing features such as size, 
shape and biocompatibility. Keeping in view the versatile and durable nature of 
nanoconstructs, the development of nanoparticle based nBalsamin delivery system 
carries a great importance. Thus, in the near future, our research will be focused in 
this area. 
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3.4 Conclusions 
The present study identifies the role of nBalsamin in exerting anti-tumor effects on 
hepatoma (HepG2 and H4IIE) and breast cancer (MCF-7 and BT549) cells, and its 
associated mechanism of action. The results indicated that nBalsamin could inhibit 
the growth and viability of liver and breast cancer cells in a dose and time dependent 
manner. nBalsamin could induce cell cycle arrest at G phase in HepG2 cells and S 
phase in H4IIE, MCF-7 and BT549 cells. Based on our findings, it may be proposed 
that nBalsamin induces apoptosis through three mechanisms: (i) by activating the 
extrinsic cell death pathway as indicated by increased level of caspase-8 leading to 
activation of the downstream effector caspase-3, (ii) by inducing the intrinsic 
apoptotic pathway as manifested by upregulaton of Bax, Bid, Bad and p53 and 
downregulation of Bcl-2 and Bcl-XL and (iii) by triggering ER-stress mediated 
apoptosis in liver cancer cells and not in breast cancer cells, as indicated by 
overexpression of CHOP and GRP78. The signaling pathways involved in 
nBalsamin-induced apoptosis in liver and breast cancer cells are summarized in 
Figure 3.12a and b. This characteristic of nBalsamin might prove beneficial in the 
treatment of liver and breast cancer, as the cells would be less likely to mutate and 
develop resistance compared to other chemotherapeutic agents that activate a 
specific apoptotic pathway. Moreover, compared to synthetic drugs, natural products 
such as nBalsamin can be added as a valuable dietary supplement in the diet of 
cancer patients for the treatment of cancer. Further analysis of nBalsamin-induced 
apoptosis and in vivo studies are needed to develop this biomolecule as an effective 
therapeutic and/or functional food. 
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Figure 3.12: Signaling pathways involved in nBalsamin-induced apoptosis in 
liver (a) and breast (b) cancer cells.  
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Chapter 4: Molecular cloning, expression and functional analysis of 
recombinant Balsamin (rBalsamin) from Momordica balsamina. 
  
Chapter 4 
 
92 
4.1 Introduction 
Balsamin isolated from Momordica balsamina is a type-I RIP that can inhibit HIV-1 
replication at the translation step occurring prior to viral budding and release (Kaur 
et al. 2013). Our recent studies have shown that natural balsamin (nBalsamin) also 
possesses antibacterial and DNase-like activity (Ajji, Walder & Puri 2016), 
however, the amount of nBalsamin in Momordica balsamina seeds is limited. 
Moreover, recovery and purification of balsamin from natural sources involves 
multiple purification steps that compromises protein yield. Heterologous protein 
expression in a suitable recombinant strain offers an attractive alternative with 
higher yields, shorter fermentation time and cheaper production costs. Therefore, in 
this study the balsamin gene was cloned and expressed, and the biological functions 
of recombinant balsamin (rBalsamin) were investigated. 
Several RIP genes from Momordica species have been cloned and expressed in 
E.coli. α-MMC was the first gene to be cloned using a λgt11 cDNA library 
constructed from Momordica charantia seeds, followed by its mass production in a 
heterologous system, the E.coli Rosetta (DE3) pLysS strain (Ho et al. 1991; Wang et 
al. 2012). The MAP30 gene was cloned in a pET-28 vector and expressed in E.coli 
BL21(DE3) cells (Han et al. 2011). In other studies, MAP30 was fused with the 
human-derived cell penetrating peptide (HBD) to overcome the low uptake 
efficiency by tumor cells and improve the cytotoxicity of MAP30 (Lv et al. 2015). In 
our previous studies, we investigated the anti-tumor effect of nBalsamin on liver and 
breast cancer cells. However, to explore animal studies and clinical trials a large 
quantity of pure protein is required. Thus, in this study we attempted heterologous 
expression of balsamin. 
Immobilized metal affinity chromatography (IMAC) is a versatile technology used 
for industrial scale purification of proteins fused to short affinity tags consisting of 
polyhistidine residues and provides high specificity and ease of purification (Chaga 
2001). A polyhistidine tag consists of at least 6 histidine residues, often fused at the 
N- or C-terminus of the protein. The ability of histidine residues to bind to an 
immobilized metal ion matrix with high affinity in the presence of denaturing agents 
and mild elution conditions has made the His-tag a powerful tool for protein 
purification (Bornhorst & Falke 2000). The immobilization of a His-tag on an IMAC 
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matrix is a rapid and inexpensive method used to study protein-protein interactions 
and to purify recombinant proteins with up to 95% purity (Porath et al. 1975). 
In this study, we describe an IMAC based method of obtaining a biologically active 
rBalsamin from an E.coli expression system. In addition, physicochemical 
parameters were optimized to obtain maximum expression of balsamin. Further, 
biophysical characterization of rBalsamin and its other functional properties were 
investigated. Of all expression systems, E.coli was used for this study because of its 
advantage over other host cells, namely fast growth kinetics, ease of transformation 
with exogenous DNA and low cost of rich complex growth medium.  
Here we report the successful heterologous expression of balsamin in E.coli. It is 
noteworthy that the cloning and expression of His-tagged rBalsamin has not been 
attempted before. This study carries great importance as it not only enables large-
scale production of balsamin, but also a versatile system for genetic manipulation in 
the rational development of this potential therapeutic agent. 
4.2 Materials and methods 
4.2.1 Enzymes, chemicals and purification kits 
All chemicals used in this study were of analytical grade and were obtained from 
either Sigma-Aldrich (St. Louis, MO, USA) or Bio-Rad Laboratories (Hercules, CA, 
USA). DNA modifying enzymes and DNA markers were from New England 
Biolabs Inc (Ipswich, MA, USA). Precision PlusTM dual colour protein marker was 
from Bio-Rad Laboratories (Hercules, CA, USA). Restriction enzymes (BamHI and 
XhoI) and pET- 30a(+) were procured from Novagen Inc. (Wisconsin, USA). 
RNAqueous® Total RNA Isolation Kit was obtained from Life Technologies 
Corporation (California, USA). Plasmid DNA purification kit, QIAquick PCR 
purification kit and QIAquick gel extraction kit were from Qiagen Pty. Ltd. (Hilden, 
Germany). MasterPure™ DNA Purification Kit was from Epicentre (Wisconsin, 
USA). Immobilized metal affinity gel (Ni2+ Sepharose 6 fast flow) and Hi LoadTM 
26/60 SuperdexTM 75 preparation grade column were procured from GE Healthcare 
(Little Chalfont, UK). 
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4.2.2 Bacterial strains 
E.coli DH10β and BL21(DE3) were obtained from New England Biolabs Inc. 
(Ipswich, MA, USA). Bacterial strains Salmonella enterica ATCC 43971, 
Entercoccus faecalis ATCC 10100, Staphylococcus aureus ATCC 25923, 
Staphylococcus epidermidis ATCC 12228, Escherichia coli ATCC 2348 and 
Pseudomonas aeruginosa ATCC 27853 were procured from American Type Culture 
Collection (Rockville, MD).  
4.2.3 Molecular cloning of the gene encoding balsamin 
4.2.3.1 Genomic DNA extraction 
Genomic DNA was extracted from Momordica balsamina seeds using MasterPure™ 
DNA Purification Kit. Seeds were ground to powder form under liquid nitrogen. 500 
μl of lysis buffer and 2 μl of RNase were added to 50 mg of seed powder and 
incubated at 65°C for 30 min. After incubation, the sample was placed on ice for 10 
min and 200 μl of protein precipitation reagent was added. The suspension was 
vortexed for 10 sec and centrifuged at 10,000 X g for 15 min. To the supernatant, an 
equal volume of phenol: chloroform: isoamyl alcohol (25:24:1) was added followed 
by centrifugation at 10,000 X g for 15-20 min. The aqueous layer obtained after 
centrifugation was transferred into a fresh eppendorff tube and mixed with an equal 
volume of 100% ethanol. The sample was placed at -20°C for 30-45 min and then 
centrifuged at 10,000 X g for 15-20 min at 4°C to obtain a DNA pellet.  The pellet 
was washed with 70% ethanol, air dried under laminar airflow and resuspended in 
35 μl of Milli Q water. 5 μl of the above sample was visualized on a 0.8% agarose 
gel. 
4.2.3.2 Agarose gel electrophoresis 
Integrity and quality of isolated genomic DNA was checked by agarose gel 
electrophoresis. A 0.8% agarose gel (50 ml) was prepared in 1X TAE buffer (40 mM 
Tris, pH 7.6, 20 mM acetic acid and 1 mM EDTA) in an Erlenmeyer flask using a 
microwave oven. The gel was allowed to cool and 2.5 μl of 10 mg/ml of ethidium 
bromide was added with proper mixing. The gel was poured into a horizontal gel 
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electrophoresis tray with a comb inserted in place and allowed to stand at room 
temperature until solidified (covered with aluminium foil).  After solidification, the 
comb was removed and the gel was placed in the electrophoresis chamber. The 
chamber was filled with 1X TAE buffer until the wells were fully submerged. 1 μg 
of genomic DNA sample was mixed with 2 μl of 6X DNA loading dye (40% sucrose 
and 0.04% bromophenol blue) and loaded into the respective well with 1KB DNA 
ladder. Electrophoresis was carried out at 100 V for 50 min. After electrophoresis, 
the DNA was visualized under UV light using a Gel Doc™ XRS+ system (Bio-Rad, 
Hercules, CA, USA). 
4.2.3.3 PCR gene amplification 
Seven different degenerate PCR primers were designed for balsamin (Bal) gene 
amplification based on published data (Barthelemy et al. 1993; Han et al. 2011; Liu 
et al. 2010; Nolan, Garrison & Better 1993; Poyet & Hoeveler 1997; Poyet, Radom 
& Hoeveler 1994; Wang et al. 2012). The list of forward and reverse primers used is 
given in Table 4.1. The PCR reaction was performed in 50 μl volume containing; 0.5 
μg of genomic DNA as template, 0.5 μM each of forward and reverse primer, 1 μl of 
10mM dNTP, 1.5 μl of DMSO, 0.02 U/μl of Phusion DNA polymerase, 10 μl of 5X 
Phusion HF buffer and 30 μl of Milli Q water. The PCR procedure included: 98°C 
for 2 min as initial denaturation, 35 cycles at 98°C for 15 sec (denaturation), 65°C 
for 30 sec (annealing), 72°C for 60 sec (extension) and then 72°C for 5 min as a 
final extension step. Finally, the PCR products were analyzed by electrophoresis on 
a 0.8% agarose gel.  
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Table 4.1 Degenerate primers used for balsamin gene amplification. 
Gene Primer sequence 
MAP 
Forward primer: 5’-CATGCGGGATCCATGGTGAAATGCTTAC-3’ 
Reverse primer: 5’-CGAGCCTCGAGTCAATTCACAACAG-3’ 
Gel 
Forward primer: 5’-CATGCGGGATCCACYTGRTCNACNGCNGTNACRTARTAYTTYTT-3’ 
Reverse primer: 5’-CGAGCCTCGAGTTYAARGAYGCNCCNGAYGCNGCNTAYGARGG-3’ 
Sap 
Forward primer: 5’-CATGCGGGATCCCTGCAGAATTCGCATGGATCCTGCAAT-3’ 
Reverse primer: 5’-CGAGCCTCGAGCTGCAGAATTCGCCTCGTTTGACTACTTTG-3’ 
Luf 
Forward primer: 5’-CATGCGGGATCCCAGATGTGAGGTTCAGTTTGTCAGGT-3’ 
Reverse primer: 5’-CGAGCCTCGAGCGCAACATTTTGTTTGTA-3’ 
PAP 
Forward primer: 5’-CATGCGTCCCTTCAGCTGATAAATACGATCACCTTTGATC-3’ 
Reverse primer: 5’-CGAGCCTCGAGCGGGATCCGAATCCTTCAAATAGATCAC-3’ 
Mom 
Forward primer: 5’-CATGCGGGATCCGATGTTAGCTTTCGTTTG-3’ 
Reverse primer: 5’-CGAGCCTCGAGTTAGGGCATTCTAGTAGCTC-3’ 
PAPII 
Forward primer: 5’-CATGCGGGATCCATRTAYTTRAATCTIGCIGCYT-3’ 
Reverse primer: 5’-CGAGCCTCGAGTGAAYATHGTITTYGAYGTIGARAA-3’ 
MAP: Momordica antiviral protein; gel: gelonin; sap: saporin; Luf: α-luffin; PAP: pokeweed antiviral protein; Mom: α –momorcharin and PAPII: 
pokeweed antiviral protein II.
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4.2.3.4 Extraction and purification of DNA fragments from an agarose gel 
The gene fragments obtained after PCR were purified from the gel using a QIAquick 
gel extraction kit. The DNA fragment of interest was excised from the agarose gel 
using a clean razor blade and placed in 2 ml eppendorff tubes and 3 volumes of 
buffer QG was added to 1 volume of gel. To help dissolve the gel, the sample was 
incubated at 50°C with regular mixing every 2-3 min until completely dissolved. 
The sample was then applied to a QIAquick spin column and centrifuged for 1 min 
at 10,000 X g for proper binding of DNA to the column. After centrifugation, the 
flow through was discarded and the column was washed with 750 μl of Buffer PE by 
centrifugation at 10,000 X g for 60 sec. The above step was repeated for proper 
column washing. The spin column was then dried by centrifugation at 10,000 X g 
for 1 min and transferred to a fresh collection tube for DNA elution. 30 μl of milliQ 
water was added to the centre of the column. After 2 min, the column was 
centrifuged as before. The DNA fragment was stored at -20°C.  
4.2.3.5 DNA sequencing 
The samples (prepared by mixing 0.5 μg DNA template; 0.5 μM forward primer; 2.5 
μl Milli Q water) were sent to Macrogen Inc. (Seoul, Korea) for sequencing.  
4.2.3.6 Primer design and DNA amplification 
Specific sense and antisense primers were designed to obtain balsamin mature 
peptide: forward primer: 5’-CGGGATCCATGTTTATCAAAGC-3’; and reverse 
primer: 5’-CAGCTCGAGTTAGGAGCTGAAGCCT-3’. The underlined bases in 
the primers were designated as BamHI and XhoI restriction sites, respectively.  The 
PCR reaction mixture was performed in 50 μl volume containing; 0.5 μg of DNA 
fragment (sequenced), 0.5 μM each of specific forward and reverse primer, 1 μl of 
10mM dNTP, 1.5 μl of DMSO, 0.02 U/μl of Phusion DNA polymerase, 10 μl of 5X 
Phusion HF buffer and 30 μl of Milli Q water. The PCR procedure included: 98°C 
for 1 min (initial denaturation), 30 cycles at 98°C for 10 sec, 64°C for 20 sec, 72°C 
for 45 sec and then 72°C for 5 min as a final extension step. The PCR product was 
analyzed on a 0.8% agarose gel and purified from the gel using a QIAquick gel 
extraction kit as described in section 4.2.3.4. 
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4.2.3.7 Restriction digestion and ligation of amplified gene and pET-30a(+) 
Digestion of DNA and pGEM-T with restriction enzymes was performed using type 
II restriction endonucleases. The sample volume and the amount of enzyme were 
adjusted according to the amount of DNA. The restriction mixture consisted of 1 μg 
of DNA/ pGEM-T, 1X digestion buffer (enzyme specific), 10 U/μl BamHI and XhoI 
restriction enzymes, Milli Q water to make the final volume to 50 μl. The restriction 
digestions were performed for 4 h at 37°C. The DNA fragments obtained after 
restriction digestion of DNA and pGEM-T were directly analyzed by agarose gel 
electrophoresis and purified from the gel using a QIAquick gel extraction kit as 
described in section 4.2.3.4. 
The ligation reaction was performed by using T4 ligase, which catalyzes the 
formation of a phosphodiester bond between 3'-OH and free 5'-phosphate of double-
stranded DNA fragments. The ligation reaction mixture consisted of 50 ng vector 
DNA, 150 ng insert, 1.5 μl of 10X T4 DNA ligase buffer, 10 U/μl T4 DNA ligase, 
nuclease-free water to make the final volume to 20 μl. The components were mixed 
and incubated overnight at 16°C for ligation. The ligated product (pGEM-T-Bal) 
was then transformation into E.coli DH10β. Besides colony PCR with vector-
specific primers, the correct insertion of Bal gene was confirmed by DNA 
sequencing (Macrogen, Inc., South Korea). The plasmid was double digested and 
directionally subcloned between the BamHI and XhoI sites of the pET-30a(+) vector, 
as described above. The recombinant vector thus generated was designated pET-Bal. 
4.2.3.8 Preparation of competent cells 
Competent cells were prepared from the BL21(DE3) strain of E.coli bacteria using 
the calcium chloride method. 50 μl of E.coli BL21(DE3) culture was inoculated in 5 
ml of Luria-Bertani (LB) broth and incubated overnight at 37°C at 250 rpm in a 
shaker incubator. The next day, 0.5 ml of these cells were cultured in 50 ml of LB 
broth and incubated at 37°C at 250 rpm until the O.D600nm reached between 0.4-0.6. 
After incubation, the culture was transferred to a 50 ml falcon tube (pre-chilled) and 
placed on ice for 30 min. The culture was then centrifuged at 4000 X g and 4°C for 
15 min. The supernatant was discarded and 5 ml of 0.1 M calcium chloride solution 
(cold) was added to the pellet and mixed gently. The suspension was further placed 
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on ice for 30 min and then centrifuged at 4000 X g at 4°C for 15 minutes. The 
supernatant was discarded and 2 ml of 0.1 M calcium chloride containing 20% 
glycerol (cold) was added to the pellet and mixed gently. From this, 50 μl aliquots 
were prepared in 1.5 ml pre-chilled eppendorff tubes and stored at -80°C until 
further use. 
4.2.3.9 Transformation of competent cells 
Transformation of ligated products into E.coli BL21(DE3) was carried out using the 
heat shock method. Around 100 ng of the ligated product was mixed with competent 
E.coli BL21(DE3) (thawed on ice for 10 min) and incubated on ice for 30 min. The 
cells were given heat shock for 45 sec at 42°C followed by incubation on ice for 5 
min. 950 μl LB broth was added to the cells and incubated at 37°C and 250 rpm for 
45 min. After incubation, 100 μl of the bacterial suspension was spread onto LB agar 
plates containing kanamycin. The plates were incubated overnight at 37°C. 
4.2.4 Expression of rBalsamin and optimization of parameters 
For bacterial expression of the gene encoding Balsamin, pET-Bal was transformed 
into freshly prepared E.coli BL21(DE3) competent cells. A single colony harbouring 
the pET-Bal recombinant plasmid was inoculated into 20 ml of LB broth containing 
50 μg/ml of kanamycin and grown overnight at 37°C and 250 rpm. The next day, the 
overnight culture was inoculated into 500 ml of LB broth containing 50 μg/ml of 
kanamycin at a ratio 1:100 and grown at 37°C and 250 rpm until an OD600nm of 0.4-
0.6 was reached. Protein expression was induced by addition of isopropyl β-D-1-
thiogalactopyranoside (IPTG). Culture conditions, such as growth temperature 
(20°C, 25°C, 30°C and 37°C), IPTG concentration (0.2, 0.4, 0.6, 0.8 and 1.0 mM) 
and culture time (4, 8, 12, 16 and 20 h) were optimized for the production of 
rBalsamin. After induction, the cells were harvested by centrifugation at 12,000 X g 
for 20 min at 4°C. The cell pellet was dissolved in lysis buffer (50 mM Tris-HCl 
buffer, pH 7.5, 300 mM NaCl and 20 mM imidazole) and the cells were disrupted 
using an ultra-sonicator (Vibra-Cell VCX 500, Sonics, USA). Sonication was 
performed for 15 min at 30% amplitude using a 3mm tapered micro tip probe. After 
sonication, the cells were centrifuged at 12,000 X g for 15 min at 4°C. Samples of 
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the soluble (supernatant) and insoluble (cell pellet) fractions were analysed by SDS-
PAGE.  
The insoluble fraction obtained after centrifugation was dissolved in buffer A (50 
mM Tris-HCl buffer, pH 7.5, 300 mM NaCl, 20 mM imidazole and 8M urea) and 
stirred at room temperature for 30 min for cell disruption. The suspension was then 
centrifuged at 12,000 X g for 20 min at 4°C and then passed through a 0.22 µm 
filter. 
4.2.5 Purification of rBalsamin  
4.2.5.1 Ni2+ affinity chromatography 
Immobilized metal affinity chromatography (IMAC) is a common technique used to 
purify proteins fused to a His-tag. Since the rBalsamin included an N-terminal His-
tag, therefore Ni2+ Sepharose 6 fast flow was used for purification. A suspension of 
Ni2+ Sepharose 6 fast flow was poured gently in the column of dimensions 10 X 1.5 
cm through the sides avoiding bubble formation and plugging the column at the 
bottom with a stopper. The Ni2+ Sepharose 6 fast flow was allowed to settle to make 
a bed and the column was then flushed with 10-column volumes of Milli Q water. 
Once the resin in the column settled, the column was equilibrated with 30-40 ml 
buffer A (50 mM Tris-HCl buffer, pH 7.5, 300 mM NaCl, 20 mM imidazole and 8M 
urea). The protein solution was loaded on the top of Ni2+ Sepharose column and 
incubated for 1 h for effective binding of the proteins to the matrix. To remove the 
unbound protein, the column was washed with 5-column volumes of buffer A. To 
refold the bound protein on the column, the column was washed with 5-column 
volumes of linear gradient of urea (8-0 M) in buffer A. The bound proteins were 
then eluted from the column using 15 ml of Buffer B (50 mM Tris-HCl buffer, pH 
7.5, 300 mM NaCl, and 250 mM imidazole). The protein content in each fraction 
was measured using the Bradford method (1976) and analysed on SDS-PAGE. 
Finally, the fractions were concentrated using an ultrafiltration membrane (Amicon 
Ultra-15, 10 kDa, US) and stored at -20⁰C until further use. 
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4.2.5.2 Gel filtration chromatography 
Gel filtration is a simplest and mildest chromatographic technique used to separate 
molecules based on their size and molecular weight. In our study, a Hi LoadTM 26/60 
SuperdexTM 75 prepacked column was used for further purification of rBalsamin. 
Prior to its use, the tubing connected to the column and the pump valves (A1, A2, 
B1, and B2) was flushed with distilled water to remove any salt residues left over 
from previous runs. Using a syringe and a needle, the sample loop was flushed with 
ethanol and then with water. The column was washed with 2 column volumes of 
20% ethanol (degassed) and 2 column volumes of distilled water (degassed). Once 
the prewashing cycles were complete, the column was equilibrated with 2 column 
volumes of 50 mM Tris-HCl, pH 7.5 (degassed). Using a syringe and needle, 2 ml of 
concentrated fraction was loaded onto the column. The protein was eluted with 50 
mM Tris-HCl, pH 7.5 (degassed) at a flow rate of 0.5 ml min-1 and 6 ml of fraction 
were collected. The absorbance (A280) of each fraction was measured automatically 
with a Quad Tech 280 spectrophotometer attached to the system. The peak fractions 
were pooled and analysed on SDS-PAGE. The fractions containing the target protein 
were concentrated by ultrafiltration, and stored in aliquots at -80⁰C. 
4.2.6 rRNA N-glycosidase activity 
RNA N-glycosidase activity is a unique characteristic exhibited by RIPs that causes 
hydrolysis of the N-glycosylic bond at A-4324 in 28S rRNA resulting in the release 
of a 400 bp fragment (the Endo-fragment) on aniline treatment. The assay was 
conducted as described by (Bagga S 2003) with minor modification. Rabbit 
reticulocyte lysate was used as a source of ribosome.  70 μl of rabbit reticulocyte 
was incubated with 50 μg/ml of nBalsamin and rBalsamin at 30°C for 30 min.  10 μl 
of 10% SDS (w/v) and 170 μl of diethylpyrocarbonate (DEPC) water was added to 
terminate the reaction.  Following termination, total rRNA from the reaction mixture 
was extracted using RNAqueous® Total RNA Isolation Kit. For this, equal volume 
of lysis buffer was added to the sample. The sample was vortexed and centrifuged 
for 2-3 min at top speed to remove debris. An equal volume of 64% ethanol was 
then added to the supernatant. The sample was vortexed and the suspension was 
applied onto the spin column. The column was centrifuged at 12,000 X g for 1 min 
Chapter 4 
 
102 
to ensure that the RNA was completely bound to the column. After centrifugation, 
the flow through was discarded and the column was washed with 700 μl of wash 
solution-1, to remove any unbound biomolecules, followed by centrifugation at 
12,000 X g for 1 min. The flow through collected in the column was removed and a 
second column washing was given with 500 μl wash solution-2/3. The column was 
centrifuged at 12,000 X g for 1 min and flow through was discarded. The above step 
was repeated for proper column washing. The spin column was dried by centrifuging 
at 12,000 X g for 30 sec and then transferred to a fresh collection tube for RNA 
elution. 25 μl of prewarmed Milli Q water was added to the spin column. The 
column was incubated for 2 min and then centrifuged at 12,000 X g for 30 sec at 
room temperature. The above step was repeated to elute any remaining RNA from 
the column. 
50 μl of RNA was divided into two parts. One part was treated with 25 μl of aniline 
acetate (10% aniline and 12% glacial acetic acid in DEPC water, pH 4.5), whereas 
the other part was left untreated. The samples were incubated at 60°C for 3 min, 
aniline was evaporated under vacuum and the RNA pellet was dissolved in 25 μl of 
DEPC water. The samples were analysed on a 2% agarose gel. For this, a loading 
buffer containing 32% formamide, 4mM EDTA, 0.04% xylene cyanol and 0.04% 
bromophenol blue was added to the aniline treated and untreated samples. The 
samples were heated at 65°C for 5 mins and loaded on the agarose gel. The gel was 
stained with ethidium bromide and the RNA was visualized using a Gel Doc™ 
XRS+ system (Bio-Rad, Hercules, CA, USA). 
4.2.7 Biophysical characterization of rBalsamin 
4.2.7.1 Circular dichroism (CD) spectroscopy 
The secondary structure of rBalsamin (450 μg/ml in 50 mM Tris-HCl buffer, pH 7.8) 
was determined using a Jasco J-815 CD spectrometer (Jasco Inc., Easton, MD, US) 
with a temperature controlled cuvette chamber. Spectra in the far UV range (190-
260 nm) were recorded at a scanning speed of 100 nm/min in 1 mm path length 
cells.  
To study the effect of temperature on the secondary structure of rBalsamin (450 
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μg/ml in 50 mM Tris-HCl buffer, pH 7.8), the spectra were recorded over a 
temperature range from 20 to 90°C with a heating rate of 1°C/min. In addition, to 
study the effect of pH, spectra of rBalsamin dissolved in buffer with pH ranging 
from 4-11, were measured. The analysis of the CD spectra was then performed using 
Spectra managerTM software. 
4.2.7.2 Fluorescence spectroscopy 
The fluorescence of the rBalsamin was recorded using a spectroflurometer. The 
intrinsic fluorescence of rBalsamin (100 μg/ml in 50 mM Tris-HCl buffer, pH 7.8) 
was measured over a temperature range of 20 to 90°C with a heating rate of 1 
°C/min. Fluorescence spectra were recorded by excitation at 280 nm (slit width 5 
nm) and emission in the range of 300-500 nm (slit width 5 nm). To study the effect 
of pH on the tertiary structure, the spectra of rBalsamin dissolved in buffer with pH 
ranging from 4-11 were recorded.  
4.2.8 Bioinformatics analysis 
4.2.8.1 Protein sequence identification and homology 
EXPASY translate is a tool that allows the translation of nucleotide (DNA/RNA) 
sequence to a protein sequence. The Bal gene sequence obtained after sequencing 
was submitted to the EXPASY translate tool to obtain a protein sequence. The 
similarity of the predicted protein sequence with other RIP sequences was 
determined using the BLASTP tool. The BLASTP program searches for similarity 
between query protein sequence and other protein sequences available in the NCBI 
database. The protein sequence obtained from the EXPASY translate tool was 
submitted to BLASTP and the % sequence identity of the protein with other proteins 
in the database was reported. 
4.2.8.2 Prediction of biochemical, biophysical and physicochemical parameters 
The PROTPARAM program of the expasy protein analysis tool computes various 
physico-chemical parameters (such as molecular weight, theoretical pI, amino acid 
composition, extinction coefficient, estimated half-life, instability index and 
aliphatic index) from a protein sequence. The protein sequence obtained from the 
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EXPASY translate tool was submitted to PROTPARAM. The values of various 
predicted physico-chemical parameters were reported. 
4.2.9 DNase-like activity of rBalsamin 
4.2.9.1 Optimization of rBalsamin concentration for DNase-like activity 
DNase-like activity of rBalsamin was evaluated as described in Chapter 2. pUC19 
plasmid (0.25 μg) was incubated with different amounts of rBalsamin (0.5 μg, 1 μg, 
1.5 μg or 2 μg) for 2 h at 37°C in a final volume of 10 μl made with DNase buffer 
(50 mM Tris HCl, pH 7.5, 50 mM KCl, 0.1 mM MgCl2). Plasmid DNA (without any 
protein) and treated with the restriction endonuclease EcoRI (10 U/μl) served as 
negative and positive controls, respectively. 
4.2.9.2 DNase-like activity of nBalsamin and rBalsamin 
To compare the DNase-like activity of nBalsamin and rBalsamin with other 
restriction endonucleases, 0.25 μg of pUC 19 plasmid was incubated with 1.5 μg of 
nBalsamin and rBalsamin, and 10 U/μl restriction enzymes (BamHI, HindIII and 
NdeI) for 2 h at 37°C in a final volume of 10 μl made with DNase buffer (50 mM 
Tris HCl, pH 7.5, 50 mM KCl, 0.1 mM MgCl2). Plasmid DNA (without any protein) 
served as a negative control. At the end of the reaction, DNA was extracted and 
analysed on a 0.8% agarose gel. 
4.2.9.3 DNase-like activity for the evaluation of stability of rBalsamin 
To determine the stability of rBalsamin, 0.25 μg of pUC 19 plasmid was incubated 
with 1.5 μg of five months old rBalsamin sample (stored at -80°C), and 10 U/μl 
restriction enzyme (BamHI) for 2 h at 37°C in a final volume of 10 μl made with 
DNase buffer (50 mM Tris HCl, pH 7.5, 50 mM KCl, 0.1 mM MgCl2). Plasmid 
DNA (without any protein) served as a negative control. At the end of the reaction, 
DNA was extracted and analysed on a 0.8% agarose gel. 
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4.2.10 Antioxidant activity 
4.2.10.1 Determination of DPPH radical scavenging activity 
The activity was determined using 2, 2-Diphenyl-1-picrylhydrazyl (DPPH) as 
described by (Boonmee et al. 2011). For the analysis, 40 μl of various concentrations 
of rBalsamin (0.1, 0.5, 1, 1.5, 2, 2.5 mg/ml) and standard solution of ascorbic acid 
(1.56-200 μg/ml) were incubated with 160 μl of 0.2 mM DPPH solution at room 
temperature for 30 min in the dark. After incubation, the absorbance of the samples 
was measured at 517 nm. The DPPH free radical scavenging activity was calculated 
using the formula: 
% scavenging activity = [Ab (control) – Ab (sample) / Ab (control)] *100 
4.2.10.2 Determination of superoxide radical scavenging activity 
Superoxide radical scavenging activity is based on the capacity of the protein to 
inhibit photochemical reduction of nitroblue tetrazolium (NBT).  For this, 100 μl of 
various concentrations of rBalsamin (0.1, 0.5, 1, 1.5, 2, 2.5 mg/ml) and standard 
solution of ascorbic acid (25-500 μg/ml) were mixed with 100 μl riboflavin (20 μg), 
200 μl EDTA solution (12 mM), 200 μl methanol and 100 μl NBT (0.1 mg). The 
final volume of each sample was made up to 3.0 ml with 50 mM phosphate buffer 
(pH 7.8). The samples were kept in front of fluorescent light for 5 min and 
absorbance was then measured at 590 nm using phosphate buffer as a blank. The 
superoxide scavenging activity was calculated with the formula: 
% scavenging activity = [Ab (control) – Ab (sample) / Ab (control)]*100 
4.2.10.3 Evaluation of reducing power ability 
The reducing power of the proteins was determined according to (Hong et al. 2014) 
with minor modifications. For this, 0.2 ml of rBalsamin was mixed with 0.5 ml of 
0.2 M sodium phosphate buffer (pH 7.4) and 0.5 ml of 1% (w/v) potassium 
ferricyanide solution. The reaction mixture was incubated at 50°C for 20 min. At the 
end of incubation, 0.5 ml of 10% (w/v) trichloroacetic acid was added to terminate 
the reaction. The mixture was then centrifuged at 2500 X g at 25°C for 10 min. 0.5 
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ml of the supernatant was mixed with 0.5 ml distilled water and 0.1 ml of 0.1% 
(w/v) ferric chloride. The absorbance was then measured at 700 nm. Phosphate 
buffer and ascorbic acid served as blank and positive controls, respectively.  
4.2.11 Antimicrobial activity of rBalsamin 
The antimicrobial activity of rBalsamin was determined by disc diffusion and broth 
microdilution methods, as described in Chapter 2. 
4.3 Results and discussion 
4.3.1 PCR amplification of Bal gene 
RIP genes have been reported to be intronless, therefore obtaining an open reading 
frame of the Bal gene from genomic DNA by PCR was possible. Genomic DNA 
from the seeds of Momordica balsamina was extracted (Figure 4.1) and used as a 
template for the amplification of the gene encoding balsamin. Among the 7 
degenerate primers used to amplify the Bal gene fragment, one primer resulted in the 
amplification of an open reading frame of the mature peptide (Figure 4.2). The 
amplified gene  (Figure 4.3) was purified and sent for sequencing. The sequencing 
results were confirmed by comparing the sequence with the nucleotide database 
using basic local alignment search tool (BLAST software, NCBI). A BLAST search 
of the sequenced gene showed 89% homology to α-MMC, a type-I RIP obtained 
from Momordica charantia (Figure 4.4). To obtain the maximum efficiency of 
translation, the sequence was sent to GenScript (NJ, USA) for rare codon 
optimization. The analysis report showed that the codon adaptation index (CAI) of 
the balsamin open reading frame was adjusted to 0.87 (a CAI of 0.1 was considered 
to be ideal) with average GC content of 52.51% (Annexure 8.1). 
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Figure 4.1 Genomic DNA isolated from Momordica balsamina seeds. Lane 1: 
1KB DNA ladder; Lane 2 and 3: genomic DNA. 
 
Figure 4.2 PCR amplification of genomic DNA with 7 degenerate primers. Lane 
1: 1 KB DNA ladder; Lane 2-8: amplification with MAP, gel, sap, luf, PAP, 
mom and PAP-II primers, respectively. Arrow points to an amplified product. 
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Figure 4.3: Gene amplification with mom primers. Lane 1: 1 KB DNA ladder; 
Lane 2: amplification with mom primer. 
4.3.2 Cloning of the Bal gene in pGEM-T cloning vector 
Based on the sequence, specific primers with restriction sites (BamHI and XhoI) 
were designed. The sequenced gene (Bal gene) was amplified using these primers 
and purified from the gel. The Bal gene with restriction sites and pGEM-T cloning 
vector were double digested with BamHI and XhoI and ligated. The resultant 
recombinant plasmid (pGEM-Bal) was then transformed into E.coli DH10β. The 
cloning of the Bal open reading frame into the pGEM-T cloning vector was 
confirmed by purifying the plasmid from ampicillin-resistant colonies and 
performing colony PCR analysis (Figure 4.5 a) and digesting it with the 
endonucleases BamHI and XhoI (Figure 4.5 b). 
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Figure 4.4: Homology of Bal gene sequence with α-MMC, a type-I RIP obtained 
from Momordica charantia. 
Chapter 4 
 
110 
 
 
Figure 4.5: Recombinant plasmid screening. (a) Colony PCR of recombinant 
plasmid. Lane 1: 1 KB DNA ladder; Lane 2: pGEM-T vector; Lane 3: Bal gene; 
Lane 4-7: colony PCR of recombinant plasmids. (b) Restriction digestion of 
recombinant plasmid. Lane 1: 1 KB DNA ladder; Lane 2: pGEM-T vector; 
Lane 3: Bal gene; Lane 4-7: recombinant plasmids digested with BamHI and 
XhoI restriction enzymes. 
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4.3.3 Cloning of Bal gene in pET-30a(+) expression vector 
The Bal gene was excised from pGEM-T vector by digestion with BamHI and XhoI 
and ligated into pET-30a(+) vector digested with the same endonucleases, BamHI 
and XhoI. The resultant recombinant plasmid pET-Bal was then transformed into 
E.coli BL21(DE3) competent cells (Figure 4.6).  
 
Figure 4.6 Schematic representations of steps involved in the cloning of Bal 
gene in pET-30a(+) vector. 
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4.3.4 Optimization of rBalsamin expression 
A single colony harbouring the Bal gene was grown in LB broth containing 50 
μg/ml kanamycin overnight at 37°C. 1% of the overnight culture was inoculated in 1 
L of LB broth containing kanamycin, and incubated at 37°C, 250 rpm until an 
OD600 reached approximately 0.6. The expression of rBalsamin was then induced 
by IPTG. The recombinant bacterial cells were collected by centrifugation and 
disrupted by sonication. The expression and molecular weight of rBalsamin was 
assessed in the supernatant and cell pellet by 12% SDS-PAGE. A band at the 
expected size (~ 29 kDa) was observed in the cell pellet of the induced cells (Figure 
4.7, Lane 3, arrow). No band was visible at this position in the supernatant (Figure 
4.7, Lane 2) indicating that rBalsamin was expressed in the insoluble fraction and 
possibly got accumulated in inclusion bodies rather than the soluble fraction. Also, 
the absence of a protein band corresponding to the rBalamin in the uninduced cells 
(Figure 4.7, Lane 1) indicated tight control of induction of expression. 
 
Figure 4.7: SDS-PAGE analysis of expression of rBalsamin in E.coli. Lane M: 
protein marker, Lane 1: cell lysate of uninduced E.coli BL21(DE3) cells, Lane 
2: supernatant (soluble fraction) of the induced E.coli BL21(DE3) cells, Lane 3: 
cell pellet (insoluble fraction) of the induced E.coli BL21(DE3) cells. 
To obtain a maximum yield of the rBalsamin, parameters such as temperature (20-
37°C), IPTG concentration (0.2-1.0 mM) and induction time (4-20 h) were 
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optimized. It was observed that the optimum expression of insoluble rBalsamin was 
obtained at 30 °C (Figure 4.8a) after 4 h (Figure 4.8b) of induction with 0.4 mM 
IPTG (Figure 4.8c). 
 
Figure 4.8: Optimization of expression of rBalsamin in E.coli. Cultures were 
induced with IPTG at an OD600nm of 0.6. Equal volumes (10 μl) of culture 
supernatants from different conditions were analysed by 12% SDS-PAGE. a) 
Temperature optimization. SDS-PAGE analysis of supernatants of the 
uninduced (UI) and induced cultures grown at different temperatures (20-37 
°C). b) Time kinetics of balsamin expression in E.coli BL21(DE3). SDS-PAGE 
analysis of the supernatants of the induced cultures harvested at different time 
periods (4-20 h). c) Optimisation of IPTG concentration. SDS-PAGE analysis of 
the supernatants of the UI and cultures induced with different IPTG 
concentrations (0.2-1.0 mM). M in all the panels denotes protein marker and 
the arrow points to the rBalsamin. 
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4.3.5 Purification of rBalsamin 
The His-tagged rBalsamin was purified by a two-step purification strategy. 
rBalsamin was expressed in the insoluble fraction, therefore, the purification of 
rBalsamin was carried out in a Ni Sepaharose 6 fast flow column under denaturing 
conditions (buffer containing 8M urea). The rBalsamin in the cell suspension was 
adsorbed to the Ni2+ Sepharose column. The majority of the unadsorbed proteins 
were removed by washing the column with 15-column volumes of buffer A (wash 
buffer). Refolding of the bound protein was performed by the use of a linear gradient 
of urea (8-0 M) in the wash buffer. Finally, the rBalsamin was eluted from the 
column by increasing the concentration of imidazole to 250 mM in the elution buffer 
(with no urea). 10 μl of sample from each of the collected fractions was loaded on a 
12% SDS-PAGE gel to assess the purity of the protein. The fractions were pooled 
and concentrated for gel filtration chromatography. The affinity tag has previously 
been used to facilitate purification of many recombinant proteins expressed in E.coli 
BL21(DE3) by employing Ni2+ Sepharose affinity chromatography (Han et al. 
2011). 
Gel filtration (GF) chromatography was carried out immediately after the first step 
of IMAC purification using a Superdex 75 gel-filtration column. The column was 
washed with 50 mM Tris-HCl, pH 7.5 (degassed) at a flow rate of 0.5 ml/min until a 
baseline was achieved. Two peaks were obtained (Figure 4.9) and analyzed using 
12% SDS-PAGE. The purified fraction PII was subsequently found to contain most 
of the protein of approximately 29 kDa, corresponding to the predicted molecular 
mass of rBalsamin. The purity of the eluted rBalsamin was confirmed by the 
presence of single band on the gel. Figure 4.10 summarizes the purification of 
rBalsamin. Approximately 45 mg rBalsamin was purified from 1 L of culture 
medium, by this two-step purification procedure. A similar strategy has previously 
been employed for purification of other RIPs in E.coli strains. α-luffin, a type-I RIP, 
was expressed in E. coli BL21(DE3)pLysS strain and purified by Ni- nitrilotriacetic 
acid (NTA) agarose affinity chromatography. However, the final yield of soluble 
protein was reported to be 0.45 mg/l bacterial cell culture (Liu et al. 2010), 100 
times lower compared to the protein yield in our study. α-MMC expressed in E.coli 
Rosetta (DE3)pLysS strain and purified by Ni- NTA agarose affinity 
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chromatography produced 85 mg/l of soluble α-MMC (Wang et al. 2012), around 
double the yield reported in our study. This difference might be due to the fact that 
rBalsamin was expressed in the insoluble fraction, which required additional 
purification and protein-refolding steps leading to reduced protein yield.  
 
 
Figure 4.9: Profile of superdex-75 gel filtration chromatography. Fractions 
corresponding the peaks were pooled separately and designated as PI and PII. 
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Figure 4.10: SDS-PAGE analysis of rBalsamin expressed in E.coli. Lane M: 
protein marker, Lane 1: cell lysate of uninduced E.coli BL21(DE3) cells, Lane 
2: cell lysate of IPTG induced E.coli BL21 (DE3) cells, Lane 3: supernatant of 
the cell lysate loaded onto Ni2+ sepharose column, Lane 4: flow through, Lane 5 
& 6: Ni2+ fractions, Lane 7: concentrated Ni2+ fraction, Lane 8: GF PII fraction 
and Lane 9: concentrated PII fraction (purified rBalsamin). 
4.3.6 rRNA N-glycosidase activity 
Reports have shown that RIP-mediated cleavage of the 28S rRNA leads to the 
release of a 300-400 nucleotide product, named the Endo-fragment (Choudhary, 
Yadav & Lodha 2008; Girbes et al. 2004). To confirm whether the purified 
rBalsamin was properly refolded during purification and is biologically active, an 
rRNA N-glycosidase assay was performed. The activity was determined by 
analyzing rRNA treated with the purified rBalsamin. It was observed that the 28S 
rRNA generated a typical Endo fragment after treatment with rBalsamin. The 
rRNAs seemed stable towards rBalsamin without the treatment of aniline as no 
fragment appeared at this stage on a 0.8% agarose gel. Only after the treatment with 
aniline, the rRNA was cleaved resulting in generation of the Endo-fragment (Figure 
4.11). nBalsamin isolated from Momordica balsamina served as a positive control. 
These results were in agreement with previous reports on RIPs from different plant 
species (Choudhary, Yadav & Lodha 2008; Sharma et al. 2004).  
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Figure 4.11: RNA N-glycosidase activity of rBalsamin when incubated with 
rabbit reticulocyte lysate. The rRNA was extracted and treated (+) with or 
without aniline (-) and analysed on a 2% agarose gel. The Endo-fragment 
generated after balsamin treatment is denoted with an arrow. 
4.3.7 Biophysical characterization of rBalsamin 
4.3.7.1 Circular dichroism (CD) spectroscopy  
CD spectra of rBalsamin indicated the presence of predominantly α-helices and 
random coils. rBalsamin exhibited 34.8% α-helix, 19.3% β-sheets, 12.5% turns and 
32.5% random coils at 25°C, which is comparable to the CD profile reported for 
nBalsamin (Kaur et al. 2012). Some similar structures have been reported with other 
RIPs. CD spectral analysis of pulchellin isoforms from Abrus pulchellus showed the 
presence of α-helix (10-16%), β-sheets (30-32%), turns (20-24%) and random coils 
(33-36%) (Castilho et al. 2008). Trichosanthin (TCS), a type-I RIP purified from 
Trichosanthes kirilowii maxim, comprises of α-helices, β-sheets, random coils and 
turns and the percentage of secondary structure confirmation of TCS varies with 
change in pH (Xia & Sui 2000).  
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In our study, the secondary structure of rBalsamin was found to be stable in the 
temperature range of 20-60°C as little or no change in the CD spectrum was 
observed within this temperature range. However, above 60°C, a slight distortion 
was observed in the secondary structure indicating that rBalsamin is unstable at high 
temperatures (Figure 4.12a). 
The effect of pH on the secondary structure of rBalsamin was studied to determine 
the stability of the protein. rBalsamin seemed stable as no change in the secondary 
structure was noted between pH 6-11. However, below pH 6, a slight disruption in 
the secondary structure was observed indicating that rBalsamin is unstable under 
acidic conditions (Figure 4.12b).  
4.3.7.2 Fluorescence spectroscopy 
The effect of temperature and pH on the native structure of rBalsamin was studied 
using fluorescence spectroscopy. rBalsamin was found to be stable in the 
temperature range of 20-60°C as no shift in the emission maximum was observed 
within this temperature range. However, above 60°C, a decrease in the fluorescence 
intensity with a shift in emission maximum was observed, indicating that rBalsamin 
is unstable at higher temperatures (Figure 4.13a). 
An increase in the relative fluorescence intensity with a slight red shift was observed 
with an increase in pH from 4 to 5. rBalsamin seemed stable between pH 6 to 9 as 
no change in the emission maximum was observed within this pH range. A further 
increase in pH from 9 to 11 resulted in a decrease in relative fluorescence and slight 
shift in the emission maximum, suggesting that rBalsamin is unstable at pH below 6 
and above 9 (Figure 4.13b). 
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Figure 4.12: CD spectra of rBalsamin at different temperature (a) and pH (b). 
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Figure 4.13: Fluorescence spectra of rBalsamin at different temperature (a) and pH (b). 
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4.3.8 Bioinformatics analysis 
4.3.8.1 Protein sequence identification and homology 
The Bal gene sequence was translated using the EXPASY translate tool. The 
conceptually translated rBalsamin sequence was used to determine the homology of 
the protein with other type-I RIPs in GenBank. A BLAST search of the predicted 
amino acid sequence of rBalsamin was performed to determine its similarity with 
other RIP sequences (Table 4.2). The analysis showed that the rBalsamin has highest 
similarity (91%) with α-MMC from Momordica charantia followed by 89% with 
momordin from Momordica charantia. The protein has less similarity, ranging 
between 64-72%, with luffaculin 1, luffin-B, trichomislin, trichosanthin, trichobakin, 
bryodin-I and karasurin-C (Table 4.2). 
4.3.8.2 Prediction of biochemical, biophysical and physicochemical parameters 
The biochemical, biophysical and physicochemical parameters of rBalsamin were 
deduced using the PROTPARAM program of the EXPASY protein analysis tool. 
The analysis showed that rBalsamin consisted of 247 amino acids with a predicted 
molecular weight of 27.23 kDa and isoelectric point of 9.19. The protein consisted 
of 25 positively and 20 negatively charged amino acids. The instability index was 
estimated to be 33.40 indicating that rBalsamin is a stable protein (Table 4.3). 
Through EXPASY analysis, the predicted molecular weight of the protein was 27.23 
kDa. However, the calculated molecular mass of rBalsamin obtained from SDS-
PAGE was around 29 kDa. This difference was due to the presence of His-tag at the 
N-terminal of the purified rBalsamin.   
In contrast, nBalsamin consisted of 262 amino acids with a molecular weight of 
28.90 kDa and isoelectric point of 9.43. The protein consisted of 27 positively and 
20 negatively charged amino acids with estimated index stability of 28.45 (Kaur et 
al. 2012). This difference in the physicochemical parameters of rBalsamin and 
nBalsamin might be due to the fact that open reading frame of Bal gene was selected 
for expression instead of the whole gene. 
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Table 4.2 BLASTP analysis of rBalsamin with the protein sequences in the 
NCBI database. 
Species Name of protein Accession no. Identity (%) E-value 
Momordica charantia α-MMC AAB22586.1 91 4e-164 
Momordica charantia Momordin prfII1918208A 89 1e-149 
Luffa acutangula Luffaculin 1 P84530.2 72 1e-109 
Luffa aegyptiaca Luffin-B P22851.1 70 1e-109 
Trichosanthes kirilowii Trichomislin AA592579.1 66 1e-104 
Trichosanthes kirilowii Alpha- TCS P09989.2 65 6e-108 
Trichosanthes kirilowii Trichobakin BAA92530.1 65 2e-104 
Bryonia dioica Bryodin-I P33185.3 65 7e-111 
Trichosanthes kirilowii Karasurin-C P24478.2 64 4e-109 
E-value (Expect value) describes the likelihood that a sequence with a similar 
score will occur by chance when searching a database of particular size. The 
lower the E-value, the more significant a match to a database sequence is. 
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Table 4.3 Biophysical and physicochemical parameters of rBalsamin predicted 
using the PROTPARAM tool of the EXPASY protein analysis server. 
Biochemical/biophysical/physicochemical 
parameters 
Predicted values 
Number of amino acids 247 
Molecular weight 27231.23 Da 
Theoretical pI 9.19 
Total number of negatively charged residues 
(Asp + Glu) 
20 
Total number of positively charged residues 
(Arg + Lys) 
25 
Total number of atoms 3877 
Extinction coefficient 24870 
Estimated half-life 
30 h (mammalian reticulocytes, in vitro) 
>20 h (yeast, in vivo) 
>10 h (E. coli, in vivo) 
Instability index 33.40 
Aliphatic index 103.12 
Grand average of hydrophathicity (GRAVY) -0.011 
 
 
Chapter 4 
124 
4.3.9 DNase-like activity  
4.3.9.1 Optimization of rBalsamin concentration for DNase-like activity 
To optimize rBalsamin concentration for DNase-like activity, pUC19 plasmid was 
used as a substrate. Treatment of supercoiled pUC19 with various concentrations of 
rBalsamin (0.5-2 μg) resulted in conversion of supercoiled plasmid into the open 
circular and linear forms (Figure 4.14). 0.5 and 1 μg of rBalsamin treatment partially 
converted the supercoiled form into the open circular form. However, when the 
concentration of rBalsamin was increased to 1.5 μg, almost complete disappearance 
of supercoiled plasmid was observed with the appearance of the linear form of the 
DNA. At a concentration of 2 μg, rBalsamin completely converted supercoiled and 
open circular forms of DNA to the linear form, suggesting that 2 μg of rBalsamin is 
the optimum concentration for DNase-like activity (Figure 4.14). 
 
Figure 4.14: Effect of rBalsamin concentration on DNase-like activity. “NC”, 
untreated plasmid DNA (negative control); “PC”, plasmid treated with EcoRI 
(positive control); remaining lanes represent plasmid treated with different 
concentrations of balsamin (0.5-2 μg). “OC”, “L” and “SC” denotes open 
circular, linear and supercoiled plasmid respectively.   
4.3.9.2 DNase-like activity of nBalsamin and rBalsamin 
To compare DNase-like activity, pUC19 plasmid was treated with 2.0 μg of 
nBalsamin, rBalsamin and restriction enzymes (HindIII, BamHI and NdeI). The 
experiments showed that rBalsamin completely converted supercoiled form of 
plasmid into the linear form, equivalent to the results observed with restriction 
enzymes. However, nBalsamin could only partially convert the supercoiled form of 
Chapter 4 
125 
plasmid as a mixture of both open circular and linear confirmations were observed 
after the treatment (Figure 4.15). These results suggest that rBalsamin is more 
effective in terms of DNase-like activity at a concentration of 2.0 μg compared to 
nBalsamin.   
 
Figure 4.15: DNase-like activity of rBalsamin, nBalsamin and various 
restriction enzymes. “NC”, untreated plasmid DNA (negative control); 
remaining lanes represent plasmid treated with rBalsamin, nBalsamin and 
restriction enzymes (positive controls). “OC”, “L” and “SC” denotes open 
circular, linear and supercoiled plasmid respectively.   
4.3.9.3 DNase-like activity for the evaluation of stability of rBalsamin 
To evaluate the stability and efficacy of rBalsamin, pUC19 plasmid was treated with 
2.0 μg of five months old rBalsamin (stored at -80°C) sample and restriction 
enzyme, BamHI. The experiments showed that rBalsamin completely converted 
supercoiled form of DNA into the linear form (Lane 1-3, Figure 4.16) equivalent to 
the results observed with restriction enzyme (Lane PC, Figure 4.16). These results 
suggest that rBalsamin is stable when stored at -80°C for several months, confirming 
the efficacy and stability of rBalsamin. 
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Figure 4.16: DNase-like activity of five months old rBalsamin sample. “NC”, 
untreated plasmid DNA (negative control); “PC”, plasmid treated with BamHI; 
“Lane 1-3”, plasmid treated with rBalsamin taken from three different aliquots 
stored at -80°C for 5 months. “OC”, “L” and “SC” denotes open circular, 
linear and supercoiled plasmid respectively.   
4.3.10 Antioxidant activity of rBalsamin 
DPPH is a free radical compound and has been widely used to test free radical-
scavenging ability (Priyanka et al. 2013; Yan, Cao & Yang 2014; Yang, Li & 
Chuang 2012). This stable free radical with a characteristic absorption at 517 nm 
was used to determine the radical scavenging activity of rBalsamin with ascorbic 
acid as a standard. The results showed that rBalsamin concentration did not affect 
free radical scavenging of DPPH as no DPPH reduction was observed (Annexure 
8.2a). 
The superoxide radical scavenging assay is based on the capacity of the protein to 
inhibit the photochemical reduction of nitroblue tetrazolium (NBT) (Harman 1992). 
However, in our study, it was observed that rBalsamin did not exhibit this activity as 
no NBT reduction was observed (Annexure 8.2b). Some RIPs such camphorin from 
C. camphora (Li et al. 1997) and C. moschata (Park et al. 2004) have been reported 
to exhibit superoxide dismutase activity. However, reports on similar RIPs such as 
α-MMC and MAP30 from Momordica charantia have shown that these RIPs do not 
possess superoxide dismutase activity (Meng et al. 2014).  
Reducing power measures the total antioxidant ability of a compound and the 
efficiency of an antioxidant to donate electrons. The reducing ability of the 
compound ferricyanide complex (Fe3+) to ferrous serves as an important indicator of 
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antioxidant activity (Benzie & Strain 1999). The assay showed that the reducing 
power ability tended to increase as the concentration of rBalsamin increased. 
However, none of these results were statistically significant demonstrating that the 
protein does not possess reducing ability (Annexure 8.2c).  
It is interesting to note that Balsamin extracted from a natural source (nBalsamin) 
exhibits free radical scavenging and reducing power ability, however, rBalsamin 
does not. Further investigation is required to identify the main cause of this 
difference. 
4.3.11 Antimicrobial activity of rBalsamin 
RIPs have been classified as defense proteins, which could function as antimicrobial 
agents (Girbes et al. 2004). α-MMC from Momordica charantia inhibited the growth 
of several bacterial and fungal pathogens such as Fusarium oxysporum, Fusarium 
solani, E. coli, P. aeruginosa, S. aureus and Bacillus subtilis (Wang et al. 2012). 
ME1 and ME2, two type I RIPs, from Mirabilis expansa roots exhibited strong 
inhibitory activity against an array of fungal pathogens including Fusarium and 
Trichoderma species (Vivanco, Savary & Flores 1999). Therefore, we investigated 
the antimicrobial potential of rBalsamin. The disc diffusion method was performed 
to determine the zone of inhibition of different dilutions of rBalsamin on various 
pathogenic microorganisms. The assay demonstrated that rBalsamin inhibited the 
growth of pathogens in a dose dependent manner with a maximum inhibition 
observed at the highest dose. S. epidermidis, S. aureus, S. enterica and E. coli 
demonstrated higher susceptibility to rBalsamin while P. aeruginosa and E. faecalis 
demonstrated comparatively less susceptibility to rBalsamin (Figure 4.17). The zone 
of inhibition caused by different dilutions of rBalsamin on the different pathogens 
ranged between 2.2-9.0 mm (Table 4.4).  
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Figure 4.17: Antibacterial activity of different dilutions of rBalsamin against 
Staphylococcus aureus ATCC 25923 (A), Pseudomonas aeruginosa ATCC 27853 
(B), Escherichia coli ATCC 2348 (C), Staphylococcus epidermidis ATCC 12228 
(D), Salmonella enterica ATCC 43971 (E), Entercoccus faecalis ATCC 10100 
(F). Disc 1 contains PBS (control); Disc 2, 3 and 4 contains 50 μg/ml, 100 μg/ml, 
and 200 μg/ml of rBalsamin respectively, in each plate. 
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Table 4.4: Antibacterial activity of rBalsamin towards different pathogenic 
microorganisms.  
Microorganisms 
Zone of inhibition in mm ± SD 
rBalsamin concentration (μg/ml) 
50 100 200 
Staphylococcus aureus 3.1 ± 0.2 6.2 ± 0.5 8.0 ± 0.4 
Pseudomonas aeruginosa ND 2.2 ± 0.3 5.1 ± 0.7 
Escherichia coli 2.2 ± 0.1 4.4 ± 0.3 6.3 ± 0.5 
Staphylococcus epidermidis 4.1 ± 0.3 6.2 ± 0.4 9.0 ± 0.7 
Salmonella enterica 2.7 ± 0.2 5.5 ± 0.6 7.1 ± 0.5 
Enterococcus faecalis ND ND 3.3 ± 0.2 
Values are mean ± SD based on three sets of experiments; ND denotes not 
detected. 
The minimum inhibitory concentrations (MIC’s) of rBalsamin were determined by 
the broth microdilution method. The MIC’s of rBalsamin were found to be in the 
following order: S. epidermidis < S. aureus < S. enterica = E. coli < P. aeruginosa 
= E. faecalis (Annexure 8.3, Table 4.5). A number of RIPs have been reported to 
function as antimicrobial agents to defend plants from various fungal, viral and 
bacterial attacks (Girbes et al. 2004). α-MMC from Momordica charantia inhibited 
the replication of chilli veinal mottle virus, tobacco mosaic virus and cucumber 
mosaic virus in plants treated with various concentration of α-MMC (Zhu et al. 
2013). α-MMC has also been found to inhibit the growth of several pathogens 
including Fusarium oxysporum, Fusarium solani, E. coli, P. aeruginosa, S. aureus 
and Bacillus subtilis (Wang et al. 2012). Our studies demonstrated that rBalsamin 
exhibited growth inhibitory activity towards various pathogens that could prove 
beneficial in plant protection. 
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Table 4.5: Minimum inhibitory concentrations (MICs) of rBalsamin against 
different pathogenic microorganisms. 
 
Microorganisms MICs of rBalsamin (µg/ml) 
Staphylococcus aureus 6.25 
Pseudomonas aeruginosa 25.00 
Escherichia coli 12.50 
Staphylococcus epidermidis 1.56 
Salmonella enterica 12.50 
Enterococcus faecalis 25.00 
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4.4 Conclusions 
The present study discusses the development of a two-step purification procedure for 
the production of functionally bioactive balsamin from Momordica balsamina. The 
open reading frame of the Bal gene was successfully obtained from Momordica 
balsamina genomic DNA. After optimizing the expression parameters such as 
induction time, IPTG concentration and temperature, maximum protein yield was 
obtained at 0.4 mM IPTG induction at 30°C for 4 h in the E.coli BL21(DE3) 
expression system. The incorporation of a His-tag on the N-terminus of the protein 
allowed purification of rBalsamin by Ni2+ Sepharose affinity chromatography. A 
total of 45 mg of protein was obtained from a 1 L culture of induced E.coli 
BL21(DE3) cells. Functional analysis indicated that rBalsamin exhibited RNA N-
glycosidase activity, releasing the Endo-fragment from rabbit reticulocyte rRNA, 
and DNase-like activity, converting the supercoiled form of a plasmid DNA into the 
linear form in a concentration-dependent manner. The structure of rBalsamin was 
found to be sensitive to change in temperature and pH, suggesting that any changes 
in pH and temperature are likely to affect its structure and function. Antimicrobial 
assay revealed that rBalsamin could inhibit the growth of various pathogens with 
MICs ranging between 1.56-25 µg/ml, which may enable the development of 
transgenic crops resistant to microbial infections. However, further investigation of 
the cytotoxicity of rBalsamin on cancer cells would be beneficial to explore its 
potential use in the field of cancer therapeutics.  
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5.1 Introduction 
In our previous study, we developed a molecular based strategy to produce 
rBalsamin in an E.coli strain. We reported that besides RNA N-glycosidase activity, 
rBalsamin exhibits DNase-like activity towards the pUC-19 plasmid and broad-
spectrum antimicrobial activity towards various pathogens. Further in depth 
investigation is required to ascertain its function as a potent therapeutic agent for 
cancer. Therefore, in this study, we extended the potential biological application of 
rBalsamin from nuclease and bactericide to cancer.  
RIPs are considered by some as a potential future treatment against various tumors 
as they have the potential to inhibit tumor growth and induce apoptosis in vitro and 
in vivo through different molecular mechanisms. rMAP30 from Momordica 
charantia has been reported to inhibit the viability of  bladder (5637), colorectal 
(LoVo), breast (MCF-7), cervical (HeLa), liver (SMMC-7221), gastric (BGC823 
and MGC803) and skin (B16) cancer cells in a dose and time dependent manner 
(Fan et al. 2008; Fan et al. 2015; Hao et al. 2014). The apoptotic events in rMAP30 
treated LoVo cells included increased Bax and decreased Bcl-2 expression (Fan et al. 
2008), and in BGC823 cells, included decreased mitochondrial membrane potential 
and increased caspase-3, caspase-9, cyt C content and Apaf-1 mRNA expression 
(Han et al. 2011). rTCS from Trichosanthes kirilowii demonstrated cytotoxicity 
towards various cancer cells, including lung (95D), cervical (HeLa), lung (A549), 
hepatocellular (SMMC-7221), breast (MCF-7), colorectal (LoVo) and cervical 
(Caski) cancer cells (Gao et al. 2010; Lu et al. 2016; Peng et al. 2011). rTCS-
induced apoptosis in Caski cells involved activation of caspase-9, decreased Bcl-
2/Bax ratio and cleavage of PARP (Lu et al. 2016). Although a number of studies 
have shown that recombinant RIPs could inhibit proliferation and induce apoptosis 
in a variety of cancer cells, little is known about their cytotoxicity and the 
underlying mechanism(s) of apoptosis in liver and breast cancer cells. Therefore, in 
this study, we investigated the anti-proliferative activity of rBalsamin towards liver 
(HepG2 and H4IIE) and breast (MCF-7 and BT549) cancer cells and investigated 
the possible molecular mechanism(s) of action. 
Breast cancer is the second most common cancer worldwide. Estrogen receptor α 
(ERα) plays an important role in breast carcinogenesis as more than 70% of breast 
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cancer tissues express elevated levels of ERα compared to normal breast tissue (Ali 
& Coombes 2000). The most common treatment available for ERα-positive breast 
cancer is endocrine therapy that involves the use of drugs that are either endocrine 
receptor modulators (such as tamoxifen) or endocrine receptor downregulators (such 
as fluvestrant). However, the majority of ERα-positive breast cancer does not 
respond to endocrine therapy and eventually become resistant (Osborne & Schiff 
2011; Pan et al. 2013). Therefore, identification of therapeutic agents that can target 
both ERα-positive and ERα-negative tumors without developing resistance would 
prove beneficial for breast cancer therapy. Therefore, in this study, we investigated 
the antitumor potential of rBalsamin on MCF-7 (ERα-positive) and BT549 (ERα-
negative) breast cancer cells. 
In addition, hepatocellular carcinoma (HCC) is the most common type of liver 
cancer (Venook et al. 2010). Surgical treatments (such as liver transplantation and 
partial liver resection) and non-surgical treatments (such as percutaneous ethanol 
injection and radiofrequency ablations) are available, however they have limitations 
associated with their use (Peng et al. 2015; Shi et al. 2013). Thus, in this study we 
also explored the efficacy of rBalsamin on liver (HepG2 and H4IIE) cancer cells as 
developing a single therapeutic bioactive that can target a variety of cancer cell types 
would be a promising tool in the field of cancer therapeutics.  
5.2 Materials and methods 
5.2.1 Chemicals, reagents and kits 
RPMI and DMEM media, and FBS were purchased from Life Technologies 
Corporation (California, USA). Trypsin, In vitro toxicology assay kit, Caspase-3 
assay kit and Caspase-8 assay kit were purchased from Sigma-Aldrich (USA). Total 
RNA isolation kit was purchased from Qiagen (Hilden, Germany). Propidium iodide 
(PI) flow cytometry kit was procured from BD Biosciences (San Jose, CA). Pierce 
high-capacity endotoxin removal spin columns were purchased from Thermo Fisher 
Scientific (Victoria, Australia). Reagents for electrophoresis were procured from 
Bio-Rad Laboratories (California, USA). All other reagents were purchased from 
either Sigma-Aldrich (USA) or Bio-Rad Laboratories (California, USA) and were of 
analytical grade. 
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5.2.2 Cell lines and cell culture 
The two liver cancer cell lines, HepG2 (human hepatoma) and H4IIE (rat hepatoma), 
and two breast cancer cell lines, MCF-7 (ERα-positive) and BT549 (ERα-negative) 
were used for the present study. These cell lines were obtained from the ATCC 
(Rockville, MD). HepG2 and H4IIE cells were maintained in RPMI medium 
supplemented with 10% FBS, in an atmosphere of 5% CO2 at 37°C. The cells were 
grown in T-25 flasks until 80% confluence and split 1:10 in culture dishes before 
assays were performed. MCF-7 and BT549 cells were maintained in DMEM 
supplemented with 10% FBS, in an atmosphere of 5% CO2 at 37°C. The cells were 
grown in T-25 flasks until 80% confluence and split 1:4 in culture dishes before 
assays were performed. 
5.2.3 Endotoxin removal from rBalsamin 
Since rBalsamin was expressed and purified from E.coli (bacterial) strain, there were 
chances that the purified product (rBalsamin) could contain endotoxin, which could 
contaminate the mammalian cell cultures used in the study. Therefore, prior to use, 
rBalsamin was made endotoxin free by the use of Pierce high-capacity endotoxin 
removal spin columns as per manufacturer’s protocol. Briefly, the spin column was 
placed in a collection tube and centrifuged at 500 X g for 1 min to remove the 
storage buffer. The flow through was discarded. The column was then washed with 
0.2 N NaOH in 95% ethanol and 2 M NaCl. After discarding the flow through, the 
column was finally washed 4 times with endotoxin-free buffer. The column was then 
placed in a fresh collection tube. rBalsamin was loaded onto the column and 
incubated at 4°C for 1 h. The column was then centrifuged at 500 X g for 1 min to 
collect the sample (endotoxin free rBalsamin), which was stored at -20°C until 
further use. 
5.2.4 rBalsamin treatment groups 
For cell viability assays, rBalsamin at doses of 3.125-200 µg/ml was used. PBS was 
used as a negative (vehicle) control. For all other assays, liver (HepG2 and H4IIE) 
and breast (MCF-7 and BT549) cancer cells were categorized into four groups: 
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control (PBS); low (6.25 µg/ml), medium (25 µg/ml) and high (100 µg/ml) dose 
rBalsamin groups, unless otherwise stated. 
5.2.5 Cell viability assay 
The cell viability assay was performed as described in section 3.2.3. 
5.2.6 DNA fragmentation assay 
The DNA fragmentation assay was performed as described in section 3.2.4. 
5.2.7 Cell cycle analysis 
The cell cycle distribution was analysed by FACSCantoTM II (BD Biosciences, US) 
using propidium iodide (PI), as described in section 3.2.5. 
5.2.8 Caspase-3/-8 activity assay 
The caspase-3 and -8 activity was determined using caspase-3 and caspase-8 
colorimetric assay kits (Sigma, USA), as described in section 3.2.6. 
5.2.9 RNA extraction and RT-PCR for gene expression studies 
The gene expression studies were carried out as described in section 3.2.7. 
5.2.10 Statistical analysis 
Data was analyzed using SPSS Statistics software version 22.0. Data was presented 
as the mean ± SD for at least three independently performed experiments unless 
otherwise stated. Data was assessed for normality using Kolmogorov-Smirnov test. 
One-way ANOVA was used to compare the difference among multiple groups and 
repeated measurements within one group. Two-way ANOVA was used to compare 
the mean difference between groups that have been separated based on two 
independent factors. Probability values with p < 0.05 were considered to be 
statistically significant. 
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5.3 Results and discussion 
5.3.1 Growth inhibitory effect of rBalsamin on liver and breast cancer cells 
RIPs occurring naturally in plants have gained attention as potential anticancer 
therapeutic agents because of their ability to inhibit tumor growth with nominal or 
no side effects (Fang et al. 2012b; Schreiber et al. 1999). Recombinant RIPs from 
Momordica charantia have been shown to produce different degrees of inhibition on 
various tumor cells, including bladder (5637), colorectal (LoVo), breast (MCF-7), 
cervical (HeLa), liver (SMMC-7221), gastric (BGC823 and MGC803) and skin 
(B16) cancer (Zeng et al. 2015). However, little has been reported about the efficacy 
of recombinant RIPs on breast and liver cancer cells and associated mechanisms. 
Therefore, in this study, we evaluated the cytotoxic effect of rBalsamin on liver 
(HepG2 and H4IIE) and breast (MCF-7 and BT549) cancer cells and explored the 
mechanism(s) by which it induces apoptosis in these cell lines.  
Firstly, the effect of rBalsamin treatment on cell viability was evaluated. Liver and 
breast cancer cells were treated with different concentrations of rBalsamin (3.125-
200 µg/ml) to investigate the dose- and time-dependent response of rBalsamin. The 
results showed that rBalsamin suppressed cell proliferation in a dose and time-
dependent manner with IC50 values ranging from 25.53 to 190.57 µg/ml in HepG2 
cells (Figure 5.1a), 43.82 to > 200 µg/ml in H4IIE cells (Figure 5.1b), 18.92 to 
112.17 µg/ml in MCF-7 cells (Figure 5.1c), and 38.09 to > 200 µg/ml in BT549 cells 
(Figure 5.1d). rBalsamin exhibited maximum cytotoxicity towards MCF-7 followed 
by HepG2, BT549 and H4IIE cells. From this, it can be concluded that rBalsamin 
possesses different degrees of cytotoxicity in these cell lines. 
In contrast to nBalsamin, rBalsamin was found to be more effective towards HepG2 
and MCF-7 cells and less effective towards H4IIE and BT549 cells after 72 hr of 
treatment. It is interesting to note that the level of cytotoxicity of rBalsamin and 
nBalsamin varies within the same cells. Further investigation is required to identify 
the cause of this variability of nBalsamin and rBalsamin.  
Cell death occurs as a result of apoptosis (Type I programmed cell death), autophagy 
(Type II programmed cell death), or necrosis (non-physiological process that occurs 
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as a result of infection or injury to the cell) (Kroemer et al. 2009). Since RIPs have 
been reported to induce apoptosis in cancer cells by regulating the activation of 
various apoptotic pathways, we decided to focus towards studying the key hallmarks 
of apoptosis (including DNA fragmentation, cell cycle arrest and expression of 
various apoptotic genes) in rBalsamin treated liver and breast cancer cells.  
 
Figure 5.1: Effect of different concentrations of rBalsamin on the viability of 
HepG2 (a), H4IIE (b), MCF-7 (c) and BT549 (d) cells after 24 h, 48 h and 72 h 
treatment. All values are mean ± SD. SD, standard deviation; n = 3; *P < 0.001, 
main effect of protein concentration; main effect of time; interaction between 
rBalsamin and time, Two-way ANOVA. 
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5.3.2 rBalsamin induces changes in apoptotic morphology and DNA 
fragmentation in liver and breast cancer cells 
Apoptosis is characterized by specific morphological changes in the cell. These 
morphological changes include cell shrinkage, condensation of nuclear chromatin, 
nuclear membrane twisting, and loss of cell connections (Ziegler & Groscurth 2004). 
Therefore, we examined the morphology of HepG2, H4IIE, MCF-7 and BT549 cells 
after rBalsamin treatment. Brightfield microscopy showed that cancer cells treated 
with PBS (negative control) grew efficiently in a uniform pattern with prominent 
cellular outlines. However, after rBalsamin treatment, the growth of HepG2, H4IIE, 
MCF-7 and BT549 cells was inhibited. The inhibition increased with increased 
rBalsamin concentration. Cells treated with rBalsamin exhibited characteristics of 
apoptosis including cell shrinkage, decrease or disappearance of cell connections, 
increased cytoplasmic density and increased cell detachment from the surface. A 
significant increase in the proportion of dead cells was observed in rBalsamin treated 
groups compared to untreated groups (Figure 5.2), similar to the result observed with 
nBalsamin (Figure 3.3). 
Apart from the morphological changes of apoptosis observed in most of the cell 
types, one of the main causes of cell death is DNA fragmentation (Roos & Kaina 
2006). Therefore, we analysed the DNA of H4IIE, HepG2, MCF-7 and BT549 cells 
treated with different concentrations of rBalsamin (6.25, 25 and 100 µg/ml) on 1.5% 
agarose gels. As shown in Figure 5.3, rBalsamin treatment resulted in fragmentation 
of DNA into small oligonucleotides appearing at an interval of 180-200 bp in all 
four cell lines, however, no DNA fragmentation was observed in the cells treated 
with PBS (negative control). DNA laddering appeared to be more conspicuous with 
increasing rBalsamin concentration. These results were similar to the result observed 
with nBalsamin (Figure 3.4). 
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Figure 5.2: Morphology of HepG2, H4IIE, MCF-7 and BT549 cells treated with 
different concentration of rBalsamin for 48 h.  
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Figure 5.3: DNA fragmentation in HepG2 (a), H4IIE (b), MCF-7 (c) and BT549 
(d) cells treated with different concentrations of rBalsamin for 48 h. M and C 
denotes marker (1 KB DNA ladder) and control, respectively. 
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5.3.3 rBalsamin induces cell cycle arrest in liver and breast cancer cells 
Regulation of cell cycle is coupled to cell death and has major significance in cell 
turnover and tumorigenesis (Alenzi 2004). It has been reported that extensive DNA 
damage can result in activation of cell cycle checkpoints and lead to cell cycle arrest 
and apoptosis (Pietenpol & Stewart 2002). Therefore, in our study, we determined 
the distribution of rBalsamin-treated HepG2, H4IIE, MCF-7 and BT549 cells in 
different phases of the cell cycle. Cell proliferation is regulated by the cell cycle; 
therefore sub G1 phase of the cell cycle can also give an estimate of apoptosis. As 
shown in Figure 5.4 a and b, treatment with different concentrations of rBalsamin 
for 48 h led to a dose-dependent increase in the proportion of HepG2 (p < 0.001) and 
H4IIE (P < 0.001) cells in the apoptotic phase compared to the untreated cells. This 
increase in the apoptotic population in HepG2 cells was accompanied by a dose-
dependent increase in the proportion of cells in G phase (p < 0.001) and decrease in 
S phase (Figure 5.4a), suggesting that rBalamin induces apoptosis in HepG2 cells by 
blocking the cell cycle at the G phase, similar to the result observed with nBalsamin 
(Figure 3.5a). Comparatively, an opposite trend was observed in the case of H4IIE 
cells (Figure 5.4b), indicating that rBalsamin induces apoptosis by arresting the cell 
cycle at the S phase in H4IIE cells, similar to the result observed with nBalsamin 
(Figure 3.5b). 
In the case of breast cancer cells, treatment with different concentrations of 
rBalsamin for 48 h led to a dose-dependent increase in the distribution of cells in the 
apoptotic phase in MCF-7 (p < 0.001) and BT549 cells (p < 0.05). This increase was 
accompanied by an increase in the proportion of cells in G phase at rBalsamin 
concentration of 6.25 µg/ml in MCF-7 and BT549 cells. However, with further 
increases in the rBalsamin dose (25 µg/ml and 100 µg/ml), the proportion of cells 
decreased in G phase in MCF-7 and BT549 cells. Comparatively, the proportion of 
cells decreased in a dose-dependent manner in S phase in both cell lines (Figure 5.5 
a and b). These results indicated that rBalsamin tends to arrest the cell cycle at the G 
phase at low rBalsamin dose (6.25 µg/ml) in both MCF-7 and BT549 cells. 
However, when the dose is increased (25 µg/ml and 100 µg/ml), rBalsamin drives 
the cells more towards apoptosis from G phase of the cell cycle. Unlike rBalsamin, 
nBalsamin isolated from Momordica balsamina induced S-phase cell cycle in MCF-
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7 and BT549 cells which was accompanied by decrease in the proportion of cells in 
M and G phase (Figure 3.6 a and b). 
It is noteworthy that rBalsamin induced cell cycle arrest varies with cancer cell type. 
Similar evidence has been reported with other RIPs. α-MMC from Momordica 
charantia blocks cell cycle at S phase in lung cancer (A549) cells (Fan et al., 2015). 
While in breast cancer cells, α-MMC induces cell cycle arrest at G phase in MDA-
MB-231 cells and M phase in MDA-MB-453 and MCF-7 cells (Cao et al., 2015), 
suggesting that RIPs could act differently in similar cancer cell types as well.  
 
Figure 5.4: Cell cycle analysis of HepG2 (a) and H4IIE (b) cells treated with 
different concentrations of rBalsamin for 48 h. All values are mean ± SD. SD, 
standard deviation; n = 3; *P < 0.001, One-way ANOVA. 
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Figure 5.5: Cell cycle analysis of MCF-7 (a) and BT549 (b) cells treated with 
different concentrations of rBalsamin for 48 h. All values are mean ± SD. SD, 
standard deviation; n = 3; *P < 0.001; **P < 0.05, One-way ANOVA. 
5.3.4 rBalsamin induced apoptosis involves activation of caspases in liver and 
breast cancer cells 
Caspases are a family of cysteine proteases that are considered as the key regulators 
of apoptosis. Caspase-3, a key effector is activated by several initiator caspases, 
including caspase-2, -8, -9, -10, -11 and -12, that in turn executes apoptosis by 
regulating the expression of various apoptotic genes (Shi 2004). Therefore, in our 
study, we determined the activity of caspase-3 and -8 in rBalsamin treated liver and 
breast cancer cells. It was observed that rBalsamin significantly increased the 
activity of caspase -3 (P < 0.001) and -8 (P < 0.001) in H4IIE, HepG2, MCF-7 and 
BT549 cells in a dose dependent manner. The increase in caspase-3 and -8 activity 
appeared to be more pronounced in liver cancer (H4IIE and HepG2) cells compared 
to breast cancer (MCF-7 and BT549) cells (Figure 5.6 a and b), similar to the effect 
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observed with nBalsamin (Figure 3.7 a and b). The results indicated that apoptosis in 
rBalsamin treated liver and breast cancer cells involves the activation of caspase-
dependent pathways, most likely the death receptor (extrinsic) apoptotic pathway as 
both caspase-3 and -8 are associated with this pathway. However, caspase-8 is also 
involved in activation of the mitochondrial (intrinsic) cell death pathway. Therefore, 
we investigated the expression of pro-apoptotic and anti-apoptotic genes involved in 
the mitochondrial cell death pathway. 
 
Figure 5.6: Effect of different concentrations of rBalsamin on caspase-3 (a) and 
caspase-8 (b) activity in HepG2, H4IIE, MCF-7 and BT549 cells after 48 h 
treatment. All values are mean ± SD. SD, standard deviation; n = 3; *P < 0.001, 
One-way ANOVA. 
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5.3.5 rBalsamin-induced apoptosis involves regulation of various pro-apoptotic 
and anti-apoptotic genes in liver and breast cancer cells 
During mitochondrial apoptosis, caspase-8 cleaves Bid to release a truncated form of 
the protein named tBid that rapidly accumulates in the mitochondria and activates 
molecular interactions between different members of the Bcl-2 family (Kantari & 
Walczak 2011; Wei et al. 2000). Therefore, we evaluated the expression of Bid in 
rBalsamin treated liver and breast cancer cells. The qRT-PCR confirmed that the 
level of Bid was significantly upregulated in rBalsamin treated H4IIE, HepG2, 
MCF-7 and BT549 cells compared to the untreated cells. The effect appeared to be 
more conspicuous in HepG2 cells compared to the other cell lines (Figure 5.7a), 
similar to the effect observed with nBalsamin (Figure 3.8b). It has been reported that 
Bid is transcriptionally upregulated in response to stabilized p53 (Sax et al. 2002). 
The tumor suppressor protein, p53, is a key regulator of apoptosis. It integrates 
multiple stress signals into a diverse series of antiproliferative responses to execute 
apoptosis (Fridman & Lowe 2003). Consequently, we determined the expression of 
p53 in rBalsamin treated cancer cells. The qRT-PCR results showed that the 
expression of p53 significantly increased in a dose dependent manner in rBalsamin 
treated H4IIE, HepG2 and MCF-7 and BT549 cells compared to the untreated cells. 
The effect was similar in HepG2, H4IIE and MCF-7 cells, while it appeared to be 
less prominent in BT549 cells (Figure 5.7b). Unlike rBalsamin, the effect appeared 
to be similar in HepG2 and H4IIE cells while it appeared to be less prominent in 
MCF-7 and BT549 cells treated with nBalsamin (Figure 3.8a). 
The cleavage of Bid and activation of p53 can increase the expression of pro-
apoptotic (Bax, Bad, Bak and Bok) genes and reduce the expression of anti-apoptotic 
(Bcl-2 and Bcl-XL) genes to promote mitochondrial apoptosis (Lee & Chang 2010; 
Pawlowski & Kraft 2000; Westphal et al. 2011). Therefore, to confirm the 
involvement of the mitochondrial apoptotic pathway in rBalsamin treated liver and 
breast cancer cells, we further evaluated the expression of pro-apoptotic (Bax and 
Bad) and anti-apoptotic (Bcl-2 and Bcl-XL) genes. The qRT-PCR results showed that 
the expression of Bax significantly increased in rBalsamin treated liver and breast 
cancer cells with a maximum effect observed in HepG2 and BT549 cells (Figure 
5.8a), similar to the effect observed with nBalsamin (Figure 3.9a). The expression of 
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Bad increased with rBalsamin treatment in all the four cell lines. However, the effect 
appeared to be more pronounced in HepG2 cells while it was similar in all the other 
cell lines (Figure 5.8b). These observations were similar to those observed with 
nBalsamin (Figure 3.9b). 
 
Figure 5.7: Expression of Bid (a) and p53 (b) genes in HepG2, H4IIE, MCF-7 
and BT549 cells treated with different concentrations of rBalsamin for 48 h. All 
values are mean ± SD. SD, standard deviation; n = 3; *P < 0.001, One-way 
ANOVA. 
Chapter 5 
148 
 
Figure 5.8: Expression of Bax (a) and Bad (b) genes in HepG2, H4IIE, MCF-7 
and BT549 cells treated with different concentrations of rBalsamin for 48 h. All 
values are mean ± SD. SD, standard deviation; n = 3; *P < 0.001; **P = 0.001; 
***P = 0.013, One-way ANOVA. 
In addition, we also evaluated the expression of anti-apoptotic genes (Bcl-2 and Bcl-
XL) in rBalsamin treated liver and breast cancer cell lines. The qRT-PCR results 
showed that the expression of Bcl-2 and Bcl-XL decreased in a dose dependent 
manner when HepG2, H4IIE, MCF-7 and BT549 cells were treated with different 
concentrations of rBalsamin (Figure 5.9 a and b). In contrast, nBalsamin decreased 
Chapter 5 
149 
the expression of Bcl-2 and Bcl-XL in MCF-7 and BT549 in a dose dependent 
manner with no effect observed in HepG2 and H4IIE cells (Figure 3.10 a and b), 
indicating that the function of nBalsamin and rBalsamin varies within the same cell 
type. 
 
Figure 5.9: Expression of anti-apoptotic genes, Bcl-2 (a) and Bcl-XL (b), in 
HepG2, H4IIE, MCF-7 and BT549 cells treated with different concentrations of 
rBalsamin for 48 h. All values are mean ± SD. SD, standard deviation; n = 3; *P 
< 0.001; **P = 0.004, One-way ANOVA. 
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Results of cell cycle arrest, the activation of caspases, upregulation of pro-apototic 
genes (Bax, Bid, Bad and p53) and downregulation of anti-apoptotic genes (Bcl-2 
and Bcl-XL) confirm the involvement of the mitochondrial apoptotic pathway in 
rBalsamin induced apoptosis in HepG2, H4IIE, MCF-7 and BT549 cells. A number 
of RIPs naturally occurring in plants exhibit anti-liver and anti-breast cancer activity. 
α-MMC from Momordica charantia, and TCS from Trichosanthes kirilowii induced 
apoptosis in MCF-7, MDA-MB-231 and MDA-MB-453 via the mitochondrial cell 
death pathway and cell cycle arrest (Cao et al. 2015; Fang et al. 2012c). MAP30 
from Momordica charantia induced apoptosis in HepG2 cells via cell cycle arrest, 
extrinsic and intrinsic (mitochondrial) apoptotic pathways (Fang et al. 2012b). 
However, little has been reported on the anti-liver and anti-breast cancer potential of 
recombinant RIPs. rMAP30 and rMAP30 fused with human derived cell penetrating 
peptide (HBD) have been shown to induce apoptosis in  HeLa, MCF-7, 5637, 
SMMC-7721, MGC803 and B16 cells (Lv et al. 2015). However, the actual 
mechanism by which it promotes apoptosis in MCF-7 cells has not been described.  
5.3.6 rBalsamin induces ER-stress mediated apoptosis in liver and breast 
cancer cells 
In addition to the mechanisms of death receptor and mitochondrial mediated 
apoptosis, ER-stress can also lead to programmed cell death (Zhang & Kaufman 
2004). C/EBP homologous protein (CHOP), also known as DNA damage-inducible 
gene 153 (GADD153), is one of the key mediators of ER stress-mediated apoptosis. 
It is usually expressed at undetectable levels, however, its expression is induced by 
cellular stress (Bento, Andersson & Aman 2009). The 78 kDa glucose regulated 
protein (GRP78), also known as BiP, is a major regulator of ER function and is 
involved in protein folding and assembly, targeting misfolded proteins for 
degradation and regulating the activation of ER stress signals. In response to ER 
stress, GRP78 expression is upregulated to assist proper protein folding and it is 
considered to be an important component involved in ER stress-induced apoptosis 
(Li & Lee 2006). RIPs have also been reported to induce ER stress-mediated 
apoptosis in cancer cells (Pan et al. 2013). TCS, a type I RIP induced apoptosis in 
cervical cancer (HeLa) cells and leukemia (HL-60) cells via ER stress signaling 
pathway (Huang et al. 2010; Li et al. 2007a). Therefore, we studied the expression of 
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genes (CHOP and GRP78) involved in this pathway. The qRT-PCR results showed 
that the expression of GRP78 and CHOP was significantly upregulated in rBalsamin 
treated liver cancer (H4IIE and HepG2) cells, however, the expression of neither 
GRP78 nor CHOP were affected in rBalsamin treated breast cancer (MCF-7 and 
BT549) cells, compared to the untreated cells (Figure 5.10 a and b). Interestingly, 
our results indicate that the apoptotic effect of rBalsamin on liver cancer (H4IIE and 
HepG2) cells but not on breast cancer (MCF-7 and BT549) cells may be partially 
attributed to ER stress. These observations were similar to those observed with 
nBalsamin (Figure 3.11 a and b).  
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Figure 5.10: Expression of genes involved in ER-stress mediated apoptosis, 
GRP78 (a) and CHOP (b), in HepG2, H4IIE, MCF-7 and BT549 cells treated 
with different concentrations of rBalsamin (6.25, 25 and 100 µg/ml) for 48 h. All 
values are mean ± SD. SD, standard deviation; n = 3; *P < 0.001, One-way 
ANOVA. 
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5.4 Conclusions 
The present study demonstrates for the first time the potential cytotoxicity of 
rBalsamin on liver (HepG2 and H4IIE) and breast (MCF-7 and BT549) cancer cells. 
It was found that rBalsamin could inhibit the proliferation of liver and breast cancer 
cells in a dose and time dependent manner with IC50 ranging between 18.92 to > 200 
µg/ml. rBalsamin induced apoptosis in these cells via DNA fragmentation, cell cycle 
arrest and regulating the expression of various pro-apoptotic and anti-apoptotic 
markers. Cell cycle analysis revealed that rBalsamin could arrest cell cycle at G and 
S phases of the cell cycle suggesting that rBalsamin interferes with the cell cycle 
progression and induces apoptosis in cancer cells. In addition, caspase-3 and -8 
activity significantly increased in a dose dependent manner in these cell lines after 
rBalsamin treatment. RT-PCR results demonstrated that rBalsamin significantly 
upregulated the expression of pro-apoptotic genes, Bax, Bid, Bad and p53, and 
downregulated the expression of anti-apoptotic genes, Bcl-2 and Bcl-XL, in liver and 
breast cancer cells, indicating that the intrinsic and extrinsic cell death pathways are 
involved in rBalsamin-induced apoptosis in liver and breast cancer cells. Interesting, 
the expression of genes, GRP78 and CHOP, involved in ER-stress mediated 
apoptosis significantly increased in liver cancer cells but not in breast cancer cells, 
suggesting that rBalsamin might activate an additional pathway of apoptosis (ER-
stress mediated pathway) in liver cancer cells. This multifunctional biomolecule 
with variable characteristics could be a new hope for cancer patients. However, 
further in vivo studies would be beneficial to develop this biomolecule as an 
effective therapeutic agent.  
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Chapter 6: Combination of nBalsamin and flavonoids enhances in 
vitro cytotoxicity in HepG2 and MCF-7 cells. 
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6.1 Introduction 
Flavonoids are group of polyphenolic compounds found in fruits, vegetables, herbs, 
cereals and dairy products (Cook & Samman 1996). The basic structure of 
flavonoids consists of 15 carbon atoms and two benzene rings (A and B, Figure 6.1), 
connected via a heterocyclic pyran ring (C, Figure 6.1). Based on their chemical 
structure, flavonoids are categorized into 12 major subclasses, six of which, namely 
anthocyanidins, flavonols, flavanones, flavan-3-ols, flavones and isoflavones are of 
dietary significance (Kumar & Pandey 2013). Flavonoids as a complementary 
medicine have attracted the attention of researchers due to their diverse 
pharmacological properties, including antioxidation, antibacterial, antiviral, 
antitumor, anti-atherosclerosis, antidiabetic, anti-inflammatory, antithrombogenic, 
hypolipidemic, and neuroprotective effects (Huang et al. 2016). Such biological 
diversity of flavonoids appears to be associated with their ability to regulate a 
number of cell signaling cascades, and could play a pivotal role in human health 
(Williams, Spencer & Rice-Evans 2004).  
 
Figure 6.1: Basic chemical structure of flavonoids (Kumar & Pandey 2013). 
Of all the polyphenols known, naringenin (Nar) and its derivatives are known to 
possess strong antioxidant potential along with other biologically beneficial effects 
(Sumathi, Tamizharasi & Sivakumar 2015). Nar is a flavone, a type of flavonoid that 
is abundantly found in citrus fruits. It is derived from the hydrolysis of the glycone 
form of flavanone, such as naringin (Figure 6.2a) (Erlund 2004; Puri et al. 2012). 
Naringin (Nir) consists of two sugar units (glucose and rhamnose) attached to its 
aglycon portion, naringenin, at the 7-carbon atom (Figure 6.2a) (Alam et al. 2014). 
Studies have shown that both Nar and Nir exert a variety of common 
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pharmacological effects including antioxidant, anti-inflammatory, anticarcinogenic 
and hepatoprotective effects (Bharti et al. 2014). Quercetin (Qu) is a flavonol, 
another type of flavonoid that is abundantly found in edible fruits and vegetables, 
and has also gained attention in human health. It consists of two aromatic rings 
connected via oxygen containing heterocyclic ring (Figure 6.2b) (Gibellini et al. 
2011). Qu has reported health benefits similar to Nar and Nir, and it has also been 
used therapeutically in allergic conditions (such as asthma, hayfever, eczema and 
hives), arthritis, metabolic syndrome and mood disorders (Kelly 2011). 
 
Figure 6.2: Structure of naringin and its hydrolysed product (a), and quercetin 
(b). 
Several studies have demonstrated that these flavonoids exhibit anticancer properties 
towards various cancers, including liver, breast, lung, colon, and bladder cancer 
(Park & Pezzuto 2012). Nar inhibited the proliferation of breast cancer (MCF-7) 
cells by blocking insulin stimulated glucose uptake in GLUT4 (insulin responsive 
glucose transporter) expressing, insulin responsive MCF-7 cells. Nar blocked 
glucose uptake by impairing the activation of phosphoinositide3-kinase (P13K), a 
key regulator of insulin induced GLUT4 translocation, and inhibiting the 
phosphorylation of p44/p42 mitogen-activated protein kinase (MAPK), a step 
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essential for the insulin signaling pathway (Harmon & Patel 2004). Nir induced 
apoptosis in breast cancer cells (MDA-MB-231 and BT549) by increasing the 
expression of p21 and decreasing the expression of survivin (inhibitor of apoptosis 
protein, IAP) and active β-catenine (Li et al. 2013). Similarly, Qu supressed the 
expression of survivin and induced G0/G1 phase cell cycle arrest in breast cancer 
(MCF-7) cells (Deng et al. 2013). In the case of liver cancer (HepG2) cells, Qu 
induced apoptosis via inhibition of FASN (fatty acid synthase), a metabolic enzyme 
that is usually upregulated during early stages of tumorigenesis (Zhao et al. 2014). 
Nar and Nir induced apoptosis in HepG2 cells via mitochondrial mediated activation 
of caspase-9 and caspase-8 mediated proteolysis of Bid (Arul & Subramanian 2013; 
Banjerdpongchai, Wudtiwai & Khaw-on 2016). This evidence suggests that the anti-
cancer effects of these flavonoids involve various mechanisms, a desirable trait in 
cancer therapeutics.  
Balsamin, a type I RIP from Momordica balsamina, exhibits potent anti-HIV 
activity. It blocks the replication of HIV by inhibiting the translation step, occurring 
prior to viral budding and release (Kaur et al. 2013). Our recent studies have shown 
that nBalsamin (nBal) exhibits DNase-like activity, and broad spectrum 
antimicrobial and antioxidant activity (Ajji, Walder & Puri 2016). Further, in 
subsequent studies on the anti-proliferative effects of nBal on liver (HepG2 and 
H4IIE) and breast cancer (MCF-7 and BT549) cells, we observed that nBal induced 
apoptosis in liver cancer cells via increasing the expression of pro-apoptotic markers 
involved in mitochondrial mediated (caspase-3, Bax, Bid, Bad and p53), death 
receptor mediated (caspase -3 and -8) and ER-stress mediated (GRP78 and CHOP) 
apoptotic pathways, with no profound effect observed in the expression of anti-
apoptotic genes (Bcl-2 and Bcl-XL). However, in breast cancer cells, nBal increased 
the expression of pro-apoptotic markers and also simultaneously decreased the 
expression of anti-apoptotic genes, triggering mitochondrial mediated and death 
receptor mediated apoptosis. Interestingly, nBal did not activate the ER stress-
mediated pathway in breast cancer cells, suggesting diverse mechanisms of 
apoptosis induction in different cancer cells. 
nBal and flavonoids (Nar, Nir and Qu) appear to exert antitumor effects and induce 
apoptosis through similar mechanisms in liver (HepG2) and breast (MCF-7) cancer 
Chapter 6 
158 
cells, therefore, we hypothesized that nBal-flavonoid (Nar, Nir and Qu) 
combinations might have additive apoptotic effects on these cells. Thus, in this 
study, we examined the effect of co-treatment of nBal and three flavonoids, namely 
Nar, Nir and Qu, on HepG2 and MCF-7 cells. 
6.2 Materials and methods 
6.2.1 Chemicals, reagents and kits 
Nar, Nir and Qu, trypsin, In vitro toxicology assay kit, caspase-3 assay kit and 
caspase-8 assay kit were procured from Sigma-Aldrich (USA). RPMI and DMEM 
media, and FBS were purchased from Life Technologies Corporation (California, 
USA). Total RNA isolation kit was purchased from Qiagen (Hilden, Germany). 
Propidium iodide (PI) flow cytometry kit was procured from BD Biosciences (San 
Jose, CA). All other reagents were either purchased from Sigma-Aldrich (USA) or 
Bio-Rad Laboratories (California, USA), and were of analytical grade. 
6.2.2 Cell lines and cell culture 
For the present study, liver (HepG2) and breast (MCF-7) cancer cells lines were 
investigated. These cell lines were procured from the ATCC (Rockville, MD). 
HepG2 and MCF-7 cells were maintained in RPMI and DMEM media supplemented 
with 10% FBS, respectively, as described in section 3.2.2. 
6.2.3 Treatment groups 
For cell viability assay, HepG2 and MCF-7 cells were treated for 24 h with a 
treatment regime given in Figure 6.3. Based on data, treatments highlighted in 
Figure 6.3 were selected for all the other assays. 
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Figure 6.3: Treatment regime used for the study.  
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6.2.4 Cell viability assay 
The cell viability was determined using In vitro toxicology assay kit, as described in 
section 3.2.3. 
6.2.5 DNA fragmentation assay 
The DNA fragmentation assay was performed as described in section 3.2.4. 
6.2.6 Caspase-3/-8 activity assay 
The caspase-3 and -8 activity was determined using caspase-3 and caspase-8 
colorimetric assay kits, as described in section 3.2.6. 
6.2.7 RNA extraction and RT-PCR for gene expression studies 
The gene expression studies were carried out as described in section 3.2.7. 
6.2.8 Statistical analysis 
Data was analysed using SPSS Statistics software version 22.0. Data was presented 
as the mean ± SD for at least three independently performed experiments unless 
otherwise stated. The non-parametric test, Kruskal-Wallis H test, also known as one-
way ANOVA on ranks, was used to compare the difference between two or more 
groups. Mann-Whitney U test was used to compare the difference between two 
groups. Probability values with p < 0.05 were considered to be statistically 
significant. 
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6.3 Results and discussion 
6.3.1 Growth inhibitory effects of nBal combined with flavonoids on HepG2 
and MCF-7 cells. 
The relationship between diet and cancer has been implicated in number of 
epidemiological studies (Ross 2010). Vegetables, fruits and cereals contain 
flavonoids that have antioxidant, anti-inflammatory and anticancer properties. Nar, 
Nir and Qu are three such flavonoids that have been explored for their anti-
proliferative effects towards various cancer cells. Nar, a natural flavone exhibits 
anti-tumor activity towards various tumor cell types including hepatoma (HepG2), 
breast cancer (MCF-7, HTB26 and HTB132), leukemia (K562), human epidermoid 
carcinoma (A431), colorectal cancer (SW1116 and SW837) and glioma cells (C6) 
(Abaza et al. 2015; Ahamad et al. 2014; Arul & Subramanian 2013; Harmon & Patel 
2004; Li et al. 2015; Sabarinathan, Mahalakshmi & Vanisree 2011). Nir exerts 
antiproliferative effects on cancer cells such as breast cancer (MDA-MB-231 and 
BT549), liver cancer (HepG2), bladder cancer (5637), melanoma (A375) and 
glioblastoma (U87MG) (Guo et al. 2016; Kim et al. 2008; Li et al. 2016). Qu 
possesses antitumor activity against liver cancer (HepG2), breast cancer (MCF-7), 
leukemia (HL-60) and prostate cancer (DU-145 and PC-3) cells (Deng et al. 2013; 
Nair et al. 2004; Niu et al. 2011; Zhao et al. 2014). 
Several studies have reported that flavonoids with antioxidant properties synergize 
the effect of chemotherapeutic agents (Lewandowska et al. 2014). Qu increased 
cisplatin-induced apoptosis in human laryngeal cancer (Hep-2) cells (Kuhar, Imran 
& Singh 2007). 4T1 breast tumor mice treated with Qu and doxorubicin 
demonstrated inhibition of tumor growth and reduction of doxorubicin side effects, 
leading to prolonged survival of the mice (Du et al. 2010). Qu enhanced the 
antitumor effect of trichostatin-A, a novel anticancer agent, in human lung cancer 
cells through upregulation of p53 expression (Chan et al. 2013). Our previous 
studies demonstrated that nBal, a type-I RIP isolated from Momordica balsamina, 
exhibits inhibitory effects towards liver and breast cancer cells, highlighting its 
potential as a therapeutic agent. However, nothing is known about the combined 
effects of RIPs and flavonoids on cancer cells. Therefore, in this study, we 
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investigated the apoptotic effects of nBal in the presence of three flavonoids, namely 
Nar, Nir and Qu, on liver (HepG2) and breast (MCF-7) cancer cells.  
To test this, we first examined the effect of co-treatment of nBal (25 µg/ml) and 
flavonoids (Nar, Nir or Qu) on the viability of HepG2 and MCF-7 cells using an In 
vitro toxicology assay kit. As shown in Figure 6.4a and b, the combination of nBal 
with low dose (0.5 X IC50) of Nar appeared to inhibit the viability of HepG2 and 
MCF-7 cells compared to the cells treated with nBal. When the concentration of Nar 
(1.0 X IC50 and 2.0 X IC50) was increased in combination with nBal, the inhibitory 
effect tended to increase compared with nBal treatment, however, did not increase 
much compared to Nar treatment. Interestingly, the effects appeared to be additive at 
low dose of Nar with nBal, but not at higher doses of Nar (Figure 6.4a and b). 
Further, the trend appeared to be similar when HepG2 and MCF-7 were treated with 
nBal-Qu combinations (Figure 6.5a and b). However, when HepG2 and MCF-7 cell 
were co-treated with low dose (0.5 X IC50) of Nir and nBal, the cell viability tended 
to decrease slightly compared to singly treated groups, however, the effect was not 
as prominent as observed with low dose (0.5 X IC50) of Nar or Qu with nBal. 
Further, when the concentration of Nir (1.0 X IC50 and 2.0 X IC50) was increased in 
combination with nBal, the inhibitory effect tended to increase compared with nBal 
treatment alone, however, did not increase much compared to Nir treatment alone. 
(Figure 6.6a and b). These results suggest that these flavonoids could increase the 
anti-proliferative effects of nBal on HepG2 and MCF-7 cells, with low dose (0.5 X 
IC50) of flavonoids (Nar, Nir and Qu) tending to have an additive effect in 
combination with nBal. Therefore, we selected this flavonoid dose in combination 
with nBal for further study. 
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Figure 6.4: Effect of nBal and Nar on the viability of HepG2 (a) and MCF-7 (b) 
cells compared with nBal. All values are mean ± SD. SD, standard deviation; n 
= 3; *P < 0.05, Kruskal-Wallis H test. 
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Figure 6.5: Effect of nBal and Qu on the viability of HepG2 (a) and MCF-7 (b) 
cells compared with nBal. All values are mean ± SD. SD, standard deviation; n 
= 3; *P < 0.05, Kruskal-Wallis H test. 
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Figure 6.6: Effect of nBal and Nir on the viability of HepG2 (a) and MCF-7 (b) 
cells compared with nBal. All values are mean ± SD. SD, standard deviation; n 
= 3; *P < 0.05, Kruskal-Wallis H test. 
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6.3.2 Effect of nBal-flavonoid combinations on the morphology of HepG2 and 
MCF-7 cells 
Flavonoids, such as Nar, Nir and Qu are known to induce apoptosis in various 
cancer cells by regulating the expression of apoptotic markers (Arul & Subramanian 
2013; Banjerdpongchai, Wudtiwai & Khaw-on 2016). In addition, our studies have 
also shown that nBal induces apoptosis via a similar pathway to flavonoids. 
Therefore, we next investigated whether flavonoids (Nar, Nir or Qu) could increase 
nBal induced apoptotic effects in HepG2 and MCF7 cells. For this, we examined the 
morphology of HepG2 and MCF-7 cells treated with combinations of nBal and Nar, 
Nir or Qu, and compounds alone under brightfield microscopy. The results showed 
that apoptotic morphological changes, such as loss in cell connections, cell 
shrinkage, cell surface detachment, increased cytoplasmic density and more dead 
cells appeared to be more prominent in cells treated with nBal-flavonoid (Nar, Nir or 
Qu) combinations compared to single treatments (Figure 6.7).  
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Figure 6.7: Morphology of HepG2 and MCF-7 cells treated with nBal-Nar, 
nBal-Qu and nBal-Nir compared with nBal, Nar, Qu and Nir alone. 
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6.3.3 Caspase-3 and -8 activity of nBal combined with Nar, Nir or Qu in HepG2 
and MCF-7 cells 
Apoptosis is a programmed and often energy dependent process that involves 
activation of caspases, a group of cysteine proteases, and a complex cascade of 
signals (Elmore 2007). Flavonoids such as Nar, Nir and Qu have been reported to 
activate caspase dependent apoptosis in cancer cells (Ramos 2007). Nar and Nir 
induced apoptosis in HepG2 cells via activating caspase-8 and caspase-9 mediated 
cell death pathways (Arul & Subramanian 2013; Banjerdpongchai, Wudtiwai & 
Khaw-on 2016). Qu induced cell death in glioblastoma U373MG cells through 
proteolytic activation of caspase-3 and caspase-7, a decrease in mitochondrial 
membrane potential and increases in caspase-3 and caspase-9 activities (Kim et al. 
2013). Our studies have demonstrated that nBal also induces apoptosis by increasing 
the activity of caspase-3 and -8 in liver and breast cancer cells. Therefore, we further 
decided to evaluate whether flavonoids (Nar, Nir and Qu) increase caspase-mediated 
apoptotic effects in nBal treated HepG2 and MCF-7 cells. As shown in Figure 6.8a, 
nBal-Nar treatment tended to increase and appeared to have an additive effect on 
caspase-3 and -8 activity in HepG2 and MCF-7 cells compared to nBal and Nar 
alone. However, no significant differences were observed between co-treated, nBal 
and Nar treated groups. Further, the trend appeared to be similar in HepG2 and 
MCF-7 cells treated with the nBal-Qu combination (Figure 6.8b). However, when 
HepG2 and MCF-7 cells were treated with the nBal-Nir combination, the caspase-3 
and -8 activity tended to increase as compared to Nir and nBal treatment alone, 
however, did not appear to have an additive effect (Figure 6.8c).  
These results indicate that out of all the nBal-flavonoid combinations tested, nBal-
Nar and nBal-Qu appeared to be a more effective combination compared to nBal-Nir 
in HepG2 and MCF-7 cells.  
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Figure 6.8: Effect of nBal-Nar (a), nBal-Qu (b) and nBal-Nir (c) on caspase-3 
and -8 activity compared with nBal in HepG2 and MCF-7 cells. All values are 
mean ± SD. SD, standard deviation; n = 3; *P < 0.05, Kruskal-Wallis H test. 
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6.3.4 Effect of nBal-flavonoid combinations on the expression of various 
apoptotic genes involved in the mitochondrial cell death pathway. 
Apoptosis is an essential physiological process that is regulated by the Bcl-2 family 
of pro-apoptotic and anti-apoptotic genes. Flavonoids, such as Nar, Nir and Qu, have 
been reported to trigger apoptosis via regulating the expression of pro-apoptotic and 
anti-apoptotic genes involved in the mitochondrial cell death pathway (Ramos 
2008). Nar isolated from Thymus vulgaris upregulated pro-apoptotic markers, p18, 
p19, p21, Bax and Bak, and downregulated anti-apoptotic markers, Cdk4, Cdk6, 
Cdk7 and Bcl-2 in human colorectal and breast cancer cells leading to apoptosis 
(Abaza et al. 2015). Qu induced apoptosis in HepG2 hepatoma cells by decreasing 
the Bcl-XL:Bcl-XS ratio, activating caspase-3 and -9 and increasing the translocation 
of Bax to the mitochondrial membrane, leading to mitochondrial mediated apoptosis 
(Granado-Serrano et al. 2006). Our previous studies demonstrated that nBal induces 
the mitochondrial cell death pathway in HepG2 and MCF-7 cells by increasing the 
expression of pro-apoptotic genes, Bax, Bid, Bad and p53, and decreasing the 
expression of anti-apoptotic genes, Bcl-2 and Bcl-XL. Therefore, we studied whether 
these flavonoids could increase nBal-induced mitochondrial apoptotic effects in 
HepG2 and MCF-7 cells. The qRT-PCR results showed that nBal-Nar treatment 
tended to increase and appeared to have an additive effect on the expression of Bax, 
Bid, Bad and p53 compared to nBal treatment alone in HepG2 and MCF-7 cells. 
However, no significant difference was observed between the groups (Figure 6.9a). 
Further, the trend appeared to be similar in HepG2 and MCF-7 cells treated with the 
nBal-Qu combination (Figure 6.9b), suggesting that Nar and Qu increase nBal-
induced apoptotic effect in HepG2 and MCF-7 cells.  
In addition, the nBal-Nir combination appeared to increase the expression of Bax, 
Bid, Bad and p53 as compared nBal treatment alone in HepG2 and MCF-7 cells. 
However, the effect did not appear to be pronounced and additive compared to nBal-
Nar and nBal-Qu treatment (Figure 6.9c), suggesting that the nBal-Nar and nBal-Qu 
combinations could be considered more effective than the nBal-Nir combination. 
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Figure 6.9: Effect of nBal-Nar (a), nBal-Qu (b) and nBal-Nir (c) on the 
expression of pro-apoptotic genes, Bax, Bid, Bad and p53, compared with nBal 
in HepG2 and MCF-7 cells. All values are mean ± SD. SD, standard deviation; 
n = 3; *P < 0.05, Kruskal-Wallis H test. 
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Further, we also evaluated the expression of anti-apoptotic genes (Bcl-2 and Bcl-XL) 
in HepG2 and MCF-7 cells treated with nBal-flavonoid (Nar, Nir or Qu) 
combinations. The qRT-PCR results showed that nBal-Nar treatment tended to 
decrease the expression of Bcl-2 and Bcl-XL compared to nBal and Nar treatment 
alone in HepG2 and MCF-7 cells, indicating a possible additive effect. However, no 
significant difference was observed between the groups (Figure 6.10a). Likewise, 
the trend appeared to similar, but less pronounced in HepG2 and MCF-7 cells treated 
with nBal-Qu and nBal-Nir combinations (Figure 6.10b and c). 
Increase in activation of caspase-3 and -8, upregulation of pro-apoptotic genes (Bax, 
Bid, Bad, p53) and downregulation of anti-apoptotic genes (Bcl-2 and Bcl-XL) with 
nBal-Nar, nBal-Nir and nBal-Qu treatment compared to nBal and flavonoid (Nar, 
Nir or Qu) treatment alone in HepG2 and MCF-7 cells, suggests that these 
flavonoids increase nBal-induced mitochondrial mediated apoptosis with a possible 
additive effect in HepG2 and MCF-7 cells, which could be considered as a 
promising strategy to sensitize cells to nBal treatment. 
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Figure 6.10: Effect of nBal-Nar (a), nBal-Qu (b) and nBal-Nir (c) on the 
expression of anti-apoptotic genes, Bcl-2 and Bcl-XL, compared with nBal in 
HepG2 and MCF-7 cells. All values are mean ± SD. SD, standard deviation; n = 
3; *P < 0.05, Kruskal-Wallis H test. 
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6.3.5 Effect of nBal-flavonoid combinations on the expression of genes involved 
in ER-stress mediated apoptosis 
The ER-stress response has been reported to initiate apoptosis in various cancer 
cells, through three different pathways; (i) activation of CHOP, also known as DNA 
damage-inducible gene 153 (GADD153), (ii) activation of ER associated caspases 
and (iii) activation of c-Jun N- terminal kinase (JNK)-mediated cell death (G 
Johnson, C White & Grimaldi 2011). Qu induced ER-stress mediated apoptosis by 
increasing the expression of ATF, GRP78 and CHOP in prostate cancer PC-3 cells 
(Liu et al. 2014). It has been reported that Qu pre-treatment elicits ER-stress to 
enhance cisplatin cytotoxicity in ovarian cancer cells, indicating that Qu has a 
potential to enhance the efficacy of cisplatin induced apoptosis in ovarian cancer 
cells (Yang et al. 2015). Our studies have shown that nBal induces ER-stress 
mediated apoptosis in liver cancer (H4IIE and HepG2) cells by increasing the 
expression of CHOP and GRP78, however, it does not activate this pathway in 
breast cancer (MCF-7 and BT549) cells. Therefore, to investigate whether nBal-
flavonoid treatment could increase nBal-induced ER stress in HepG2 cells and 
activate this pathway in breast cancer (MCF-7) cells, we evaluated the expression of 
CHOP and GRP78 in nBal-flavonoid (Nar, Nir and Qu) treated HepG2 and MCF-7 
cells. 
The qRT-PCR results showed that the expression of GRP78 and CHOP tended to 
increase in HepG2 cells treated with nBal-Nar (Figure 6.11a), nBal-Qu (Figure 
6.11b) and nBal-Nir (Figure 6.11c) combinations compared to nBal and flavonoids 
(Nar, Nir and Qu) treatment alone, indicating a possible additive effect of co-
treatment in HepG2 and MCF-7 cells. In the case of MCF-7 cells, nBal treatment 
alone did not increase the expression of GRP78 and CHOP. However, when nBal 
was combined with the flavonoids (Nar, Qu and Nir), the expression tended to 
increase with respect to nBal treatment, but did not increase significantly with 
respect to flavonoid (Nar, Qu and Nir) treatment alone, suggesting that the effect 
was entirely due to the presence of the flavonoid (Nar, Qu or Nir) in the nBal-
flavonoid combinations (Figure 6.11a, b and c). It is interesting to note that these 
flavonoids activate ER-stress mediated apoptosis, an additional apoptotic pathway, 
in breast cancer MCF-7 cells that is not activated by nBal treatment alone. 
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Figure 6.11: Effect of nBal-Nar (a), nBal-Qu (b) and nBal-Nir (c) on the 
expression of genes, GRP78 and CHOP, involved in ER-stress mediated 
apoptosis, compared with nBal in HepG2 and MCF-7 cells. All values are mean 
± SD. SD, standard deviation; n = 3; *P < 0.05, Kruskal-Wallis H test. 
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6.4 Conclusions 
The present study demonstrates the efficacy of flavonoids (Nar, Qu and Nir) to 
enhance nBal-induced apoptosis in HepG2 and MCF-7 cells. Three doses (0.5 X 
IC50, 1.0 X IC50 and 2.0 X IC50) of flavonoids (Nar, Qu and Nir) were tested in 
combination with nBal (25 µg/ml). It was observed that low dose (0.5 X IC50) of 
flavonoid in combination with nBal appeared to inhibit the viability of HepG2 and 
MCF-7 cells compared to the cells treated with nBal. When the concentration of 
flavonoid (1.0 X IC50 and 2.0 X IC50) was increased in combination with nBal, the 
inhibitory effect tended to increase compared with nBal treatment, however, did not 
increase much compared to flavonoid (Nar, Nir and Qu) treatment. Interestingly, low 
dose of flavonoid with nBal appeared to produce an additive effect but higher doses 
didnot. Based on this, low dose of flavonoids in combination with nBal was selected 
for further study. Our studies demonstrated that combination of nBal and low dose 
(0.5 X IC50) of flavonoids (Nar, Qu and Nir) appears to exhibit a more apparent anti-
tumor activity in vitro compared to each of them alone. Mechanically, these 
flavonoids (Nar, Qu and Nir) tended to increase the activation of caspase-3 and -8, 
upregulate pro-apoptotic genes (Bax, Bid, Bad and p53) and downregulate anti-
apoptotic genes (Bcl-2 and Bcl-XL), suggesting that these flavonoids could possibly 
enhance nBal-induced mitochondrial mediated apoptosis in HepG2 and MCF-7 
cells. Out of the three flavonoids (Nar, Qu and Nir) tested, the nBal-Nir combination 
appeared to be least effective compared with the nBal-Nar and nBal-Qu 
combinations. In addition, it was observed that these flavonoids could also activate 
ER-stress mediated apoptosis in breast cancer (MCF-7) cells, which was not 
activated by nBal treatment alone. These results suggest that nBal, in a combined 
treatment with flavonoids (Nar, Qu and Nir), could be a promising therapeutic 
strategy to reduce HepG2 and MCF-7 proliferation and to sensitize cells to nBal 
treatment. However, in vivo studies are required to further evaluate its effectiveness 
against liver and breast cancer.  
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Cancer is one of the leading causes of deaths worldwide. Although scientific 
advancements have been made to treat cancer, limitations and room for improvement 
still remains. Chemotherapy is the most common treatment available for cancer 
patients. However, drawbacks such as serious side effects and development of 
resistance to drugs limit its effectiveness. Nowadays, great deal of research efforts are 
being made to discover natural therapeutics such as plant derived products with 
minimal side effects.  
Momordica balsamina is a medicinal and nutraceutical plant advocated for health care 
management, however it has not received major international attention (Puri 2010). 
This plant comprises tendril bearing high climbing vines. The leaves, seeds, bark and 
fruits of the plant contain large number of medicinal compounds such as 
phytochemicals (alkaloids, saponins, flavonoids, glycosides and terpenes) and type I 
RIP (Thakur et al. 2009). RIPs are naturally occurring plant proteins that have 
received considerable attention in biomedical research due to their activities towards 
tumor and virus-infected cells. Balsamin, a type-I RIP, has been extracted from 
Momordica balsamina, denoted as nBalsamin in this study. Previous studies from our 
group have reported that nBalsamin exhibits potent anti-HIV activity. In this study, 
we investigated the other biological activities including antimicrobial, antioxidant and 
DNase-like activity of nBalsamin with a major focus towards exploring the 
therapeutic potential of nBalsamin against liver and breast cancer cells. In addition, 
we attempted the heterologous expression of balsamin in E.coli strain, denoted as 
rBalsamin, and investigated its various biological and anti-tumor activities. We 
further determined the efficacy of flavonoids in enhancing nBalsamin-induced 
apoptosis in liver and breast cancer cells. 
In Chapter 2, the functional properties of nBalsamin purified from Momordica 
balsamina were investigated. nBalsamin exhibited DNase-like activity, converting the 
supercoiled form of a plasmid into the linear form in a concentration dependent 
manner. DNase-like activity of nBalsamin was found ideal at pH range 6.5-7.5, 
temperature range 35°C-45°C and incubation time of 2 h. Moreover, the presence of 
Mg2+ (10-50 mM) influenced the DNA cleavage activity. nBalsamin also possessed 
antibacterial activity against various pathogens including S. aureus, S.enterica, 
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S.epidermidis and E.coli. Further, the protein demonstrated free radical and 
superoxide radical scavenging activity in a dose dependent manner. 
In Chapter 3, the role of nBalamin in exerting anti-tumor effects on liver (HepG2 and 
H4IIE) and breast (MCF-7 and BT549) cancer cells, and its associated mechanism 
was identified. The studies demonstrated that nBalsamin significantly inhibited the 
proliferation of liver and breast cancer cells in a dose and time dependent manner. 
nBalsamin induced apoptosis in these cells via DNA fragmentation, cell cycle arrest, 
activation of caspase-3 and -8, upregulating the expression of pro-apoptotic gene, 
Bax, Bid, Bad and p53, and downregulating the expression of anti-apoptotic genes 
Bcl-2 and Bcl-XL. Based on these finding, it was proposed that nBalsamin probably 
induces apoptosis through death-receptor mediated and mitochondria mediated cell 
death pathway. Interestingly, nBalsamin upregulated the expression of GRP78 and 
CHOP, genes involved in ER-stress mediated apoptosis, in liver cancer (HepG2 and 
H4IIE) cells but not in breast cancer (MCF-7 and BT549) cells, suggesting that 
nBalsamin potentially activates an additional pathway (ER-stress mediated pathway) 
in liver cancer cells and not in breast cancer cells. These findings suggested that 
nBalsamin could serve as a novel biomolecule for the treatment of liver and breast 
cancer. However, further in vivo studies are warranted to develop this biomolecule as 
an effective therapeutic agent. 
To explore animal studies and clinical trials a large quantity of pure and bioactive 
protein is required, therefore, in Chapter 4, we cloned and expressed balsamin in 
E.coli and developed a two-step purification strategy for the production of 
functionally bioactive balsamin. The open reading frame of the Bal gene was 
successfully obtained from Momordica balsamina genomic DNA. The Bal gene was 
expressed in E.coli BL21(DE3) cells and various expression parameters such as IPTG 
concentration, induction time and temperature were optimized. Optimum expression 
of balsamin was obtained at 30°C after 4 h of induction with 0.4 mM IPTG. The 
incorporation of His-tag on the N-terminus of the protein enabled purification of 
rBalsamin by Ni2+ Sepharose affinity chromatography. Approximately, 45 mg of 
rBalsamin was obtained from a 1 L culture of induced E.coli cells. The structure of 
rBalsamin was found to be stable in the temperature range of 20°-60°C and pH range 
of 6-11. Further, functional analysis revealed that rBalsamin exhibited RNA N-
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glycosidase and DNase-like activity. Also, rBalsamin inhibited the growth of various 
pathogens including S. aureus, S.enterica, S.epidermidis and E.coli with MICs 
ranging between 1.56-25 µg/ml.  
In Chapter 5, we further investigated the potential cytotoxicity of rBalsamin on liver 
(HepG2 and H4IIE) and breast (MCF-7 and BT549) cancer cells. The studies revealed 
that rBalsamin could inhibit the proliferation of liver and breast cancer cells in a dose 
and time dependent manner with IC50 ranging between 18.92-200 µg/ml. Further, 
rBalsamin induced apoptosis in liver and breast cancer cells through DNA 
fragmentation and by increasing caspase-3/8 activities, arresting cell cycle at G and S 
phase, increasing Bax, Bid, Bad and p53 gene expression and decreasing Bcl-2 and 
Bcl-XL gene expression, indicating that death-receptor and mitochondrial cell death 
pathways are involved in rBalsamin-induced apoptosis in liver and breast cancer cells. 
Interestingly, rBalsamin increased the expression of genes (GRP78 and CHOP) 
involved in ER-stress mediated apoptosis in liver cancer cells but not in breast cancer 
cells, indicating that rBalsamin activates an additional, ER-stress mediated apoptotic 
pathway in liver cancer cells. In vivo studies would further enable us to highlight the 
potential of rBalsamin as an effective therapeutic agent. 
In Chapter 6, the potential of three flavonoids (Nar, Nir and Qu) in enhancing 
nBalsamin (nBal)-induced apoptosis in HepG2 and MCF-7 cells was investigated. 
Three doses (0.5 X IC50, 1.0 X IC50 and 2.0 X IC50) of flavonoids were tested in 
combination with nBal (25µg/ml). MTT assay results indicated that flavonoids, Nar 
Nir and Qu, increased the inhibitory effects of nBal on HepG2 and MCF-7 cells 
compared to nBal treatment alone. The effect appeared to be more pronounced with 
increasing flavonoids concentration. Interestingly, low concentration (0.5 X IC50) of 
flavonoids appeared to produce an additive effect but higher concentrations (1.0 X 
IC50 and 2.0 X IC50) didnot. Based on these findings, lower concentration of 
flavonoids, Nar, Nir and Qu in combination with nBal were selected for further study. 
Combination of low dose of flavonoids with nBal appeared to exhibit enhanced anti-
tumor activity compared to nBal treatment alone. Mechanically, Nar, Nir and Qu 
tended to increase the activation of caspase-3 and -8, upregulate pro-apoptotic genes 
(Bax, Bid, Bad and p53) and downregulate anti-apoptotic genes (Bcl-2 and Bcl-XL), 
suggesting that these flavonoids could possibly enhance nBal-induced mitochondrial 
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mediated apoptosis in HepG2 and MCF-7 cells. Interestingly, out of the three 
combinations (nBal-Nar, nBal-Nir and nBal-Qu) tested, nBal-Nir combination was 
found to be least effective compared to other two combinations. These flavonoids 
appeared to activate genes, GRP78 and CHOP, involved in ER-stress mediated 
apoptosis, which were not activated with nBal treatment alone in MCF-7 cells, 
suggesting that nBal-flavonoid combination activates an additional, ER-stress 
mediated, apoptotic pathway in MCF-7 cells. These findings suggested that 
combinational therapy could be considered as a promising strategy to increase nBal-
induced apoptosis in HepG2 and MCF-7 cells. However, in vivo studies are further 
required to explore the potential of nBal-flavonoid combinations in liver or breast 
cancer therapy. 
To the best of our knowledge, this is the first study that explored the anti-tumor 
potential of Balsamin, a type-I RIP, on liver and breast cancer cells. This biomolecule 
could be considered as a potential therapeutic agent for liver and breast cancer. 
However, further in vivo studies are warranted to ascertain its effectiveness. 
Moreover, possible side effects and toxicity of this novel biomolecule on normal cells 
could limit its use in cancer therapeutics. Therefore, an efficient delivery system needs 
to be explored to overcome this problem. Nowadays, nanoparticle based drug delivery 
system has received majority of attention due to their stability, greater surface area 
and ease of modification. Several different natural materials have been explored for 
nanoparticle-based delivery. They may be of biological origin such as chitosan, 
phospholipids, dextran, lipids, or chemical origin such as polymers, carbon, silica and 
gold. Nanoparticles obtained from these materials can be tailored-made to achieve 
controlled drug release or drug-specific localization in cells. Thus, in the near future, 
an attempt would be made to encapsulate balsamin in a nanoparticle conjugated with 
ligand that specifically binds to the receptor expressed on the surface of breast cancer 
cells. It is expected that the fusion of ligand with the receptor will facilitate selective 
targeting of balsamin into the cytosol of cancer cells where it will interfer with the 
cellular machinery and lead to the activation of apoptotic markers resulting in cell 
death. Developing this efficient delivery system aimed to mitigate toxicity of 
balsamin to normal cells could prove significant and remarkable discovery in the field 
of cancer therapeutics.  
Bibliography 
182 
Bibliography 
Abaza, MSI, Orabi, KY, Al-Quattan, E & Rajaa, J 2015, 'Growth inhibitory and 
chemo-sensitization effects of naringenin, a natural flavanone purified from Thymus 
vulgaris, on human breast and colorectal cancer', Cancer Cell International, vol. 15, 
no. 1, p. 1. 
Adwan, H, Bayer, H, Pervaiz, A, Sagini, M & Berger, MR 2014, 'Riproximin is a 
recently discovered type II ribosome inactivating protein with potential for treating 
cancer', Biotechnology Advances, vol. 32, no. 6, pp. 1077-90. 
Ahamad, MS, Siddiqui, S, Jafri, A, Ahmad, S, Afzal, M & Arshad, M 2014, 
'Induction of apoptosis and antiproliferative activity of naringenin in human 
epidermoid carcinoma cell through ROS generation and cell cycle arrest', PloS ONE, 
vol. 9, no. 10, p. e110003. 
Ajji, PK, Walder, K & Puri, M 2016, 'Functional analysis of a type-I ribosome 
inactivating protein balsamin from Momordica balsamina with anti-microbial and 
DNase activity', Plant Foods for Human Nutrition, vol. 71, no. 3, pp. 265-71. 
Akkouh, O, Ng, TB, Cheung, RCF, Wong, JH, Pan, W, Ng, CCW, Sha, O, Shaw, 
PC & Chan, WY 2015, 'Biological activities of ribosome-inactivating proteins and 
their possible applications as antimicrobial, anticancer, and anti-pest agents and in 
neuroscience research', Applied Microbiology and Biotechnology, pp. 1-17. 
Alam, MA, Subhan, N, Rahman, MM, Uddin, SJ, Reza, HM & Sarker, SD 2014, 
'Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and 
their mechanisms of action', Advances in Nutrition: An International Review 
Journal, vol. 5, no. 4, pp. 404-17. 
Alenzi, FQ 2004, 'Links between apoptosis, proliferation and the cell cycle', British 
Journal of Biomedical Science, vol. 61, no. 2, pp. 99-102. 
Ali, S & Coombes, RC 2000, 'Estrogen receptor alpha in human breast cancer: 
occurrence and significance', Journal of Mammary Gland Biology and Neoplasia, 
vol. 5, no. 3, pp. 271-81. 
Arias, FJ, Antolin, P, de Torre, C, Barriuso, B, Iglesias, R, Rojo, MA, Ferreras, JM, 
Benvenuto, E, Mendez, E & Girbes, T 2003, 'Musarmins: three single-chain 
ribosome-inactivating protein isoforms from bulbs of Muscari armeniacum L. and 
Miller', The International Journal of Biochemistry & Cell Biology, vol. 35, no. 1, pp. 
61-78. 
Arul, D & Subramanian, P 2013, 'Naringenin (citrus flavonone) induces growth 
inhibition, cell cycle arrest and apoptosis in human hepatocellular carcinoma cells', 
Pathology & Oncology Research, vol. 19, no. 4, pp. 763-70. 
Au, KY, Wang, RR, Wong, YT, Wong, KB, Zheng, YT & Shaw, PC 2014, 
'Engineering a switch-on peptide to ricin A chain for increasing its specificity 
Bibliography 
183 
towards HIV-infected cells', Biochimica et Biophysica Acta (BBA)-General Subjects, 
vol. 1840, no. 3, pp. 958-63. 
Au, T, Collins, R, Lam, T, Ng, T, Fong, W & Wan, D 2000, 'The plant ribosome 
inactivating proteins luffin and saporin are potent inhibitors of HIV-1 integrase', 
FEBS Letters, vol. 471, no. 2, pp. 169-72. 
Bagga, S, Seth, D & Batra, JK 2003, 'The cytotoxic activity of ribosome inactivating 
protein saporin-6 is attributed to its rRNA N- glycosidase and internucleosomal 
DNA fragmentation activities. ', Journal of Biological Chemistry, vol. 278, no. 7, pp. 
4813-20. 
Banjerdpongchai, R, Wudtiwai, B & Khaw-On, P 2016, 'Induction of human 
hepatocellular carcinoma HepG2 cell apoptosis by naringin', Asian Pacific Journal 
of Cancer Prevention, vol. 17, no. 7, p. 3289. 
Barbieri, L, Battelli, MG & Stirpe, F 1993, 'Ribosome-inactivating proteins from 
plants', Biochimica et Biophysica Acta (BBA)-Reviews on Biomembranes, vol. 1154, 
no. 3, pp. 237-82. 
Barbieri, L, Polito, L, Bolognesi, A, Ciani, M, Pelosi, E, Farini, V, Jha, AK, Sharma, 
N, Vivanco, JM, Chambery, A, Parente, A & Stirpe, F 2006, 'Ribosome-inactivating 
proteins in edible plants and purification and characterization of a new ribosome-
inactivating protein from Cucurbita moschata', Biochimica et Biophysica Acta, vol. 
1760, no. 5, pp. 783-92. 
Barbieri, L, Valbonesi, P, Bonora, E, Gorini, P, Bolognesi, A & Stirpe, F 1997, 
'Polynucleotide: adenosine glycosidase activity of ribosome-inactivating proteins: 
effect on DNA, RNA and poly (A)', Nucleic Acids Research, vol. 25, no. 3, pp. 518-
22. 
Barthelemy, I, Martineau, D, Ong, M, Matsunami, R, Ling, N, Benatti, L, Cavallaro, 
U, Soria, M & Lappi, D 1993, 'The expression of saporin, a ribosome-inactivating 
protein from the plant Saponaria officinalis, in Escherichia coli', Journal of 
Biological Chemistry, vol. 268, no. 9, pp. 6541-8. 
Belghiti, J & Kianmanesh, R 2005, 'Surgical treatment of hepatocellular carcinoma', 
HPB, vol. 7, no. 1, pp. 42-9. 
Bento, C, Andersson, MK & Aman, P 2009, 'DDIT3/CHOP and the sarcoma fusion 
oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2', BMC Cell 
Biology, vol. 10, no. 1, p. 89. 
Benzie, IF & Strain, J 1999, 'Ferric reducing/antioxidant power assay: Direct 
measure of total antioxidant activity of biological fluids and modified version for 
simultaneous measurement of total antioxidant power and ascorbic acid 
concentration', Methods in Enzymology, vol. 299, pp. 15-27. 
Bibliography 
184 
Bharti, S, Rani, N, Krishnamurthy, B & Arya, DS 2014, 'Preclinical evidence for the 
pharmacological actions of naringin: a review', Planta Medica, vol. 80, no. 06, pp. 
437-51. 
Bhaskar, A, Deb, U, Kumar, O & Rao, PL 2008, 'Abrin induced oxidative stress 
mediated DNA damage in human leukemic cells and its reversal by N-
acetylcysteine', Toxicology in Vitro, vol. 22, no. 8, pp. 1902-8. 
Blanco, FDV, Cafaro, V, Di Maro, A, Scognamiglio, R, Siniscalco, G, Parente, A & 
Di Donato, A 1998, 'A recombinant ribosome-inactivating protein from the plant 
Phytolacca dioica L. produced from a synthetic gene', FEBS Letters, vol. 437, no. 3, 
pp. 241-5. 
Boehm, M & Nabel, EG 2001, 'Cell Cycle and Cell Migration New Pieces to the 
Puzzle', Circulation, vol. 103, no. 24, pp. 2879-81. 
Bonness, MS, Ready, MP, Irvin, JD & Mabry, TJ 1994, 'Pokeweed antiviral protein 
inactivates pokeweed ribosomes; implications for the antiviral mechanism', The 
Plant Journal, vol. 5, no. 2, pp. 173-83. 
Boonmee, A, Srisomsap, C, Karnchanatat, A & Sangvanich, P 2011, 'An antioxidant 
protein in Curcuma comosa Roxb. Rhizomes', Food Chemistry, vol. 124, no. 2, pp. 
476-80. 
Bora, N, Gadadhar, S & Karande, AA 2010, 'Signaling different pathways of cell 
death: abrin induced programmed necrosis in U266B1 cells', The International 
Journal of Biochemistry & Cell Biology, vol. 42, no. 12, pp. 1993-2003. 
Bornhorst, JA & Falke, JJ 2000, 'Purification of proteins using polyhistidine affinity 
tags', Methods in Enzymology, vol. 326, pp. 245-54. 
Bourinbaiar, AS & Lee-Huang, S 1996, 'The activity of plant-derived antiretroviral 
proteins MAP30 and GAP31 against herpes simplex virus infection in vitro', 
Biochemical and Biophysical Research Communications, vol. 219, no. 3, pp. 923-9. 
Brigotti, M, Alfieri, R, Sestili, P, Bonelli, M, Petronini, PG, Guidarelli, A, Barbieri, 
L, Fiorenzo, S & Sperti, S 2002, 'Damage to nuclear DNA induced by shiga toxin 1 
and ricin in human endothelial cells', The FASEB Journal, vol. 16, no. 3, pp. 365-72. 
Cai, Y, Xiong, S, Zheng, Y, Luo, F, Jiang, P & Chu, Y 2011, 'Trichosanthin 
enhances anti-tumor immune response in a murine Lewis lung cancer model by 
boosting the interaction between TSLC1 and CRTAM', Cellular & Molecular 
Immunology, vol. 8, no. 4, pp. 359-67. 
Cao, D, Sun, Y, Wang, L, He, Q, Zheng, J, Deng, F, Deng, S, Chang, S, Yu, X & Li, 
M 2015, 'Alpha-momorcharin (α-MMC) exerts effective anti-human breast tumor 
activities but has a narrow therapeutic window in vivo', Fitoterapia, vol. 100, pp. 
139-49. 
Bibliography 
185 
Carnicelli, D, Brigotti, M, Alvergna, P, Pallanca, A, Sperti, S & Montanaro, L 1997, 
'Cofactor requirement of ribosome-inactivating proteins from plants', Journal of 
Experimental Botany, vol. 48, no. 8, pp. 1519-23. 
Castilho, PV, Goto, LS, Roberts, LM & Araujo, APU 2008, 'Isolation and 
characterization of four type 2 ribosome inactivating pulchellin isoforms from Abrus 
pulchellus seeds', FEBS Journal, vol. 275, no. 5, pp. 948-59. 
Chabner, BA & Roberts, TG 2005, 'Chemotherapy and the war on cancer', Nature 
Reviews Cancer, vol. 5, no. 1, pp. 65-72. 
Chaga, GS 2001, 'Twenty-five years of immobilized metal ion affinity 
chromatography: past, present and future', Journal of Biochemical and Biophysical 
Methods, vol. 49, no. 1, pp. 313-34. 
Chan, ST, Yang, NC, Huang, CS, Liao, JW & Yeh, SL 2013, 'Quercetin enhances 
the antitumor activity of trichostatin-A through upregulation of p53 protein 
expression in vitro and in vivo', PloS ONE, vol. 8, no. 1, p. e54255. 
Chan, WL, Shaw, PC, Tam, SC, Jacobsen, C, Gliemann, J & Nielsen, MS 2000, 
'Trichosanthin interacts with and enters cells via LDL receptor family members', 
Biochemical and Biophysical Research Communications, vol. 270, no. 2, pp. 453-7. 
Chan, WY, Huang, H & Tam, SC 2003, 'Receptor-mediated endocytosis of 
trichosanthin in choriocarcinoma cells', Toxicology, vol. 186, no. 3, pp. 191-203. 
Chaudhry, B, Muller‐ Uri, F, Cameron‐ Mills, V, Gough, S, Simpson, D, Skriver, K 
& Mundy, J 1994, 'The barley 60 kDa jasmonate‐ induced protein (JIP60) is a novel 
ribosome‐ inactivating protein', The Plant Journal, vol. 6, no. 6, pp. 815-24. 
Chen, Z, White, R, Antoniw, J & Lin, Q 1991, 'Effect of pokeweed antiviral protein 
(PAP) on the infection of plant viruses', Plant Pathology, vol. 40, no. 4, pp. 612-20. 
Choudhary, N, Kapoor, HC & Lodha, ML 2008, 'Cloning and expression of 
antiviral/ribosome-inactivating protein from Bougainvillea xbuttiana', Journal of 
Biosciences, vol. 33, no. 1, pp. 91-101. 
Choudhary, N, Yadav, O & Lodha, M 2008, 'Ribonuclease, deoxyribonuclease, and 
antiviral activity of Escherichia coli-expressed Bougainvillea xbuttiana antiviral 
protein 1', Biochemistry (Moscow), vol. 73, no. 3, pp. 273-7. 
Chuethong, J, Oda, K, Sakurai, H, Saiki, I & Leelamanit, W 2007, 'Cochinin B, a 
novel ribosome-inactivating protein from the seeds of Momordica cochinchinensis', 
Biological and Pharmaceutical Bulletin, vol. 30, no. 3, pp. 428-32. 
Chun-Yang, Z, Yi-Xuan, G, Hui, M, Cheng-Cai, A & Die-Yan, C 2000, 
'Trichosanthin induced calcium-dependent generation of reactive oxygen species in 
human choriocarcinoma cells', Analyst, vol. 125, no. 9, pp. 1539-42. 
Bibliography 
186 
Cimini, A, Mei, S, Benedetti, E, Laurenti, G, Koutris, I, Cinque, B, Cifone, M, 
Galzio, R, Pitari, G & Di Leandro, L 2012, 'Distinct cellular responses induced by 
saporin and a transferrin–saporin conjugate in two different human glioblastoma cell 
lines', Journal of Cellular Physiology, vol. 227, no. 3, pp. 939-51. 
Cook, N & Samman, S 1996, 'Flavonoids - chemistry, metabolism, cardioprotective 
effects, and dietary sources', The Journal of Nutritional Biochemistry, vol. 7, no. 2, 
pp. 66-76. 
Cui, L, Song, J, Wu, L, Huang, L, Wang, Y, Huang, Y, Yu, H, Huang, Y, You, CC 
& Ye, J 2015, 'Smac is another pathway in the anti-tumour activity of trichosanthin 
and reverses trichosanthin resistance in CaSki cervical cancer cells', Biomedicine 
and Pharmacotherapy, vol. 69, pp. 119-24. 
Curry, GW & Beattie, AD 1996, 'Pathogenesis of primary hepatocellular carcinoma', 
European Journal of Gastroenterology & Hepatology, vol. 8, no. 9, pp. 850-5. 
Czabotar, PE, Lessene, G, Strasser, A & Adams, JM 2014, 'Control of apoptosis by 
the BCL-2 protein family: implications for physiology and therapy', Nature Reviews 
Molecular Cell Biology, vol. 15, no. 1, pp. 49-63. 
Dai, R, Xu, G, Lin, X, Liu, L, Shen, H, Zhou, X, Gao, T & Wang, Y 1993, 'Studies 
on injury-mechanism of trichosanthin on trophoblast cells and choriocarcinoma cells 
in culture', Shi Yan Sheng Wu Xue Bao, vol. 26, no. 4, pp. 411-27. 
Das, MK, Sharma, RS & Mishra, V 2011, 'A cytotoxic type-2 ribosome inactivating 
protein (from leafless mistletoe) lacking sugar binding activity', International 
Journal of Biological Macromolecules, vol. 49, no. 5, pp. 1096-103. 
Day, PJ, Lord, JM & Roberts, LM 1998, 'The deoxyribonuclease activity attributed 
to ribosome‐inactivating proteins is due to contamination', European Journal of 
Biochemistry, vol. 258, no. 2, pp. 540-5. 
Deng, NH, Wang, L, He, QC, Zheng, JC, Meng, Y, Meng, YF, Zhang, CJ & Shen, 
FB 2016, 'PEGylation alleviates the non-specific toxicities of alpha-momorcharin 
and preserves its antitumor efficacy in vivo', Drug Delivery, vol. 23, no. 1, pp. 95-
100. 
Deng, XH, Song, HY, Zhou, YF, Yuan, GY & Zheng, FJ 2013, 'Effects of quercetin 
on the proliferation of breast cancer cells and expression of survivin in vitro', 
Experimental and Therapeutic Medicine, vol. 6, no. 5, pp. 1155-8. 
Di Maro, A, Chambery, A, Carafa, V, Costantini, S, Colonna, G & Parente, A 2009, 
'Structural characterization and comparative modeling of PD-Ls 1–3, type 1 
ribosome-inactivating proteins from summer leaves of Phytolacca dioica L', 
Biochimie, vol. 91, no. 3, pp. 352-63. 
Di Maro, A, Chambery, A, Daniele, A, Casoria, P & Parente, A 2007, 'Isolation and 
characterization of heterotepalins, type 1 ribosome-inactivating proteins from 
Phytolacca heterotepala leaves', Phytochemistry, vol. 68, no. 6, pp. 767-76. 
Bibliography 
187 
Di, R & Tumer, NE 2015, 'Pokeweed antiviral protein: Its cytotoxicity mechanism 
and applications in plant disease resistance', Toxins, vol. 7, no. 3, pp. 755-72. 
Domashevskiy, AV & Goss, DJ 2015, 'Pokeweed antiviral protein, a ribosome 
inactivating protein: activity, inhibition and prospects', Toxins, vol. 7, no. 2, pp. 274-
98. 
Domashevskiy, AV, Miyoshi, H & Goss, DJ 2012, 'Inhibition of pokeweed antiviral 
protein (PAP) by turnip mosaic virus genome-linked protein (VPg)', Journal of 
Biological Chemistry, vol. 287, no. 35, pp. 29729-38. 
Dou, CM & Li, JC 2004, 'Effect of extracts of trichosanthes root tubers on HepA-H 
cells and HeLa cells', World Journal of Gastroenterology, vol. 10, no. 14, pp. 2091-
4. 
Du, G, Lin, H, Wang, M, Zhang, S, Wu, X, Lu, L, Ji, L & Yu, L 2010, 'Quercetin 
greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its 
opposing effects on HIF-1α in tumor and normal cells', Cancer Chemotherapy and 
Pharmacology, vol. 65, no. 2, pp. 277-87. 
El-Serag, HB 2012, 'Epidemiology of viral hepatitis and hepatocellular carcinoma', 
Gastroenterology, vol. 142, no. 6, pp. 1264-73. e1. 
Elmore, S 2007, 'Apoptosis: a review of programmed cell death', Toxicologic 
Pathology, vol. 35, no. 4, pp. 495-516. 
Endo, Y, Gluck, A & Wool, IG 1991, 'Ribosomal RNA identity elements for ricin 
A-chain recognition and catalysis', Journal of Molecular Biology, vol. 221, no. 1, pp. 
193-207. 
Endo, Y, Mitsui, K, Motizuki, M & Tsurugi, K 1987, 'The mechanism of action of 
ricin and related toxic lectins on eukaryotic ribosomes. The site and the 
characteristics of the modification in 28 S ribosomal RNA caused by the toxins', 
Journal of Biological Chemistry, vol. 262, no. 12, pp. 5908-12. 
Endo, Y & Tsurugi, K 1987, 'RNA N-glycosidase activity of ricin A-chain. 
Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes', Journal of 
Biological Chemistry, vol. 262, no. 17, pp. 8128-30. 
Erlund, I 2004, 'Review of the flavonoids quercetin, hesperetin, and naringenin. 
Dietary sources, bioactivities, bioavailability, and epidemiology', Nutrition 
Research, vol. 24, no. 10, pp. 851-74. 
Fan, JM, Luo, J, Xu, J, Zhu, S, Zhang, Q, Gao, DF, Xu, YB & Zhang, GP 2008, 
'Effects of recombinant MAP30 on cell proliferation and apoptosis of human 
colorectal carcinoma LoVo cells', Molecular Biotechnology, vol. 39, no. 1, pp. 79-
86. 
Fan, X, He, L, Meng, Y, Li, G, Li, L & Meng, Y 2015, 'α MMC and MAP30, two 
ribosome inactivating proteins extracted from Momordica charantia, induce cell 
Bibliography 
188 
cycle arrest and apoptosis in A549 human lung carcinoma cells', Molecular 
Medicine Reports, vol. 11, no. 5, pp. 3553-58. 
Fang, EF, Zhang, CZY, Ng, TB, Wong, JH, Pan, WL, Ye, XJ, Chan, YS & Fong, 
WP 2012a, 'Momordica charantia lectin, a type II ribosome inactivating protein, 
exhibits antitumor activity toward human nasopharyngeal carcinoma cells in vitro 
and in vivo', Cancer Prevention Research, vol. 5, no. 1, pp. 109-21. 
Fang, EF, Zhang, CZY, Wong, JH, Shen, JY, Li, CH & Ng, TB 2012b, 'The MAP30 
protein from bitter gourd (Momordica charantia) seeds promotes apoptosis in liver 
cancer cells in vitro and in vivo', Cancer letters, vol. 324, no. 1, pp. 66-74. 
Fang, EF, Zhang, CZY, Zhang, L, Wong, JH, Chan, YS, Pan, WL, Dan, XL, Yin, 
CM, Cho, CH & Ng, TB 2012c, 'Trichosanthin inhibits breast cancer cell 
proliferation in both cell lines and nude mice by promotion of apoptosis', PloS ONE, 
vol. 7, no. 9, p. e41592. 
Fermani, S, Tosi, G, Farini, V, Polito, L, Falini, G, Ripamonti, A, Barbieri, L, 
Chambery, A & Bolognesi, A 2009, 'Structure/function studies on two type 1 
ribosome inactivating proteins: bouganin and lychnin', Journal of Structural 
Biology, vol. 168, no. 2, pp. 278-87. 
Ferreras, J, Barbieri, L, Girbes, T, Battelli, MG, Rojo, MA, Arias, FJ, Rocher, MA, 
Soriano, F, Mendez, E & Stirpe, F 1993, 'Distribution and properties of major 
ribosome-inactivating proteins (28 S rRNA N-glycosidases) of the plant Saponaria 
officinalis L. (Caryophyllaceae)', Biochimica et Biophysica Acta (BBA)-Gene 
Structure and Expression, vol. 1216, no. 1, pp. 31-42. 
Ferreras, JM, Citores, L, Iglesias, R, Jimenez, P & Girbes, T 2011, 'Use of ribosome-
inactivating proteins from Sambucus for the construction of immunotoxins and 
conjugates for cancer therapy', Toxins, vol. 3, no. 5, pp. 420-41. 
Foa-Tomasi, L, Campadelli-Fiume, G, Barbieri, L & Stirpe, F 1982, 'Effect of 
ribosome-inactivating proteins on virus-infected cells. Inhibition of virus 
multiplication and of protein synthesis', Archives of Virology, vol. 71, no. 4, pp. 323-
32. 
Fong, W, Poon, Y, Wong, T, Mock, J, Ng, T, Wong, R, Yao, Q & Yeung, H 1996, 
'A highly efficient procedure for purifying the ribosome-inactivating proteins α-and 
β-momorcharins from Momordica charantia seeds. N-terminal sequence comparison 
and establishment of their N-glycosidase activity', Life Sciences, vol. 59, no. 11, pp. 
901-9. 
Fracasso, G, Stirpe, F & Colombatti M 2010, 'Ribosome-inactivating protein 
containing conjugates for therapeutic use', Toxic Plant Proteins, vol. 18, pp. 225-
263.  
Fridman, JS & Lowe, SW 2003, 'Control of apoptosis by p53', Oncogene, vol. 22, 
no. 56, pp. 9030-40. 
Bibliography 
189 
G Johnson, G, C White, M & Grimaldi, M 2011, 'Stressed to death: targeting 
endoplasmic reticulum stress response induced apoptosis in gliomas', Current 
Pharmaceutical Design, vol. 17, no. 3, pp. 284-92. 
Gao, DF, Wang, BQ, Cao, GM & Zhang, XL 2010, 'Cloning of trichosanthin gene 
and its induction effects on the apoptpsis of colorectal carcinoma LoVo cell', Fudan 
University Journal of Medical Sciences, vol. 2, p. 008. 
Gasperi-Campani, A, Zoli, W, Volpi, A, Roncuzzi, L & Amadori, D 1991, 
'Inhibition of growth of breast cancer cells in vitro by the ribosome-inactivating 
protein Saporin 6', Anticancer Research, vol. 11, no. 2, pp. 1007-11. 
Gatehouse, AMR, Barbieri, L, Stirpe, F & Croy, RRD 1990, 'Effects of ribosome 
inactivating proteins on insect development - differences between Lepidoptera and 
Coleoptera', Entomologia Experimentalis et Applicata, vol. 54, no. 1, pp. 43-51. 
Gerl, R & Vaux, DL 2005, 'Apoptosis in the development and treatment of cancer', 
Carcinogenesis, vol. 26, no. 2, pp. 263-70. 
Gibellini, L, Pinti, M, Nasi, M, Montagna, JP, De Biasi, S, Roat, E, Bertoncelli, L, 
Cooper, EL & Cossarizza, A 2011, 'Quercetin and cancer chemoprevention', 
Evidence-Based Complementary and Alternative Medicine, vol. 2011. 
Girbes, T, Citores, L, Ferreras, JM, Rojo, MA, Iglesias, R, Munoz, R, Arias, FJ, 
Calonge, M, Garcia, JR & Mendez, E 1993, 'Isolation and partial characterization of 
nigrin b, a non-toxic novel type 2 ribosome-inactivating protein from the bark of 
Sambucus nigra L', Plant Molecular Biology, vol. 22, no. 6, pp. 1181-6. 
Girbes, T, Ferreras, JM, Arias, FJ & Stirpe, F 2004, 'Description, distribution, 
activity and phylogenetic relationship of ribosome-inactivating proteins in plants, 
fungi and bacteria', Mini Reviews in Medicinal Chemistry, vol. 4, no. 5, pp. 461-76. 
Go, TT, Yeung, H & Fong, W 1992, 'Deoxyribonucleolytic activity of α-and β-
momorcharins', Life Sciences, vol. 51, no. 17, pp. 1347-53. 
Granado-Serrano, AB, Martin, MA, Bravo, L, Goya, L & Ramos, S 2006, 'Quercetin 
induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI-3-
kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2)', The Journal 
of Nutrition, vol. 136, no. 11, pp. 2715-21. 
Guo, B, Zhang, Y, Hui, Q, Wang, H & Tao, K 2016, 'Naringin suppresses the 
metabolism of A375 cells by inhibiting the phosphorylation of c-Src', Tumor 
Biology, vol. 37, no. 3, pp. 3841-50. 
Han, XH, Xue, YJ, Chen, D, Shao, SH, Huang, H, Li, XQ & Xu, HX 2011, 
'Cloning, expression and functional analysis of MAP30 from Momordica charantia 
reveals its induction of apoptosis of the BGC-823 cells', African Journal of 
Biotechnology, vol. 10, no. 78, pp. 17925-33. 
Bibliography 
190 
Hao, L, Zhang, Z, Han, C, Zhao, Y, Liang, Q, Jiang, B, He, H, Zhang, J & Zhang, P 
2014, 'Expression of Momordica charantia MAP30 and its anti-tumor effect on 
bladder cancer cells', Minerva Urologica e Nefrologica= The Italian Journal of 
Urology and Nephrology, vol. 68, no. 3, pp. 275-81. 
Harman, D 1992, 'Role of free radicals in aging and disease', Annals of the New York 
Academy of Sciences, vol. 673, no. 1, pp. 126-41. 
Harmon, AW & Patel, YM 2004, 'Naringenin inhibits glucose uptake in MCF-7 
breast cancer cells: a mechanism for impaired cellular proliferation', Breast Cancer 
Research and Treatment, vol. 85, no. 2, pp. 103-10. 
Hartley, M & Lord, J 1993, 'Structure, function and applications of ricin and related 
cytotoxic proteins', in Biosynthesis and Manipulation of Plant Products, Springer, 
pp. 210-39. 
Hartley, MR, Chaddock, JA & Bonness, MS 1996, 'The structure and function of 
ribosome-inactivating proteins', Trends in Plant Science, vol. 1, no. 8, p. 252. 
He, D, Zheng, Y & Tam, S 2012, 'The anti-herpetic activity of trichosanthin via the 
nuclear factor-κB and p53 pathways', Life Sciences, vol. 90, no. 17, pp. 673-81. 
He, JF & Li, JC 2006, 'The growth inhibition and the apoptosis of HeLa cells 
induced with TCS', Acta Anatomica Sinica, vol. 37, no. 3, pp. 309-14. 
He, WJ & Liu, WY 2003, 'Cinnamomin: a multifunctional type II ribosome-
inactivating protein', The International Journal of Biochemistry & Cell Biology, vol. 
35, no. 7, pp. 1021-7. 
Helmy, M, Lombard, S & Pieroni, G 1999, 'Ricin RCA 60: evidence of its 
phospholipase activity', Biochemical and Biophysical Research Communications, 
vol. 258, no. 2, pp. 252-5. 
Hey, TD, Hartley, M & Walsh, TA 1995, 'Maize ribosome-inactivating protein (b-
32) homologs in related species, effects on maize ribosomes, and modulation of 
activity by pro-peptide deletions', Plant Physiology, vol. 107, no. 4, pp. 1323-32. 
Ho, WK, Liu, S, Shaw, P, Yeung, H, Ng, T & Chan, W 1991, 'Cloning of the cDNA 
of α-momorcharin: a ribosome inactivating protein', Biochimica et Biophysica Acta 
(BBA)-Gene Structure and Expression, vol. 1088, no. 2, pp. 311-4. 
Hong, CE, Park, AK & Lyu, SY 2014, 'Synergistic anticancer effects of lectin and 
doxorubicin in breast cancer cells', Molecular and Cellular Biochemistry, vol. 394, 
no. 1-2, pp. 225-35. 
Hong, J, Chen, TT, Hu, P, Yang, J & Wang, SY 2014, 'Purification and 
characterization of an antioxidant peptide (GSQ) from Chinese leek (Allium 
tuberosum Rottler) seeds', Journal of Functional Foods, vol. 10, pp. 144-53. 
Bibliography 
191 
Howard, JA 2005, 'Commercialization of biopharmaceutical and bioindustrial 
proteins from plants', Crop Science, vol. 45, no. 2, pp. 468-72. 
Huang, HC, Huang, C, Wei, YX, Shen, MC, Tu, YH & Wang, CC 2016, 'Chrysin, 
abundant in Morinda Citrifolia fruit water-EtOAc extracts, combined with apigenin 
synergistically induced apoptosis and inhibited migration in human breast and liver 
cancer cells', Journal of Agricultural and Food Chemistry, vol. 64, pp. 4235-45. 
Huang, Y, Huang, L, You, C & Hu, H 2010, 'Endoplasmic reticulum stress signaling 
pathways is involved in trichosanthin-induced apopfosis in human cervical cancer 
cell line HeLa', in 2010 4th International Conference on Bioinformatics and 
Biomedical Engineering, iCBBE 2010.  
Hudak, KA, Bauman, JD & Tumer, NE 2002, 'Pokeweed antiviral protein binds to 
the cap structure of eukaryotic mRNA and depurinates the mRNA downstream of 
the cap', RNA, vol. 8, no. 9, pp. 1148-59. 
Hudak, KA, Wang, P & Tumer, NE 2000, 'A novel mechanism for inhibition of 
translation by pokeweed antiviral protein: depurination of the capped RNA 
template', RNA, vol. 6, no. 3, pp. 369-80. 
Iglesias, R, Citores, L, Ragucci, S, Russo, R, Di Maro, A & Ferreras, JM 2016, 
'Biological and antipathogenic activities of ribosome-inactivating proteins from 
Phytolacca dioica L', Biochimica et Biophysica Acta (BBA)-General Subjects, vol. 
1860, no. 6, pp. 1256-64. 
Irvin, JD 1975, 'Purification and partial characterization of the antiviral protein from 
Phytolacca americana which inhibits eukaryotic protein synthesis', Archives of 
Biochemistry and Biophysics, vol. 169, no. 2, pp. 522-8. 
Ishag, HZ, Li, C, Huang, L, Sun, MX, Ni, B, Guo, CX & Mao, X 2013, 'Inhibition 
of japanese encephalitis virus infection in vitro and in vivo by pokeweed antiviral 
protein', Virus Research, vol. 171, no. 1, pp. 89-96. 
Jiang, Q, Bai, T, Shen, S, Li, L, Ding, H & Wang, P 2011, 'Increase of cytosolic 
calcium induced by trichosanthin suppresses cAMP/PKC levels through the 
inhibition of adenylyl cyclase activity in HeLa cells', Molecular Biology Reports, 
vol. 38, no. 4, pp. 2863-8. 
Jiao, Y & Liu, W 2010, 'Low-density lipoprotein receptor-related protein 1 is an 
essential receptor for trichosanthin in 2 choriocarcinoma cell lines', Biochemical and 
Biophysical Research Communications, vol. 391, no. 4, pp. 1579-84. 
Kantari, C & Walczak, H 2011, 'Caspase-8 and Bid: caught in the act between death 
receptors and mitochondria', Biochimica et Biophysica Acta (BBA)-Molecular Cell 
Research, vol. 1813, no. 4, pp. 558-63. 
Katsila, T, Siskos, AP & Tamvakopoulos, C 2012, 'Peptide and protein drugs: the 
study of their metabolism and catabolism by mass spectrometry', Mass Spectrometry 
Reviews, vol. 31, no. 1, pp. 110-33. 
Bibliography 
192 
Kaur, I, Gupta, R & Puri, M 2011, 'Ribosome inactivating proteins from plants 
inhibiting viruses', Virologica Sinica, vol. 26, no. 6, pp. 357-65. 
Kaur, I, Puri, M, Ahmed, Z, Blanchet, FP, Mangeat, B & Piguet, V 2013, 'Inhibition 
of HIV-1 replication by balsamin, a aibosome inactivating protein of Momordica 
balsamina', PloS ONE, vol. 8, no. 9, p. e73780. 
Kaur, I, Yadav, SK, Hariprasad, G, Gupta, R, Srinivasan, A, Batra, JK & Puri, M 
2012, 'Balsamin, a novel ribosome-inactivating protein from the seeds of balsam 
apple Momordica balsamina', Amino Acids, vol. 43, no. 2, pp. 973-81. 
Kelly, GS 2011, 'Quercetin', Alternative Medicine Rev, vol. 16, no. 2, pp. 172-94. 
Kim, DI, Lee, SJ, Lee, SB, Park, K, Kim, WJ & Moon, SK 2008, 'Requirement for 
Ras/Raf/ERK pathway in naringin-induced G1-cell-cycle arrest via p21WAF1 
expression', Carcinogenesis, vol. 29, no. 9, pp. 1701-9. 
Kim, H, Moon, JY, Ahn, KS & Cho, SK 2013, 'Quercetin induces mitochondrial 
mediated apoptosis and protective autophagy in human glioblastoma U373MG cells', 
Oxidative Medicine and Cellular Longevity, vol. 2013. 
Kober, L, Zehe, C & Bode, J 2012, 'Development of a novel ER stress based 
selection system for the isolation of highly productive clones', Biotechnology and 
Bioengineering, vol. 109, no. 10, pp. 2599-611. 
Kretowski, R, Borzym-Kluczyk, M, Stypulkowska, A, Branska-Januszewska, J, 
Ostrowska, H & Cechowska-Pasko, M 2016, 'Low glucose dependent decrease of 
apoptosis and induction of autophagy in breast cancer MCF-7 cells', Molecular and 
Cellular Biochemistry, vol. 417, no. 1-2, pp. 35-47. 
Kroemer, G, Galluzzi, L, Vandenabeele, P, Abrams, J, Alnemri, E, Baehrecke, E, 
Blagosklonny, M, El-Deiry, W, Golstein, P & Green, D 2009, 'Classification of cell 
death: recommendations of the Nomenclature Committee on Cell Death 2009', Cell 
Death & Differentiation, vol. 16, no. 1, pp. 3-11. 
Kuhar, M, Imran, S & Singh, N 2007, 'Curcumin and quercetin combined with 
cisplatin to induce apoptosis in human laryngeal carcinoma Hep-2 cells through the 
mitochondrial pathway', Journal of Cancer Molecules, vol. 3, pp. 121-8. 
Kumar, O, Nashikkar, A, Jayaraj, R, Vijayaraghavan, R & Prakash, A 2004, 
'Purification and biochemical characterisation of ricin from Castor Seeds', Defence 
Science Journal, vol. 54, no. 3, pp. 345-51. 
Kumar, S & Pandey, AK 2013, 'Chemistry and biological activities of flavonoids: an 
overview', The Scientific World Journal, vol. 2013. 
Kurinov, I, Myers, D, Uckun, F & Irvin, J 1999, 'X‐ray crystallographic analysis of 
the structural basis for the interactions of pokeweed antiviral protein with its active 
site inhibitor and ribosomal RNA substrate analogs', Protein Science, vol. 8, no. 9, 
pp. 1765-72. 
Bibliography 
193 
Kuroda, K, Liu, H, Kim, S, Guo, M, Navarro, V & Bander, NH 2010, 'Saporin 
toxin‐conjugated monoclonal antibody targeting prostate‐specific membrane antigen 
has potent anticancer activity', The Prostate, vol. 70, no. 12, pp. 1286-94. 
Kwon, SY, An, CS, Liu, JR, Kwak, SS, Lee, HS, Kim, JK & Paek, KH 2000, 
'Molecular cloning of a cDNA encoding ribosome inactivating protein from 
Amaranthus viridis and its expression in E. coli', Molecules and Cells, vol. 10, no. 1, 
pp. 8-12. 
Lakin, ND & Jackson, SP 1999, 'Regulation of p53 in response to DNA damage', 
Oncogene, vol. 18, no. 53, pp. 7644-55. 
Lee-Huang, S, Huang, P, Sun, Y, Chen, H, Kung, H & Murphy, W 1999, 'Inhibition 
of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-
tumor agents GAP31 and MAP30', Anticancer Research, vol. 20, no. 2A, pp. 653-9. 
Lee-Huang, S, Huang, PL, Bourinbaiar, A, Chen, H & Kung, H 1995a, 'Inhibition of 
the integrase of human immunodeficiency virus (HIV) type 1 by anti-HIV plant 
proteins MAP30 and GAP31', Proceedings of the National Academy of Sciences, 
vol. 92, no. 19, pp. 8818-22. 
Lee-Huang, S, Huang, PL, Chen, H-C, Huang, PL, Bourinbaiar, A, Huang, HI & 
Kung, H-f 1995b, 'Anti-HIV and anti-tumor activities of recombinant MAP30 from 
bitter melon', Gene, vol. 161, no. 2, pp. 151-6. 
Lee-Huang, S, Huang, PL, Nara, PL, Chen, HC, Kung, HF, Huang, P, Huang, HI & 
Huang, PL 1990, 'MAP 30: a new inhibitor of HIV-1 infection and replication', 
FEBS Letters, vol. 272, no. 1, pp. 12-8. 
Lee-Huang, S, Kung, HF, Huang, PL, Huang, PL, Li, BQ, Huang, P, Huang, HI & 
Chen, H-C 1991, 'A new class of anti-HIV agents: GAP31, DAPs 30 and 32', FEBS 
Letters, vol. 291, no. 1, pp. 139-44. 
Lee, WT & Chang, CW 2010, 'Bax is upregulated by p53 signal pathway in the 
SPEB-induced apoptosis', Molecular and Cellular Biochemistry, vol. 343, no. 1-2, 
pp. 271-9. 
Lewandowska, U, Gorlach, S, Owczarek, K, Hrabec, E & Szewczyk, K 2014, 
'Synergistic interactions between anticancer chemotherapeutics and phenolic 
compounds and anticancer synergy between polyphenols', Advances in Hygiene and 
Experimental Medicicne (Online), vol. 68, pp. 528-40. 
Li, CT, Lin, CH, Kao, TY, Wu, MF, Yeh, CS, Yeh, KT & Ko, JL 2010a, 'The 
mechanisms of action of tianhua™ on antitumor activity in lung cancer cells', 
Pharmaceutical Biology, vol. 48, no. 11, pp. 1302-9. 
Li, H, Yang, B, Huang, J, Xiang, T, Yin, X, Wan, J, Luo, F, Zhang, L, Li, H & Ren, 
G 2013, 'Naringin inhibits growth potential of human triple-negative breast cancer 
cells by targeting β-catenin signaling pathway', Toxicology Letters, vol. 220, no. 3, 
pp. 219-28. 
Bibliography 
194 
Li, HG, Huang, PL, Zhang, D, Sun, Y, Chen, HC, Zhang, J, Huang, PL, Kong, XP & 
Lee-Huang, S 2010b, 'A new activity of anti-HIV and anti-tumor protein GAP31: 
DNA adenosine glycosidase-structural and modeling insight into its functions', 
Biochemical Biophysical Research Communication, vol. 391, no. 1, pp. 340-5. 
Li, J, Dong, Y, Hao, G, Wang, B, Wang, J, Liang, Y, Liu, Y, Zhen, E, Feng, D & 
Liang, G 2016, 'Naringin suppresses the development of glioblastoma by inhibiting 
FAK activity', Journal of Drug Targeting (DOI: 10.1080/1061186X.2016.1184668). 
Li, J & Lee, AS 2006, 'Stress induction of GRP78/BiP and its role in cancer', 
Current Molecular Medicine, vol. 6, no. 1, pp. 45-54. 
Li, J, Xia, X, Ke, Y, Nie, H, Smith, MA & Zhu, X 2007a, 'Trichosanthin induced 
apoptosis in HL-60 cells via mitochondrial and endoplasmic reticulum stress 
signaling pathways', Biochimica et Biophysica Acta (BBA)-General Subjects, vol. 
1770, no. 8, pp. 1169-80. 
Li, MX, Yeung, HW, Pan, LP & Chan, SI 1991, 'Trichosanthin, a potent HIV-1 
inhibitor, can cleave supercoiled DNA in vitro', Nucleic Acids Research, vol. 19, no. 
22, pp. 6309-12. 
Li, M, Chen, F, Liu, CP, Li, DM, Li, X, Wang, C & Li, JC 2010c, 'Dexamethasone 
enhances trichosanthin-induced apoptosis in the HepG2 hepatoma cell line', Life 
Sciences, vol. 86, no. 1, pp. 10-6. 
Li, RF, Feng, YQ, Chen, JH, Ge, LT, Xiao, SY & Zuo, XL 2015, 'Naringenin 
suppresses K562 human leukemia cell proliferation and ameliorates adriamycin-
induced oxidative damage in polymorphonuclear leukocytes', Experimental and 
Therapeutic Medicine, vol. 9, no. 3, pp. 697-706. 
Li, XD, Chen, WF, Liu, WY & Wang, GH 1997, 'Large-scale preparation of two 
new ribosome-inactivating proteins - cinnamomin and camphorin from the seeds of 
Cinnamomum camphora', Protein Expression and Purification, vol. 10, no. 1, pp. 
27-31. 
Li, Z, Qu, Y, Li, H & Yuan, J 2007b, 'Truncations of gelonin lead to a reduction in 
its cytotoxicity', Toxicology, vol. 231, no. 2, pp. 129-36. 
Liu, KC, Yen, CY, Wu, RSC, Yang, JS, Lu, HF, Lu, KW, Lo, C, Chen, HY, Tang, 
NY & Wu, CC 2014, 'The roles of endoplasmic reticulum stress and mitochondrial 
apoptotic signaling pathway in quercetin‐mediated cell death of human prostate 
cancer PC‐3 cells', Environmental Toxicology, vol. 29, no. 4, pp. 428-39. 
Liu, L, Wang, R, He, W, He, F & Huang, G 2010, 'Cloning and soluble expression 
of mature α-luffin from Luffa cylindrica and its antitumor activities in vitro', Acta 
Biochimica et Biophysica Sinica, vol. 42, no. 8, pp. 585-92. 
Long, J, Hou, XM, Zhang, GH, Chen, MH & Zheng, YT 2008, 'Anti-HIV-1 
activities of Luffaculin 1', Chinese Journal of Natural Medicines, vol. 6, no. 5, pp. 
372-6. 
Bibliography 
195 
Lord, J & Roberts, L 1996, 'The intracellular transport of ricin: why mammalian 
cells are killed and how Ricinus cells survive: Targeting and glycosylation of plant 
secretory proteins', Plant Physiology and Biochemistry, vol. 34, no. 2, pp. 253-61. 
Lu, YZ, Li, PF, Li, YZ, Luo, F, Guo, C, Lin, B, Cao, XW, Zhao, J & Wang, FJ 
2016, 'Enhanced anti-tumor activity of trichosanthin after combination with a 
human-derived cell-penetrating peptide, and a possible mechanism of activity', 
Fitoterapia. 
Lund, K, Bostad, M, Skarpen, E, Braunagel, M, Kiprijanov, S, Krauss, S, Duncan, 
A, Høgset, A & Selbo, PK 2014, 'The novel EpCAM-targeting monoclonal antibody 
3–17I linked to saporin is highly cytotoxic after photochemical internalization in 
breast, pancreas and colon cancer cell lines', MAbs, vol. 6, pp. 1038-50. 
Lv, Q, Yang, XZ, Fu, LY, Lu, YT, Lu, YH, Zhao, J & Wang, FJ 2015, 'Recombinant 
expression and purification of a MAP30-cell penetrating peptide fusion protein with 
higher anti-tumor bioactivity', Protein Expression and Purification, vol. 111, pp. 9-
17. 
Mak, ANS, Wong, YT, An, YJ, Cha, SS, Sze, KH, Au, SWN, Wong, KB & Shaw, 
PC 2007, 'Structure-function study of maize ribosome-inactivating protein: 
implications for the internal inactivation region and the sole glutamate in the active 
site', Nucleic acids Research, vol. 35, no. 18, pp. 6259-67. 
Manoharan, G, Jaiswal, SR & Singh, J 2014, 'Effect of α, β momorcharin on 
viability, caspase activity, cytochrome c release and on cytosolic calcium levels in 
different cancer cell lines', Molecular and Cellular Biochemistry, vol. 388, no. 1-2, 
pp. 233-40. 
Mansouri, S, Choudhary, G, Sarzala, PM, Ratner, L & Hudak, KA 2009, 
'Suppression of human T-cell leukemia virus I gene expression by pokeweed 
antiviral protein', Journal of Biological Chemistry, vol. 284, no. 45, pp. 31453-62. 
Mansouri, S, Kutky, M & Hudak, KA 2012, 'Pokeweed antiviral protein increases 
HIV-1 particle infectivity by activating the cellular mitogen activated protein kinase 
pathway', PloS ONE, vol. 7, no. 5, p. e36369. 
McIlwain, DR, Berger, T & Mak, TW 2013, 'Caspase functions in cell death and 
disease', Cold Spring Harbor Perspectives in Biology, vol. 5, no. 4, p. a008656. 
Meng, Y, Lin, S, Liu, S, Fan, X, Li, G & Meng, Y 2014, 'A Novel Method for 
Simultaneous Production of Two Ribosome-Inactivating Proteins, α-MMC and 
MAP30, from Momordica charantia L', PloS one, vol. 9, no. 7, p. e101998. 
Meng, Y, Liu, S, Li, J, Meng, Y & Zhao, X 2012, 'Preparation of an antitumor and 
antivirus agent: chemical modification of α-MMC and MAP30 from Momordica 
Charantia L. with covalent conjugation of polyethyelene glycol', International 
Journal of Nanomedicine, vol. 7, p. 3133. 
Bibliography 
196 
Menkhaus, TJ, Bai, Y, Zhang, C, Nikolov, ZL & Glatz, CE 2004, 'Considerations 
for the recovery of recombinant proteins from plants', Biotechnology Progress, vol. 
20, no. 4, pp. 1001-14. 
Mi, SL, An, CC, Wang, Y, Chen, JY, Che, NY, Gao, Y & Chen, ZL 2005, 
'Trichomislin, a novel ribosome-inactivating protein, induces apoptosis that involves 
mitochondria and caspase-3', Archives of Biochemistry and Biophysics, vol. 434, no. 
2, pp. 258-65. 
Mohamed, MS, Veeranarayanan, S, Poulose, AC, Nagaoka, Y, Minegishi, H, 
Yoshida, Y, Maekawa, T & Kumar DS 2014, 'Type 1 ribotoxin-curcin conjugated 
biogenic gold nanoparticles for a multimodal therapeutic approach towards brain 
cancer', Biochimica et Biophysica Acta, vol. 1840 no. 6, pp. 1657-69. 
Montanaro, L, Sperti, S & Stirpe, F 1973, 'Inhibition by ricin of protein synthesis in 
vitro. Ribosomes as the target of the toxin', Biochemical Journal, vol. 136, pp. 677-
83. 
Mundy, J, Leah, R, Boston, R, Endo, Y & Stirpe, F 1994, 'Genes encoding 
ribosome-inactivating proteins', Plant Molecular Biology Reporter, vol. 12, no. 2, 
pp. S60-S2. 
Munoz, R, Arias, Y, Ferreras, JM, Jimenez, P, Rojo, MA & Girbes, T 2001, 
'Sensitivity of cancer cell lines to the novel non-toxic type 2 ribosome-inactivating 
protein nigrin b', Cancer Letters, vol. 167, no. 2, pp. 163-9. 
Nair, HK, Rao, KV, Aalinkeel, R, Mahajan, S, Chawda, R & Schwartz, SA 2004, 
'Inhibition of prostate cancer cell colony formation by the flavonoid quercetin 
correlates with modulation of specific regulatory genes', Clinical and Diagnostic 
Laboratory Immunology, vol. 11, no. 1, pp. 63-9. 
Narayanan, S, Surolia, A & Karande, A 2004, 'Ribosome-inactivating protein and 
apoptosis: abrin causes cell death via mitochondrial pathway in Jurkat cells', 
Biochemical Journal, vol. 377, pp. 233-40. 
Ng, T & Parkash, A 2002, 'Hispin, a novel ribosome inactivating protein with 
antifungal activity from hairy melon seeds', Protein Expression and Purification, 
vol. 26, no. 2, pp. 211-7. 
Ng, T & Wang, H 2004, 'Flammin and velin: new ribosome inactivating 
polypeptides from the mushroom Flammulina velutipes', Peptides, vol. 25, no. 6, pp. 
929-33. 
Ng, T, Wong, JH & Wang, H 2010, 'Recent progress in research on ribosome 
inactivating proteins', Current Protein and Peptide Science, vol. 11, no. 1, pp. 37-53. 
Ng, TB, Liu, WK, Sze, SF & Yeung, HW 1994, 'Action of α-momorcharin, a 
ribosome inactivating protein, on cultured tumor cell lines', General Pharmacology, 
vol. 25, no. 1, pp. 75-7. 
Bibliography 
197 
Ng, YM, Yang, Y, Sze, KH, Zhang, X, Zheng, YT & Shaw, PC 2011, 'Structural 
characterization and anti-HIV-1 activities of arginine/glutamate-rich polypeptide 
luffin P1 from the seeds of sponge gourd (Luffa cylindrica)', Journal of Structural 
Biology, vol. 174, no. 1, pp. 164-72. 
Nicolas, E, Beggs, JM, Haltiwanger, BM & Taraschi, TF 1997, 'Direct evidence for 
the deoxyribonuclease activity of the plant ribosome inactivating protein gelonin', 
FEBS Letters, vol. 406, no. 1, pp. 162-4. 
Nielsen, K & Boston, RS 2001, 'Ribosome-inactivating proteins: a plant 
perspective', Annual Review of Plant Biology, vol. 52, no. 1, pp. 785-816. 
Niu, G, Yin, S, Xie, S, Li, Y, Nie, D, Ma, L, Wang, X & Wu, Y 2011, 'Quercetin 
induces apoptosis by activating caspase-3 and regulating Bcl-2 and cyclooxygenase-
2 pathways in human HL-60 cells', Acta Biochimica et Biophysica Sinica, vol. 43, 
no. 1, pp. 30-7. 
Nolan, PA, Garrison, DA & Better, M 1993, 'Cloning and expression of a gene 
encoding gelonin, a ribosome-inactivating protein from Gelonium multiflorum', 
Gene, vol. 134, no. 2, pp. 223-7. 
Olsnes, S, Refsnes, K & Pihl, A 1974, 'Mechanism of action of the toxic lectins 
abrin and ricin', Nature, vol. 249, pp. 627-31. 
Olsnes, S, Stirpe, F, Sandvig, K & Pihl, A 1982, 'Isolation and characterization of 
viscumin, a toxic lectin from Viscum album L.(mistletoe)', Journal of Biological 
Chemistry, vol. 257, no. 22, pp. 13263-70. 
Olson, MC, Ramakrishnan, S & Anand, R 1991, 'Ribosomal inhibitory proteins from 
plants inhibit HIV-1 replication in acutely infected peripheral blood mononuclear 
cells', AIDS Research and Human Retroviruses, vol. 7, no. 12, pp. 1025-30. 
Osborne, CK & Schiff, R 2011, 'Mechanisms of endocrine resistance in breast 
cancer', Annual Review of Medicine, vol. 62, p. 233. 
Oyadomari, S & Mori, M 2004, 'Roles of CHOP/GADD153 in endoplasmic 
reticulum stress', Cell Death & Differentiation, vol. 11, no. 4, pp. 381-9. 
Pan, LZ & Levy, JA 1994, 'Inhibition of HIV replication by trichosanthin in 
peripheral blood mononuclear cells', Current Therapeutic Research, vol. 55, no. 6, 
pp. 718-27. 
Pan, WL, Wong, JH, Fang, EF, Chan, YS, Ng, TB & Cheung, RCF 2014, 
'Preferential cytotoxicity of the type I ribosome inactivating protein alpha-
momorcharin on human nasopharyngeal carcinoma cells under normoxia and 
hypoxia', Biochemical Pharmacology, vol. 89, no. 3, pp. 329-39. 
Pan, WL, Wong, JH, Fang, EF, Chan, YS, Ye, XJ & Ng, TB 2013, 'Differential 
inhibitory potencies and mechanisms of the type I ribosome inactivating protein 
marmorin on estrogen receptor (ER)-positive and ER-negative breast cancer cells', 
Bibliography 
198 
Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, vol. 1833, no. 5, pp. 
987-96. 
Park, EJ & M Pezzuto, J 2012, 'Flavonoids in cancer prevention', Anti-Cancer 
Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry Anti-Cancer 
Agents), vol. 12, no. 8, pp. 836-51. 
Park, SW, Vepachedu, R, Sharma, N & Vivanco, JM 2004, 'Ribosome-inactivating 
proteins in plant biology', Planta, vol. 219, no. 6, pp. 1093-6. 
Pawlowski, J & Kraft, AS 2000, 'Bax-induced apoptotic cell death', Proceedings of 
the National Academy of Sciences, vol. 97, no. 2, pp. 529-31. 
Peng, P, Huang, L, Wang, Y, You, C, Cao, W, Song, H, Tan, H & Wu, Y 2011, 
'Effect of recombinant trichosanthin on proliferation of human cevical cancer Caski 
cells', China Journal of Chinese Materia Medica, vol. 36, no. 18, pp. 2539-42. 
Peng, W, Hu, C, Shu, Z, Han, T, Qin, L & Zheng, C 2015, 'Antitumor activity of 
tatariside-F isolated from roots of Fagopyrum tataricum (L.) Gaertn against H22 
hepatocellular carcinoma via up-regulation of p53', Phytomedicine, vol. 22, no. 7, 
pp. 730-6. 
Petrovska, BB 2012, 'Historical review of medicinal plants' usage', Pharmacognosy 
Reviews, vol. 6, no. 11, p. 1. 
Peumans, WJ, Hao, Q & Van Damme, EJ 2001, 'Ribosome-inactivating proteins 
from plants: more than RNA N-glycosidases?', The FASEB Journal, vol. 15, no. 9, 
pp. 1493-506. 
Pietenpol, J & Stewart, Z 2002, 'Cell cycle checkpoint signaling:: Cell cycle arrest 
versus apoptosis', Toxicology, vol. 181, pp. 475-81. 
Pizzo, E & Di Maro, A 2016, 'A new age for biomedical applications of ribosome 
inactivating proteins (RIPs): from bioconjugate to nanoconstructs', Journal of 
Biomedical Science, vol. 23, no. 54, DOI 10.1186/s12929-016-0272-1 
Porath, J, Carlsson, J, Olsson, I & Belfrage, G 1975, 'Metal chelate affinity 
chromatography, a new approach to protein fractionation', Nature, vol. 258, pp. 598-
9. 
Porter, AG & Janicke, RU 1999, 'Emerging roles of caspase-3 in apoptosis', Cell 
Death and Differentiation, vol. 6, no. 2, pp. 99-104. 
Poyet, JL & Hoeveler, A 1997, 'cDNA cloning and expression of pokeweed antiviral 
protein from seeds in Escherichia coli and its inhibition of protein synthesis in vitro', 
FEBS Letters, vol. 406, no. 1-2, pp. 97-100. 
Poyet, JL, Radom, J & Hoeveler, A 1994, 'Isolation and characterization of a cDNA 
clone encoding the pokeweed antiviral protein II from Phytolacca americana and its 
expression in E. coli', FEBS Letters, vol. 347, no. 2-3, pp. 268-72. 
Bibliography 
199 
Priyanka, C, Kadam, D, Kadam, A, Ghule, Y & Aparadh, V 2013, 'Free radical 
scavenging (DPPH) and ferric reducing ability (FRAP) of some gymnosperm 
species', International Research Journal of Botany, vol. 3, no. 2, pp. 34-6. 
Pryme, I, Bardocz, S, Pusztai, A & Ewen, S 2006, 'Suppression of growth of tumour 
cell lines in vitro and tumours in vivo by mistletoe lectins'. Histology and 
Histopathology, vol. 21, no. 3, pp. 285-99. 
Puri, M 2010, 'Momordica balsamina: A medicinal and nutraceutical plant for health 
care management. Comments: Biotechnological potential of M. balsamina revealed', 
Current Pharmaceutical Biotechnology, vol. 11, no. 2, pp. 229-30. 
Puri, M, Kaur, I, Kanwar, R, Gupta, R, Chauhan, A & Kanwar, J 2009, 'Ribosome 
inactivating proteins (RIPs) from Momordica charantia for anti viral therapy', 
Current Molecular Medicine, vol. 9, no. 9, pp. 1080-94. 
Puri, M, Kaur, I, Perugini, MA & Gupta, RC 2012, 'Ribosome-inactivating proteins: 
current status and biomedical applications', Drug Discovery Today, vol. 17, no. 13, 
pp. 774-83. 
Qu, C, Zhang, W, Zheng, G, Zhang, Z, Yin, J & He, Z 2014, 'Metformin reverses 
multidrug resistance and epithelial–mesenchymal transition (EMT) via activating 
AMP-activated protein kinase (AMPK) in human breast cancer cells', Molecular and 
Cellular Biochemistry, vol. 386, no. 1-2, pp. 63-71. 
Rajamohan, F, Venkatachalam, TK, Irvin, JD & Uckun, FM 1999, 'Pokeweed 
antiviral protein isoforms PAP-I, PAP-II, and PAP-III depurinate RNA of human 
immunodeficiency virus (HIV)-1', Biochemical and Biophysical Research 
Communications, vol. 260, no. 2, pp. 453-8. 
Ramos, S 2007, 'Effects of dietary flavonoids on apoptotic pathways related to 
cancer chemoprevention', The Journal of Nutritional Biochemistry, vol. 18, no. 7, 
pp. 427-42. 
Ramos, S 2008, 'Cancer chemoprevention and chemotherapy: dietary polyphenols 
and signalling pathways', Molecular Nutrition & Food Research, vol. 52, no. 5, pp. 
507-26. 
Rao, PL, Jayaraj, R, Bhaskar, A, Kumar, O, Bhattacharya, R, Saxena, P, Dash, P & 
Vijayaraghavan, R 2005, 'Mechanism of ricin-induced apoptosis in human cervical 
cancer cells', Biochemical Pharmacology, vol. 69, no. 5, pp. 855-65. 
Rippmann, JF, Michalowski, CB, Nelson, DE & Bohnert, HJ 1997, 'Induction of a 
ribosome-inactivating protein upon environmental stress', Plant Molecular Biology, 
vol. 35, no. 6, pp. 701-9. 
Rojo, MA, Yato, M, Ishii-Minami, N, Minami, E, Kaku, H, Citores, L, Girbes, T & 
Shibuya, N 1997, 'Isolation, cDNA cloning, biological properties, and carbohydrate 
binding specificity of sieboldin-b, a type II ribosome-inactivating protein from the 
Bibliography 
200 
bark of Japanese elderberry (Sambucus sieboldiana)', Archives of Biochemistry and 
Biophysics, vol. 340, no. 2, pp. 185-94. 
Roncuzzi, L & Gasperi-Campani, A 1996, 'DNA-nuclease activity of the single-
chain ribosome-inactivating proteins dianthin 30, saporin 6 and gelonin', FEBS 
Letters, vol. 392, no. 1, pp. 16-20. 
Roos, WP & Kaina, B 2006, 'DNA damage-induced cell death by apoptosis', Trends 
in Molecular Medicine, vol. 12, no. 9, pp. 440-50. 
Ross, S 2010, 'Evidence for the relationship between diet and cancer', Experimental 
Oncology, vol. 32, no. 3, pp. 137-42. 
Ruggiero, A, Di Maro, A, Severino, V, Chambery, A & Berisio, R 2009, 'Crystal 
structure of PD‐L1, a ribosome inactivating protein from Phytolacca dioica L. 
Leaves with the property to induce DNA cleavage', Biopolymers, vol. 91, no. 12, pp. 
1135-42. 
Russo, R, Chambery, A, Severino, V, Parente, A & Di Maro, A 2015, 'Structural 
characterization of dioicin 1 from Phytolacca dioica L. gains novel insights into 
phylogenetic relationships of Phytolaccaceae type 1 RIPs', Biochemical and 
Biophysical Research Communications, vol. 463, no. 4, pp. 732-8. 
Rybak, SM, Lin, JJ, Newton, DL, Kung, HF, Monks, A, Chen, HC, Huang, PL & 
Lee-Huang, S 1994, 'In vitro anti-tumor activity of the plant ribosome inactivating 
proteins MAP 30 and GAP 31', International Journal of Oncology, vol. 5, no. 5, pp. 
1171-6. 
Ryder, SD 2003, 'Guidelines for the diagnosis and treatment of hepatocellular 
carcinoma (HCC) in adults', Gut, vol. 52, no. suppl. iii, pp. iii1-iii8. 
Sabarinathan, D, Mahalakshmi, P & Vanisree, AJ 2011, 'Naringenin, a flavanone 
inhibits the proliferation of cerebrally implanted C6 glioma cells in rats', Chemico-
Biological Interactions, vol. 189, no. 1, pp. 26-36. 
Saraste, A & Pulkki, K 2000, 'Morphologic and biochemical hallmarks of apoptosis', 
Cardiovascular Research, vol. 45, no. 3, pp. 528-37. 
Sax, JK, Fei, P, Murphy, ME, Bernhard, E, Korsmeyer, SJ & El-Deiry, WS 2002, 
'BID regulation by p53 contributes to chemosensitivity', Nature Cell Biology, vol. 4, 
no. 11, pp. 842-9. 
Schreiber, CA, Wan, L, Sun, Y, Lu, L, Krey, LC & Lee-Huang, S 1999, 'The 
antiviral agents, MAP30 and GAP31, are not toxic to human spermatozoa and may 
be useful in preventing the sexual transmission of human immunodeficiency virus 
type 1', Fertility and Sterility, vol. 72, no. 4, pp. 686-90. 
Schrot, J, Weng, A & Melzig, MF 2015, 'Ribosome-inactivating and related 
proteins', Toxins, vol. 7, no. 5, pp. 1556-615. 
Bibliography 
201 
Sha, O, Niu, J, Ng, TB, Cho, EY-P, Fu, X & Jiang, W 2013, 'Anti-tumor action of 
trichosanthin, a type 1 ribosome-inactivating protein, employed in traditional 
Chinese medicine: a mini review', Cancer Chemotherapy and Pharmacology, vol. 
71, no. 6, pp. 1387-93. 
Sharma, N, Park, SW, Vepachedu, R, Barbieri, L, Ciani, M, Stirpe, F, Savary, BJ & 
Vivanco, JM 2004, 'Isolation and characterization of an RIP (ribosome-inactivating 
protein)-like protein from tobacco with dual enzymatic activity', Plant Physiology, 
vol. 134, no. 1, pp. 171-81. 
Shi, MD, Liao, YC, Shih, YW & Tsai, LY 2013, 'Nobiletin attenuates metastasis via 
both ERK and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells', 
Phytomedicine, vol. 20, no. 8, pp. 743-52. 
Shi, Y 2004, 'Caspase activation, inhibition, and reactivation: a mechanistic view', 
Protein Science, vol. 13, no. 8, pp. 1979-87. 
Shi, Z, Shan, S, Yuan, T, Gui, Y, Cao, C & Zhang, J 2009, 'Mechanism of 
trichosanthin inducing apoptosis of mouse prostatic cancer RM-1 cells in vitro', 
Journal of Chinese Medicinal Materials, vol. 32, no. 2, pp. 239-42. 
Shih, NR, McDonald, KA, Jackman, AP, Girbes, T & Iglesias, R 1997, 'Bifunctional 
plant defence enzymes with chitinase and ribosome inactivating activities from 
Trichosanthes kirilowii cell cultures', Plant Science, vol. 130, no. 2, pp. 145-50. 
Shin, MC, Zhang, J, David, AE, Trommer, WE, Kwon, YM, Min, KA, Kim, JH & 
Yang, VC 2013, 'Chemically and biologically synthesized CPP-modified gelonin for 
enhanced anti-tumor activity', Journal of Controlled Release, vol. 172, no. 1, pp. 
169-78. 
Shiraishi, H, Okamoto, H, Yoshimura, A & Yoshida, H 2006, 'ER stress-induced 
apoptosis and caspase-12 activation occurs downstream of mitochondrial apoptosis 
involving Apaf-1', Journal of Cell Science, vol. 119, no. 19, pp. 3958-66. 
Shu, SH, Xie, GZ, Guo, XL & Wang, M 2009, 'Purification and characterization of a 
novel ribosome-inactivating protein from seeds of Trichosanthes kirilowii Maxim', 
Protein Expression and Purification, vol. 67, no. 2, pp. 120-5. 
Shu, YZ 1998, 'Recent natural products based drug development: a pharmaceutical 
industry perspective', Journal of Natural Products, vol. 61, no. 8, pp. 1053-71. 
Stirpe, F 2004, 'Ribosome-inactivating proteins', Toxicon, vol. 44, no. 4, pp. 371-83. 
Stirpe, F & Barbieri, L 1986, 'Ribosome-inactivating proteins up to date', FEBS 
Letters, vol. 195, no. 1, pp. 1-8. 
Stirpe, F, Barbieri, L, Battelli, MG, Soria, M & Lappi, DA 1992, 'Ribosome-
Inactivating Proteins from Plants: Present Status and Future Prospects', Nature 
Biotechnology, vol. 10, no. 4, pp. 405-12. 
Bibliography 
202 
Stirpe, F, Barbieri, L, Gorini, P, Valbonesi, P, Bolognesi, A & Polito, L 1996, 
'Activities associated with the presence of ribosome-inactivating proteins increase in 
senescent and stressed leaves', FEBS Letters, vol. 382, no. 3, pp. 309-12. 
Stirpe, F & Battelli, M 2006, 'Ribosome-inactivating proteins: progress and 
problems', Cellular and Molecular Life Sciences, vol. 63, no. 16, pp. 1850-66. 
Stirpe, F, Bolognesi, A, Bortolotti, M, Farini, V, Lubelli, C, Pelosi, E, Polito, L, 
Dozza, B, Strocchi, P & Chambery, A 2007, 'Characterization of highly toxic type 2 
ribosome-inactivating proteins from Adenia lanceolata and Adenia stenodactyla 
(Passifloraceae)', Toxicon, vol. 50, no. 1, pp. 94-105. 
Stirpe, F, Sandvig, K, Olsnes, S & Pihl, A 1982, 'Action of Viscumin, a toxic lectin 
from mistletoe, on cells in culture', Journal of Biological Chemistry, vol. 257, no. 
22, pp. 13271-7. 
Stirpe, F, Williams, DG, Onyon, LJ, Legg, RF & Stevens, WA 1981, 'Dianthins, 
ribosome-damaging proteins with anti-viral properties from Dianthus caryophyllus 
L.(carnation)', Biochemical Journal, vol. 195, pp. 399-405. 
Sumathi, R, Tamizharasi, S & Sivakumar, T 2015, 'Bio-dynamic activity of 
naringenin - a review', International Journal of Current Advanced Research, vol. 4, 
no. 8, pp. 234-6. 
Sun, Y, Huang, PL, Li, JJ, Huang, YQ, Zhang, L, Huang, PL & Lee-Huang, S 2001, 
'Anti-HIV agent MAP30 modulates the expression profile of viral and cellular genes 
for proliferation and apoptosis in AIDS-related lymphoma cells infected with 
kaposi's sarcoma-associated virus', Biochemical and Biophysical Research 
Communications, vol. 287, no. 4, pp. 983-94. 
Tan, QQ, Dong, DX, Yin, XW, Sun, J, Ren, HJ & Li, RX 2009, 'Comparative 
analysis of depurination catalyzed by ricin A-chain on synthetic 32mer and 25mer 
oligoribonucleotides mimicking the sarcin/ricin domain of the rat 28S rRNA and E. 
coli 23S rRNA', Journal of Biotechnology, vol. 139, no. 2, pp. 156-62. 
Tang, S, Xie, L, Hou, FJ, Liu, WY & Ruan, KC 2001, 'Non-specific deadenylation 
and deguanylation of naked RNA catalyzed by ricin under acidic condition', 
Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression, vol. 1519, no. 
3, pp. 192-8. 
Taylor, S, Massiah, A, Lomonossoff, G, Roberts, LM, Lord, JM & Hartley, M 1994, 
'Correlation between the activities of five ribosome‐inactivating proteins in 
depurination of tobacco ribosomes and inhibition of tobacco mosaic virus infection', 
The Plant Journal, vol. 5, no. 6, pp. 827-35. 
Teltow, GJ, Irvin, JD & Aron, GM 1983, 'Inhibition of herpes simplex virus DNA 
synthesis by pokeweed antiviral protein', Antimicrobial Agents and Chemotherapy, 
vol. 23, no. 3, pp. 390-6. 
Bibliography 
203 
Thakur, GS, Bag, M, Sanodiya, BS, Bhadouriya, P, Debnath, M, Prasad, GB & 
Bisen, PS 2009, 'Momordica balsamina: a medicinal and nutraceutical plant for 
health care management', Current Pharmaceutical Biotechnology, vol. 10, no. 7, pp. 
667-82. 
Thomas, B, Van Deynze, A & Bradford, K 2002, 'Production of therapeutic proteins 
in plants', University of California- Agriculture and Natural Resources Publications. 
Tomatsu, M, Kondo, T, Yoshikawa, T, Komeno, T, Adachi, N, Kawasaki, Y, Ikuta, 
A & Tashiro, F 2004, 'An apoptotic inducer, aralin, is a novel type II ribosome-
inactivating protein from Aralia elata', Biological Chemistry, vol. 385, no. 9, pp. 
819-27. 
Tomatsu, M, Ohnishi-Kameyama, M & Shibamoto, N 2003, 'Aralin, a new cytotoxic 
protein from Aralia elata, inducing apoptosis in human cancer cells', Cancer Letters, 
vol. 199, no. 1, pp. 19-25. 
Uckun, FM, Chelstrom, LM, Tuel-Ahlgren, L, Dibirdik, I, Irvin, JD, Langlie, MC & 
Myers, DE 1998, 'TXU (anti-CD7)-pokeweed antiviral protein as a potent inhibitor 
of human immunodeficiency virus', Antimicrobial Agents and Chemotherapy, vol. 
42, no. 2, pp. 383-8. 
Uckun, FM, Rustamova, L, Vassilev, AO, Tibbles, HE & Petkevich, AS 2005, 'CNS 
activity of pokeweed anti-viral protein (PAP) in mice infected with lymphocytic 
choriomeningitis virus (LCMV)', BMC Infectious Diseases, vol. 5, no. 1, p. 9. 
Veeresham, C & Chitti, P 2013, Therapeutic agents from tissue cultures of medicinal 
plants. Natural Products Chemistry and Research 1: 118 doi: 10.4172/2329-
6836.1000118 vitro. 
Venook, AP, Papandreou, C, Furuse, J & de Guevara, LL 2010, 'The incidence and 
epidemiology of hepatocellular carcinoma: a global and regional perspective', The 
Oncologist, vol. 15, no. Supplement 4, pp. 5-13. 
Vivanco, JM, Savary, BJ & Flores, HE 1999, 'Characterization of two novel type I 
ribosome-inactivating proteins from the storage roots of the andean crop Mirabilis 
expansa', Plant Physiology, vol. 119, no. 4, pp. 1447-56. 
Voss, C, Eyol, E, Frank, M, von der Lieth, CW & Berger, MR 2006, 'Identification 
and characterization of riproximin, a new type II ribosome-inactivating protein with 
antineoplastic activity from Ximenia americana', The FASEB Journal, vol. 20, no. 8, 
pp. 1194-6. 
Wachinger, M, Samtleben, R, Gerhauser, C, Wagner, H & Erfle, V 1993, 'Bryodin, a 
single-chain ribosome-inactivating protein, selectively inhibits the growth of HIV-1-
infected cells and reduces HIV-1 production', Research in Experimental Medicine, 
vol. 193, no. 1, pp. 1-12. 
Walsh, TA, Morgan, A & Hey, TD 1991, 'Characterization and molecular cloning of 
a proenzyme form of a ribosome-inactivating protein from maize. Novel mechanism 
Bibliography 
204 
of proenzyme activation by proteolytic removal of a 2.8-kilodalton internal peptide 
segment', Journal of Biological Chemistry, vol. 266, no. 34, pp. 23422-7. 
Wang, C, Yang, A, Zhang, B, Yin, Q, Huang, H, Chen, M & Xie, J 2014, 'PANC-1 
pancreatic cancer cell growth inhibited by cucurmosin alone and in combination 
with an epidermal growth factor receptor-targeted drug', Pancreas, vol. 43, no. 2, pp. 
291-7. 
Wang, JH, Nie, HL, Tam, SC, Huang, H & Zheng, YT 2002, 'Anti-HIV-1 property 
of trichosanthin correlates with its ribosome inactivating activity', FEBS Letters, vol. 
531, no. 2, pp. 295-8. 
Wang, P, Chen, LL, Yan, H & Li, JC 2009, 'Trichosanthin suppresses HeLa cell 
proliferation through inhibition of the PKC/MAPK signaling pathway', Cell Biology 
and Toxicology, vol. 25, no. 5, pp. 479-88. 
Wang, P & Tumer, NE 1999, 'Pokeweed antiviral protein cleaves double-stranded 
supercoiled DNA using the same active site required to depurinate rRNA', Nucleic 
Acids Research, vol. 27, no. 8, pp. 1900-5. 
Wang, P, Xu, J & Zhang, C 2010, 'CREB, a possible upstream regulator of Bcl-2 in 
trichosanthin-induced HeLa cell apoptosis', Molecular Biology Reports, vol. 37, no. 
4, pp. 1891-6. 
Wang, S, Zhang, Y, Liu, H, He, Y, Yan, J, Wu, Z & Ding, Y 2012, 'Molecular 
cloning and functional analysis of a recombinant ribosome-inactivating protein 
(alpha-momorcharin) from Momordica charantia', Applied Microbiology and 
Biotechnology, vol. 96, no. 4, pp. 939-50. 
Wang, S, Zheng, Y, Yan, J, Zhu, Z, Wu, Z & Ding, Y 2013, 'Alpha-momorcharin: A 
ribosome-inactivating protein from Momordica charantia, possessing DNA cleavage 
properties', Protein and Peptide Letters, vol. 20, no. 11, pp. 1257-63. 
Wang, YX, Neamati, N, Jacob, J, Palmer, I, Stahl, SJ, Kaufman, JD, Huang, PL, 
Huang, PL, Winslow, HE & Pommier, Y 1999, 'Solution structure of anti-HIV-1 and 
anti-tumor protein MAP30: structural insights into its multiple functions', Cell, vol. 
99, no. 4, pp. 433-42. 
Wei, MC, Lindsten, T, Mootha, VK, Weiler, S, Gross, A, Ashiya, M, Thompson, CB 
& Korsmeyer, SJ 2000, 'tBID, a membrane-targeted death ligand, oligomerizes BAK 
to release cytochrome c', Genes & Development, vol. 14, no. 16, pp. 2060-71. 
Westphal, D, Dewson, G, Czabotar, PE & Kluck, RM 2011, 'Molecular biology of 
Bax and Bak activation and action', Biochimica et Biophysica Acta (BBA)-Molecular 
Cell Research, vol. 1813, no. 4, pp. 521-31. 
Wicaksono, PA, Name, S, Martien, R & Ismail, H 2016, 'Formulation and 
cytotoxicity of ribosome-inactivating protein Mirabilis jalapa L. Nanoparticles 
using alginate-low viscosity chitosan conjugated with anti-Epcam antibodies in the 
Bibliography 
205 
T47D breast cancer cell line', Asian Pacific Journal of Cancer Prevention, vol. 17, 
no. 4, pp. 2277–84. 
Williams, RJ, Spencer, JP & Rice-Evans, C 2004, 'Flavonoids: antioxidants or 
signalling molecules?', Free Radical Biology and Medicine, vol. 36, no. 7, pp. 838-
49. 
Wittstock, U & Gershenzon, J 2002, 'Constitutive plant toxins and their role in 
defense against herbivores and pathogens', Current Opinion in Plant Biology, vol. 5, 
no. 4, pp. 300-7. 
Wong, JH, Wang, HX & Ng, TB 2008, 'Marmorin, a new ribosome inactivating 
protein with antiproliferative and HIV-1 reverse transcriptase inhibitory activities 
from the mushroom Hypsizigus marmoreus', Applied Microbiology and 
Biotechnology, vol. 81, no. 4, pp. 669-74. 
Wong, RNS, Mak, NK, Choi, WT & Law, PTW 1995, 'Increased accumulation of 
trichosanthin in Trichosanthes kirilowii induced by microorganisms' Journal of 
Experimental Biology, vol. 46, no. 3, pp. 355-8. 
Xia, XF & Sui, SF 2000, 'The membrane insertion of trichosanthin is membrane-
surface-pH dependent', Biochemical Journal, vol. 349, no. 3, pp. 835-41. 
Xia, X, Hou, F, Li, J, Ke, Y & Nie, H 2006, 'Two novel proteins bind specifically to 
trichosanthin on choriocarcinoma cell membrane', Journal of Biochemistry, vol. 139, 
no. 4, pp. 725-31. 
Xie, J, Que, W, Chen, M, Sun, J, Liu, T, Liu, H, Liu, M, Yang, A, Yang, P & Wang, 
Y 2011, 'Antitumor effects of cucurmosin in human chronic myeloid leukemia occur 
through cell cycle arrest and decrease the Bcl-2/Bax ratio to induce apoptosis', 
African Journal of Pharmacy and Pharmacology, vol. 5, no. 7, pp. 985-92. 
Xie, J, Wang, C, Zhang, B, Yang, A, Yin, Q, Huang, H & Chen, M 2013, 
'Cucurmosin induces the apoptosis of human pancreatic cancer CFPAC-1 cells by 
inactivating the PDGFR-β signalling pathway', Pharmacological Reports, vol. 65, 
no. 3, pp. 682-8. 
Xiong, SD, Yu, K, Liu, XH, Yin, LH, Kirschenbaum, A, Yao, S, Narla, G, DiFeo, 
A, Wu, JB & Yuan, Y 2009, 'Ribosome‐inactivating proteins isolated from dietary 
bitter melon induce apoptosis and inhibit histone deacetylase‐1 selectively in 
premalignant and malignant prostate cancer cells', International Journal of Cancer, 
vol. 125, no. 4, pp. 774-82.  
Yan, R, Cao, Y & Yang, B 2014, 'HPLC-DPPH screening method for evaluation of 
antioxidant compounds extracted from Semen oroxyli', Molecules, vol. 19, no. 4, pp. 
4409-17. 
Yang, CH, Li, RX & Chuang, LY 2012, 'Antioxidant activity of various parts of 
Cinnamomum cassia extracted with different extraction methods', Molecules, vol. 
17, no. 6, pp. 7294-304. 
Bibliography 
206 
Yang, Z, Liu, Y, Liao, J, Gong, C, Sun, C, Zhou, X, Wei, X, Zhang, T, Gao, Q & 
Ma, D 2015, 'Quercetin induces endoplasmic reticulum stress to enhance cDDP 
cytotoxicity in ovarian cancer: involvement of STAT3 signaling', FEBS Journal, 
vol. 282, no. 6, pp. 1111-25. 
Yeung, HW, Li, WW, Feng, Z, Barbieri, L & Stirpe, F 1988, 'Trichosanthin, α‐
momorcharin and β‐momorcharin: identity of abortifacient and ribosome‐
inactivating proteins', International Journal of Peptide and Protein Research, vol. 
31, no. 3, pp. 265-8. 
Zeng, M, Zheng, M, Lu, D, Wang, J, Jiang, W & Sha, O 2015, 'Anti-tumor activities 
and apoptotic mechanism of ribosome-inactivating proteins', Chinese Journal of 
Cancer, vol. 34, no. 1, pp. 1-10. 
Zhang, B, Huang, H, Xie, J, Xu, C, Chen, M, Wang, C, Yang, A & Yin, Q 2012, 
'Cucurmosin induces apoptosis of BxPC-3 human pancreatic cancer cells via 
inactivation of the EGFR signaling pathway', Oncology Reports, vol. 27, no. 3, pp. 
891-7. 
Zhang, CY, Gong, YX, Ma, H, An, CC & Chen, DY 2001, 'Reactive oxygen species 
involved in trichosanthin-induced apoptosis of human choriocarcinoma cells', 
Biochemical Journal, vol. 355, pp. 653-61. 
Zhang, D, Chen, B, Zhou, J, Zhou, L, Li, Q, Liu, F, Chou, KY, Tao, L & Lu, LM 
2015, 'Low concentrations of trichosanthin induce apoptosis and cell cycle arrest via 
c Jun N-terminal protein kinase/mitogen activated protein kinase activation', 
Molecular Medicine Reports, vol. 11, no. 1, pp. 349-56. 
Zhang, D & Halaweish, FT 2007, 'Isolation and characterization of ribosome‐
inactivating proteins from Cucurbitaceae', Chemistry & Biodiversity, vol. 4, no. 3, 
pp. 431-42. 
Zhang, F, Hu, XB, Cao, RY, Zhu, XJ & Liu, JJ 2011, 'Antitumor effect of 
trichosanthin on mouse hepatocellular carcinoma H22 cells', Journal of China 
Pharmaceutical University, vol. 42, no. 3, pp. 242-6. 
Zhang, JH & Ming, X 2000, 'DNA fragmentation in apoptosis', Cell Research, vol. 
10, no. 3, pp. 205-11. 
Zhang, K & Kaufman, RJ 2004, 'Signaling the unfolded protein response from the 
endoplasmic reticulum', Journal of Biological Chemistry, vol. 279, no. 25, pp. 
25935-8. 
Zhang, YQ, Huang, LM & Wu, JF 2009, 'Experimental study on the inhibitory effect 
of trichosanthin on tumor in U14 mice', Lishizhen Medicine and Materia Medica 
Research, vol. 10, p. 003. 
Zhao, P, Mao, JM, Zhang, SY, Zhou, ZQ, Tan, Y & Zhang, Y 2014, 'Quercetin 
induces HepG2 cell apoptosis by inhibiting fatty acid biosynthesis', Oncology 
Letters, vol. 8, no. 2, pp. 765-9. 
Bibliography 
207 
Zhao, WL, Zhang, F, Feng, D, Wu, J, Chen, S & Sui, SF 2009, 'A novel sorting 
strategy of trichosanthin for hijacking human immunodeficiency virus type 1', 
Biochemical and Biophysical Research Communications, vol. 384, no. 3, pp. 347-
51. 
Zheng, YT, Ben, KL & Jin, SW 2000, 'Anti-HIV-1 activity of trichobitacin, a novel 
ribosome-inactivating protein', Acta Pharmacologica Sinica, vol. 21, no. 2, pp. 179-
82. 
Zheng, Y, Ben, K & Jin, S 1999, 'Alpha-momorcharin inhibits HIV-1 replication in 
acutely but not chronically infected T-lymphocytes', Acta Pharmacologica Sinica, 
vol. 20, no. 3, pp. 239-43. 
Zhenwu, X, Yuxin, W & LingJi, C 1997, 'Study on the anticolon carcinoma SW-
1116 effects of TCS in vivo', Zhejiang Cancer Journal, vol. 2, p. 028. 
Zhou, H, Marks, JW, Hittelman, WN, Yagita, H, Cheung, LH, Rosenblum, MG & 
Winkles, JA 2011, 'Development and characterization of a potent immunoconjugate 
targeting the Fn14 receptor on solid tumor cells', Molecular Cancer Therapeutics, 
vol. 10, no. 7, pp. 1276-88. 
Zhou, X, Li, XD, Yuan, JZ, Tang, ZH & Liu, WY 2000, 'Toxicity of cinnamomin - a 
new type II ribosome-inactivating protein to bollworm and mosquito', Insect 
Biochemistry and Molecular Biology, vol. 30, pp. 259–64. 
Zhu, F, Zhang, P, Meng, YF, Xu, F, Zhang, DW, Cheng, J, Lin, HH & Xi, DH 2013, 
'Alpha-momorcharin, a RIP produced by bitter melon, enhances defense response in 
tobacco plants against diverse plant viruses and shows antifungal activity in vitro', 
Planta, vol. 237, no. 1, pp. 77-88. 
Ziegler, U & Groscurth, P 2004, 'Morphological features of cell death', Physiology, 
vol. 19, no. 3, pp. 124-8.  
Annexures 
208 
 
 
 
 
 
 
 
 
 
8. Annexures 
 
 
 
 
 
 
 
 
 
 
 
 
 
Annexures 
209 
Annexure 8.1: Rare codon optimization report. 
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Annexure 8.2: Antioxidant activity of rBalsamin. a) Effect of concentration on 
DPPH scavenging activity of rBalsamin. b) Effect of concentration on 
superoxide radical scavenging activity of rBalsamin. c) Effect of concentration 
on reducing power ability of rBalsamin. All values are mean ± SD. SD, 
standard deviation; n = 3.  
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Annexure 8.3: Dose dependent inhibition of Staphylococcus aureus (A), 
Pseudomonas aeruginosa (B), Escherichia coli (C), Staphylococcus epidermidis 
(D), Salmonella enterica (E) and Enterococcus faecalis (F) with rBalsamin. All 
values are mean ± SD. SD, standard deviation; n = 3; *P < 0.05. 
 
